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ABSTRACT OF THE DISSERTATION
The Physiological and Morphological Responses of the Bladder Urothelium to Differential 
Injury
By
Kristina Marie Stemler
Doctor of Philosophy in Developmental, Regenerative, and Stem Cell Biology
Washington University in St. Louis, 2013
Professor Indira U. Mysorekar, Chairperson
The bladder is the site of various diseases such as urinary tract infections (UTI), interstitial 
cystitis/bladder pain syndrome (IC/BPS), and bladder cancer. UTIs and IC/BPS primarily afflict 
women and treatment costs over $5 billion and almost $200 million respectively in 2006. Quality 
of life in IC/BPS patients is low. Recent research has identified a role for the epithelial lining of 
the bladder, which is usually targeted by these afflictions, in potentially contributing to enhancing 
pain. The bladder epithelium also showcases a rapid ability to regenerate after injury. 
Knowledge of the contribution of bladder injury to nociception (pain) is currently lacking. 
To increase our understanding of how various injuries, which target different layers of the bladder, 
affect pain response in mice we used a UTI injury model from instillation of uropathogenic E. coli 
(UPEC), a cellular damage model from single dose protamine sulfate (SDPS) instillation, and an 
inflammatory damage model from multiple instillations of lipopolysaccharide (LPS). We identified 
that UPEC injury increased the pain response to bladder distention while it was decreased by 
SDPS injury. LPS injury did not change the pain profile from distention. Secondly, we applied the 
UPEC infection model to identify that metabotropic glutamate receptor 5 (mGluR5) is necessary 
to experience inflammatory-mediated pain responses. We also correlated molecular markers and 
pain profiles to identify potential biomarkers for diagnosis or treatment of IC/BPS.
xiv
Although regeneration from bladder injury has been studied in the extremes of injury 
(UPEC and SDPS), many etiologies occur as a spectrum of tissue responses and would be better 
represented by injury models that showcase nuanced traits. New injury models were developed 
utilizing dual dose protamine sulfate (DDPS) to specifically target cellular injury to different strata 
of the bladder epithelial layer. Comparing DDPS to SDPS and UPEC injuries, we identified that 
extreme urothelial injury alone is sufficient to activate a UPEC-like renewal response originating 
from the basal most layer. However, DDPS does not require BMP signaling for activation of 
regeneration. We also identified that the glycosaminoglycan layer of the extracellular matrix is 
differentially modulated by DDPS injury. In summary, these data suggest that differential injury 
contributes to pain response and that multiple molecular mediators play a role in regulating bladder 
epithelial regeneration.
xv
EPIGRAPH
Remember
By Christina Rossetti
Remember me when I am gone away,
         Gone far away into the silent land;
         When you can no more hold me by the hand,
Nor I half turn to go yet turning stay.
Remember me when no more day by day
         You tell me of our future that you plann’d:
         Only remember me; you understand
It will be late to counsel then or pray.
Yet if you should forget me for a while
         And afterwards remember, do not grieve:
         For if the darkness and corruption leave
         A vestige of the thoughts that once I had,
Better by far you should forget and smile
         Than that you should remember and be sad.
1CHAPTER 1: Introduction to biology and pathophysiology of the urothelium and models 
to study mechanisms contributing to both
2I. Function of the Urinary Bladder
The bladder’s most important function is safe storage of toxic liquid waste. It stores up to 
500 ml of urine, and allows release of that urine at socially appropriate intervals. The ability of 
the bladder to stretch and rearrange its composite tissue components to allow for this increase in 
volume assists in the primary storage function [1]. The bladder also needs to be inert to protect 
both the bladder tissues and the underlying blood supply from the toxic chemicals present in the 
urine and this is accomplished by the mucosal lining of the bladder. The epithelial lining of the 
bladder (urothelium) is in direct contact with the luminal contents of the bladder and therefore 
provides a physical barrier to these contents [1]. However, various bladder conditions disrupt the 
function of the bladder, are painful, and costly to diagnose and treat [2-4]. In order to preserve the 
composition of urine and to sequester urine from underlying tissues [1], the bladder exhibits a high 
capacity to regenerate in response to injury, reestablishing the protective intact urothelium. 
 The urothelium is normally a slow cycling tissue in order to preserve barrier function, but 
injury-induced urothelial renewal is rapid, resulting in regeneration of the damaged tissue in a 
matter of days [5-8]. Adult urothelial cells, when challenged, are capable of completing the cell 
cycle as fast as embryonic bladder cells [5, 9, 10]. Therefore, to gain a better understanding of how 
the bladder is capable of maintaining its function, investigations into the bladder’s responses to 
injuries are needed. In this chapter, the importance of the bladder structure that allows this organ 
to meet its function and the clinical manifestations when the bladder barrier is disrupted will 
be discussed. Models that can be used to investigate bladder damage and its physiological and 
morphological consequences will also be presented.
II. Bladder Tissue Architecture
The bladder consists of three main tissue strata, the urothelium, the lamina propria 
(mesenchyme) and the muscularis propria (Figure 1.1A). The muscle is compliant to allow for 
stretch upon filling but contractions are synchronous to induce voiding of the spherical bladder. 
Bladder flexibility is assisted by the loosely connective mesenchyme that rearranges upon bladder 
3Muscularis 
propria
Lamina propria 
(mesenchyme)
Urothelium
Lumen} }}
P1 barrier
cells P2 
intermediate
cells
P3 basal cells50 µm
A
B Figure 1.1: Normal architecture of the 
murine bladder. 
A. Hematoxylin and eosin staining 
exhibiting normal architecture of the 
urothelial, lamina propria and muscle 
layers, as indicated. 
B. Tissue architecture of the urothelium. 
P3 basal cells lie adjacent to the basement 
membrane above the mesenchyme. P2 
intermediate cells are above the P3 cell 
layer. P1 barrier cells that line the lumen 
are large and multinucleated. 
Scale bar = 50 um.
cycles [1]. The urothelium is one of the most impermeable epithelial structures in the body [11-
14]. The urothelium, a major player in bladder barrier function, is a pseudo-stratified transitional 
epithelium includes a variable number of cell strata depending on the species [15-17] but with 
three distinct layers. These are the barrier, intermediate and basal cell layers (Figure 1.1B) [11, 16]. 
The various characteristics of these cell layers are discussed below.
The barrier cell layer comprises large (>100 microns) multinucleated terminally 
differentiated cells (also called P1 cells, umbrella cells, facet cells) that make up the main physical 
barrier and are in direct contact with urine [16]. The apical plasma membrane of these cells has a 
thick luminal leaflet termed the asymmetric unit membrane (AUM) [18] that primarily consists of 
uroplakin protein (UP) complexes. Uroplakins are a family of transmembrane proteins containing 
44 family members, UPIa, UPIb, UPII and UPIII that form heterodimers between UPIa/UPII and 
UPIb/UPIII to arrange into hexagonal domains conferring impermeability to the urothelium [18-
21]. Uroplakins are delivered to and recycled from the AUM utilizing discoid fusiform vesicles 
(DFVs). Upon filling of the bladder, stretch induces fusion of an apical pool of DFVs to the AUM 
to increase cell surface area accommodating urine without compromising the functional barrier 
[12-14, 16, 18, 22, 23]. During voiding, the tension on the apical membrane increases to induce 
endocytosis of the DFVs and therefore recycling of the AUM [12, 24]. UP staining is one of the 
major markers for P1 cells (Figure 1.2) although, differentiation status of the urothelium can also 
in part be tracked by the variable expression of cytokeratin intermediate filament proteins [25-28]. 
P1 cells also co-express cytokeratin 20 (K20).
Underneath the P1 cell layer are the P2 cells, which are mononucleated 10-15 micron large 
cells of intermediate differentiation [29]. The number of P2 cell layers varies during micturition 
cycle and by species; rodent models homeostatically display only one to two P2 cell layers [5, 14, 
16]. This makes marker characterization of this layer variable as well. These cells are typically 
characterized by their expression of K7, a transitional cell marker, and of P63, a common progenitor 
cell marker (Figure 1.2) [30, 31]. P2 cells that are in direct contact with P1 cells also typically 
express low levels of apical but not vesicular UPs, but will rapidly increase UP expression upon 
P1 cell injury [25]. The full function of P2 cells is not known.
The least differentiated cell layer of the urothelium is comprised of the mononucleated 
5 micron large P3 cells of the basal layer that are in direct contact with the basement membrane 
[16]. P3 cells do not express UP proteins but do express P63, sonic hedgehog (Shh) and high 
levels of K5 (Figure 1.2) [32, 33]. Histologically, these are the only mitotically active cells under 
homeostasis and have been identified as long-term label-retaining cells [31], which are capable 
of forming bladder spheres and organoids in vitro [33]. P3 cells are induced to proliferate upon 
injury, which commonly leads to a thickening of the urothelium [25, 32-35]. Hyperplasticity may 
be one way the urothelium works to rapidly re-establish the blood urine barrier as thicker layers 
of urothelial cells display higher levels of transepthelial resistance (a measure of impermeability) 
5p-Smad1
p27kip1
Bmp4
BmpR1a
P1 (UP+K20+)
Barrier cells
P2 (UP+K7+P63+)
P3 (UP-K5+P63+Shh+)
Basal cells
Stem
cell
proliferation
Terminal
Differentiation
Intermediate cells
P2 (UP-K7+P63+)
Figure 1.2: Schematic of urothelial markers.
Terminally differentiated P1 cells are marked by UP+ K20+ and express p27kip1. Intermediate P2 cells vary in 
marker expression depending on differentiation status. P2 cells at lie directly underneath P1 cells are UP+K7+P63- 
whereas P2 cells adjacent to P3 cells marker expression consists of UP-K7+P63+. Small basal P3 cells are marked by 
UP- K5+P63+Shh+. BMP ligand is expressed by the underlying mesenchyme and signals to the urothelium through 
BmpR1a to regulate proliferation and terminal differentiation status.
in vitro [36]. 
In summary, P1 cells (UP+) are the major providers of the bladder’s physical barrier. The 
number of P2 cells varies along with marker classification. These cells can be UP-K7+P63+ or 
UP+K7+P63- depending on adjacent cell contacts. Lastly, P3 cells (UP-K5+P63+) are important 
for homeostatic renewal and for rapid urothelial regeneration.
III. Diseases and Conditions of the Bladder
i) Urinary Tract Infections (UTIs)
The bladder is the site of one of the most common infectious diseases in women, urinary 
tract infection (UTI), where it is estimated that approximately 50% of all women will experience 
at least one UTI within their lifetime [37]. Almost 13 million women each year will be affected by 
this infectious disease in the U.S. [38, 39] and in 2006 treatments cost over $5 billion [Table 14-55. 
Economic Impact of Urologic Disease, In: [4]]. Clinically, UTIs are characterized by a variety of 
symptoms: urinary frequency, urgency, dysuria (painful urination), and fever. UTIs are positively 
6diagnosed by urinary culture of microorganisms >105 colony forming units/ml [40]. Pain is usually 
associated with infection, and is a frequent reason for physician visits. However, asymptomatic 
bacteriuria, diagnosed by a positive urine culture without overt pathological symptoms [41], is quite 
common in an organ typified as a sterile environment. Uropathogenic Escherichia coli (UPEC) are 
the most common causative agent of UTI [42]. 
UTIs also frequently recur, with almost one quarter of women experiencing a second UTI 
within six months [38] and almost 3% of all women will have very frequent recurrent UTIs [37]. 
Many of these recurrent infections are caused by the same strain of bacteria as the primary infection 
[43, 44] up to three years later [45]. Recurrent UTIs happen despite urinary clearance by antibiotic 
therapy, and bacteria have been isolated from bladder tissue biopsies from recurrent UTI patients 
with sterile urines [46]. However, the bladder is capable of clearing an infection without antibiotic 
treatment [47] although the mechanism is unclear. How this clearance is abrogated to result in 
recurrent UTIs is also unknown.
ii) Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC)
 Bladder pain syndrome/interstitial cystitis (BPS/IC) is a clinical condition that is 
characterized by severely debilitating chronic pelvic pain that is enhanced upon bladder filling 
(distention) leading to urinary frequency and urgency [1, 48]. This occurs in the absence of any 
other diagnosable etiology and those afflicted have sterile urine cultures [3]. BPS/IC is believed 
to be a spectrum of disorders, with less severe forms exhibiting the symptom of urgency and 
progressed stages eliciting the full gamut of symptoms, the most severe being pain [49]. Upon 
cystoscopic inspection of the bladder, severe but rare cases of BPS/IC may present with petechial 
hemorrhages of the urothelial lining [50]. Alongside intravesical potassium sensitivity [51], these 
are the only identifiable pathologies but alone cannot be used for a diagnosis. Previous attempts 
to identify a coherent symptomology or diagnosable root for BPS/IC have fallen short [52, 53] 
recognizing this syndrome truly as a disease of exclusion.
Although the bladder is not a sexual organ, it can display sexual dimorphism in disease 
susceptibility. As an example, BPS/IC is more prevalent in women than men (9:1 ratio), affecting 
73-12% of women (>9.5 million in the US alone) [3, 54]. The annual cost of managing this elusive 
pain syndrome exceeds $750 million [2, 3]. Conventional treatments are often ineffective and do 
not treat the underlying pathology [55]. Some women experience symptoms for decades with little 
relief [54, 56]. Some symptoms are so severe that even bladder cystectomy does not provide relief 
[57]. This results in a low quality of life, with pain symptoms negatively impacting both general 
and mental health [58, 59]. Despite its high prevalence and burden, the pathophysiology of the 
syndrome remains poorly understood. 
BPS/IC and UTIs share clinical symptoms of pain, urinary frequency and discomfort while 
voiding. Severe forms of BPS/IC also share barrier disruption and histologic inflammation of 
the urothelial tissue with UTIs, but in absence of bacterial titers. This suggests that even without 
bacteria, the bladder’s response of urothelial shedding and tissue inflammation may be important 
for pain sensitization. However, the mechanisms behind the types of damage observed in BPS/IC 
are not well understood. Generating injury models that reflect various aspects of tissue damage in 
BPS/IC are needed to assess their impact on bladder pain outcomes. 
iii) Bladder Cancer
 The bladder urothelium is also the key organ for a major malignancy, bladder cancer, which 
is characterized by aberrant urothelial proliferation and turnover. Bladder carcinoma displays 
sexual dimorphism and is 3-4 times more likely to occur in men [1]. It is the fourth most common 
malignancy in men with over 50,000 new cases diagnosed each year in the U.S. alone [60]. The 
principal class of bladder cancer is urothelial carcinoma and has been associated with infection 
and chronic inflammation [61, 62]. Chronic and recurrent UTIs leading to chronic irritation of the 
urothelium many lead to an increased risk of cancer due to the production of nitric oxide, which 
can stimulate the formation of carcinogenic N-nitroso compounds thereby altering DNA [63]. 
UTIs have been previously associated with the risk of bladder cancer [64-67] and associations 
were strongest for advanced cancers [68]. Therefore urothelial disruption and increased levels of 
proliferation from bladder infections alongside carcinogenic DNA damaging events may lead to 
carcinogenesis of the bladder. 
8IV. Animal Models to Study Features of Bladder Biology and Pathophysiology
UTI models are capable of recapitulating the cellular damage and innate immune cell 
infiltrate seen in human urinalysis [69]. Nevertheless, many etiologies occur as a spectrum of 
tissue responses and would be better represented by injuries that showcase these traits. New models 
are always needed to assess the nuances of both pain and regeneration of chronic conditions, 
although regeneration from bladder injury has been studied in the extremes of injury [27, 32, 33, 
70]. Work from our group and from many others over the past decades have established the models 
discussed below to reproduce various aspects of human ailments and which represent features of 
inflammation, cellular damage or a combination of the two. 
i) Urinary Tract Infection Model
UTIs come in two flavors depending on the site of bacterial colonization. Pyelonephritis 
is an infection of the kidney whereas cystitis is an infection of the bladder [71]. Infection was 
classically considered to be an extracellular colonization of the bladder lumen. However, we 
now know that bacteria participate in a far more complex pathogenic cycle that involves distinct 
intracellular phases, several stages of bacterial development, and the coordination of bacterial and 
host responses (Figure 1.3) [69, 72-76]. UPEC strains isolated from patients suffering from cystitis 
have been utilized to model UTIs in a murine system [77] that recapitulates various aspects of the 
human microbial infectious condition [69]. These animal models have provided much insight into 
the bacterial life cycle, microbial-host interactions, and host tissue resolution and will be discussed 
in depth below.
The host has multiple mechanisms to combat UTIs. To initially establish an infection in the 
bladder, bacteria must enter and ascend the urinary tract. Urine flow is thought to be the first barrier 
to infection. UPEC can be instilled directly to the bladder lumen via a catheter in in vivo murine 
models and will overcome the urine flow barrier [77, 78]. Thus in the murine model, urothelial 
cells are the first barrier to infection but play an active role in mitigating UTI occurrence. Infected 
cells are capable of producing cytokines within minutes of initial infection [41, 79] and thereafter 
9it is a race between the host responses and bacterial subversion to either clear the infection or result 
in persistence [80, 81].
Physical contact between the infecting bacterium and the host urothelial P1 cells is a 
critical step in the pathogenic cycle. The hexagonal arrangement of UPs on the AUM forms a 
small, mannose rich pore that together with UPIa can act as a direct receptor [82-84] for the 
bacterial adhesion FimH, a virulence factor, of type 1 pili. Bacterial binding can be abrogated by 
instilling free mannose or mannosides to the bladder [85, 86] or by genetically interfering with 
FimH production [87-89]. Adherence of the bacteria to the AUM is strong enough to overcome 
the force of urine flow [90] allowing bacteria to persist in the extracellular milieu. Although still 
to be determined, it is possible that bacterial entry and persistence usurps the host UP recycling 
machinery to gain access to the cells to initiate an intracellular stage of their life cycle. It is also 
possible that mechanical tension upon bacterial tethering supports intracellular invasion into the 
P1 cells [14, 90].
A bacterium in the extracellular space is vulnerable to polymorphonuclear leukocytes 
(PMNs) therefore invasion is another critical step in pathogenesis, allowing bacteria to replicate 
rapidly in a semi-protected niche [91]. But even this step is not without a host response. After 
bacteria bind to the P1 cell surface, there is a conformational change of the bacterial-bound 
hexameric UP complex that allows for host-mediated signal transduction initiated by the c-terminal 
end of UPIII [92-94]. This signaling alters cAMP levels, which can result in bacterial exocytosis 
in early infection stages [95, 96]. If bacteria evade this host response and gain entry into the 
cytosol of the P1 cells by a still unknown mechanism, the bacteria can form large densely packed, 
biofilm-like intracellular bacterial communities (IBCs) of morphologically coccoid bacteria [72-
74]. Recent work has also shown that intracellular IBCs are clonally derived, but that P1 cells can 
house multiple IBCs [97].
Continuation of the pathogenic cycle occurs when mature IBCs are capable of fluxing out 
of ruptured urothelial cells. Some of the fluxing bacteria are filamentous, which are resistant to 
clearance by PMNs [76, 98]. This bacterial strategy allows for repeated cycles of bacterial invasion 
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Figure 1.3: Uropathogenic Escherichia coli (UPEC) schematized lifecycle. 
The stages of bacterial invasion and invasion and morphological changes of the host tissue are depicted. Following 
invasion, UPEC rapidly replicate to produce intracellular bacterial communities (IBCs) and the host tissue response 
is to proliferate, thicken and then exfoliate P1 cells. Luminal bacteria can then re-infect underlying differentiating P2 
cells to establish quiescent intracellular reservoirs (QIRs) by 2 weeks post infection that can serve to seed recurrent 
UTIs. The host tissue can also resolve without the presence of QIRs. Adapted from Hunstad and Justice 2010.
for an extended period (6-48 hours) before IBC clearance from the bladder [73, 80].
The host response to an advancing intracellular infection is to remove the P1 cell layer 
in an attempt to try and clear out the infection [6, 78, 99, 100]. This occurs concomitant with 
proliferative activation of the P3 cell layer [31-33]. Removal of the infected P1 cells exposes the 
underlying P2 cells, which are rapidly differentiating and up regulating expression of UPs, and 
are susceptible to bacterial infection [25, 32]. Bacteria that invade P2 cells can remain quiescent 
in a protected intracellular niche, termed quiescent intracellular reservoirs or QIRs [32, 35, 101]. 
The hyperplastic urothelial layer initiates differentiation to replace the lost P1 cells, while innate 
immune cells work to clear extracellular bacteria [76, 98]. Thus, even after acute infection is 
resolved and the urothelium is seemingly intact, bacteria can remain in the bladder tissue until 
future conditions encourage emergence from this state, which allows P2 cells to play a major role 
in propagation of long term or recurrent UTIs.
Together these data show that UPEC have a complex and complicated pathogenic lifecycle. 
UTIs cause tissue inflammation and P1 cell exfoliation that is compensated for by initiation of P3 
cell proliferation and P2 cell differentiation to try and maintain barrier function. These murine 
models have provided us with a wealth of information, but how host-pathogen interactions lead to 
pain, the motivating factor for treatment, and P3 cell-mediated regeneration are not fully understood 
and will be explored in this thesis. 
ii) Lipopolysaccharide (LPS) Induced Inflammation Model
 Gram negative bacteria, like UPEC, display the defining characteristic of an outer 
membrane rich in lipopolysaccharide (LPS). The toll-like receptor (TLR) family recognizes a 
variety of bacterial products, including LPS [102, 103]. LPS, or endotoxin, is a major pathogen-
associated molecular pattern specifically recognized by TLR4 [104]. TLR4 is present in the AUM 
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and is expressed by resident and recruited innate immune cells, such as macrophages and PMNs 
[105-108]. Recognition of LPS by TLR4 also requires several accessory proteins including CD14, 
MD-2 and LPS binding protein [103, 109, 110]. TLR4 is necessary for bacterial invasion of P1 cells 
[106] but TLR4 activation also utilized by the host for cAMP-mediated bacterial exocytosis [96]. 
One of the end results of TLR4 signaling induction is the production of cytokines and chemokines, 
notably IL-6, IL-1β and TNF-α, that recruit innate immune cells to the site of infection [111-
116]. Acute LPS stimulation of the bladder leads to an innate response predominated by PMNs 
(Figure 1.4), whereas chronic LPS stimulation leads to a preponderance of monocyte/macrophage 
recruitment [117]. Therefore, LPS is a useful tool to investigate the role of inflammation without a 
preponderance of cellular damage in various tissue responses.
iii) Cyclophosphamide Induced Inflammatory Injury Model
An alternative chemical model used to induce bladder inflammation with cellular damage is 
cyclophosphamide (CYP) [118]. It has been previously used to investigate the effects of urothelial 
denuding on AUM regeneration, taking up to 28 days for full recovery [119]. CYP treatment 
induces a hyperplastic urothelium [120], similar to UPEC treatment. CYP treatment is administered 
intraperitoneally, which leads to inflammation and cytotoxicity not just of the bladder but also 
within other organs such as the lungs [121]. CYP can also be used to decrease the rate of skin 
healing through decreased recruitment of fibroblasts and deposition of collagen [122]. Clinically, 
CYP is a chemotherapy agent but has a well characterized side-effect of inducing hemorrhagic 
cystitis [123]. Gross hematuria is the visible presence of blood in the urine, while microhematuria 
is the microscopic presence of red blood cells in a urine sample. Greater than 90% of patients 
treated with CYP experience microhematuria [123]. This side effect can be mitigated in rodent 
models by supplementation of inducible nitric oxide synthase (iNOS) inhibitors or NO scavengers 
[124], suggesting that NO and iNOS are important for urothelial cell injury, similar to the urothelial 
response to UPEC [125-128]. Although UPEC and CYP have similar urothelial responses, injury 
due to CYP is not localized to the bladder and can result in conditions that confound experimental 
results and therefore will not be utilized in this thesis. 
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Figure 1.4: Schematic representations of bladder injuries. 
UPEC injury results in PMN recruitment and P1 cell exfoliation. Injury from SDPS results in P1 cell sloughing without 
inducing innate immune cell recruitment. Administration of LPS to the bladder lumen results in PMN recruitment 
without inducing urothelial cell damage.
iv) Protamine Sulfate (PS) Induced Urothelial Stripping Model
UPEC injury to the bladder to two fold, cellular damage results from P1 cell removal and 
inflammation from recruitment of innate immune cells. To investigate mechanisms important in 
either cellular damage or inflammation, models that solely generate either are needed. Protamine 
sulfate (PS) is a highly cationic polypeptide used clinically to reverse the effects of heparin [129]. 
Urothelial injury from single dose PS (SDPS) results from an increase in permeability due to an 
increase in the AUM conductance. The change in conductance results from an inward flow of 
positive ions such as potassium and sodium and anions of chloride and gluconate [130, 131]. P1 
cell stripping rapidly follows without inducing evidence of histological inflammation [32, 33, 
132]. 
Due to the urothelial increase in permeability to ions, SDPS has previously been used to 
model ion-related sensitivity increases in BPS/IC-related dysfunction [51, 133, 134]. Furthermore, 
Rajasekar et al., identified a cytotoxic factor in normal urine that increases urothelial permeability 
to potassium in vivo thereby leading to passive increases to infused potassium to the underlying 
nerves [135]. However, these studies focused on the functional relevance of increased potassium 
on bladder sensitivity after SDPS or urothelial injury. It is not known if removal of the P1 cells or 
disruption of the AUM directly contributes to an increased sensitivity to non-painful stimuli, like 
bladder filling. 
SDPS has also been used as an injury model to strip P1 cells and analyze the proliferative 
response of the urothelium (Figure 1.4). Unlike UPEC injury, SDPS was found to activate 
proliferation of the P2 cell layer [32, 33, 136]. This activation reaches a maximal plateau at an 
intravesical dosage of 20mg/ml [33]. It is currently unknown how SDPS preferentially activates 
the P2 layer and this question will be address in my thesis. 
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V. Bladder Responses to Infection/Damage
i) Nociceptive Response: A Distention-Induced Bladder Pain Model
Painful conditions, like UTIs and BPS/IC, display molecular profiles consisting of 
inflammatory mediators that vary from one individual to another [137, 138] and few clinical 
studies focused on urinary cytokines have been conducted [139, 140]. Understanding the cellular 
and molecular mechanisms underlying pain sensitization in response to urothelial injury and 
inflammation is necessary for generation of effective treatments for management of chronic and 
debilitating bladder pain. A model in which to assess the effect of various injuries on bladder pain 
and the resulting inflammatory profiles is also warranted.
Ness and colleagues have previously established a mouse bladder pain model where the 
nociceptive (pain) response is quantified by the visceromotor response (VMR) to distention [141-
144]. This model takes advantage of bladder distention being known to reliably produce pain and/or 
discomfort in humans [145]. The VMR displays a graded response to increasing bladder distention, 
is blunted by analgesic administration, and is enhanced by administration of inflammatory agents 
[143]. The VMR also has been used to reliably measure hypersensitivity in a CYP-induced bladder 
inflammation model [146]. An alternative method for measuring pain is by quantifying tactile pelvic 
sensitivity to von Frey filament stimulation [147]. Utilizing von Frey relies on the quantification of 
subject withdrawal from a noxious stimulus (i.e. prodding of the abdomen) instead of measuring 
the inherent pelvic muscle contraction response to natural bladder cycles of filling and voiding. 
Thus, the distension-evoked VMR has been validated as a measure of pain and represents a useful 
model for examining how different injuries to the bladder affect distention induced bladder pain, 
such as that induced during UTIs or BPS/IC.
One potential molecular mediator of painful bladder stimuli is glutamate signaling through 
metabotropic glutamate receptor 5 (mGluR5). Glutamate can mediate transmission of nociceptive 
information from the periphery (including visceral organs) to the central nervous system [148-
150]. mGluR5 is expressed throughout the nervous system and demonstrates a pro-nociceptive 
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role [149, 151, 152] by increasing hypersensitivity to mechanical and thermal stress [153-155]. 
Administration of antagonists of mGluR5, such as fenobam, can eliminate or diminish inflammatory 
induced hyperalgesia [151, 156, 157] thus suggesting a role for mGluR5 in inflammatory injury 
induced pain. However, little is known about the role of mGluR5 in mediating inflammatory or 
non-inflammatory bladder pain.
ii) Proliferation Response: BMP and Other Signaling Pathways Important in Bladder 
Renewal
The P3 layer is poised for rapid induction of proliferation as it is in direct contact with the 
basement membrane allowing it to first receive signals that arise in the mesenchyme to regulate 
urothelial responses to injury. Signaling pathways that are critical during embryonic development 
and known contributors to stem cell regulation in other tissues, such as hair follicles and the intestine 
[158-161] have been identified to play important roles in regulating the urothelial regeneration 
response to injury [7]. The study by Mysorekar et al., identified for the first time a number of 
key signaling molecules important for tissue response to an infectious insult (including bone 
morphogenetic protein 4 (BMP4), Hedgehog (Hh), Wnt, Notch and heparin sulfate proteoglycans). 
Furthermore the BMP4, Hh and Wnt signaling cascades have been found to be required for P3 cell-
mediated proliferation in response to infectious injury [32, 33] and will be discussed below.
Bone morphogenetic proteins (BMP) are members of the TGF-β superfamily of secreted 
signaling molecules and frequently acts as a negative regulator of proliferation or differentiation 
[160, 162-166] although the result of BMP signaling is largely context, dose and time dependent 
[159, 167-169]. Canonical BMP signaling activity initiates at the plasma membrane of the target 
cell, with ligand binding inducing hetero-dimerization of type I and type II receptors that leads to 
serine/threonine kinase activity to activate intracellular receptor Smad proteins [167, 170-172]. 
Smads 1/5/8 are targeted by BMP type I receptors, whereas Smads 2/3 are activated by TGF-β 
ligands [172]. Activated receptor-Smads then recruit the co-Smad, Smad-4 in order to translocate 
into the nucleus and initiate transcription of target genes (Figure 1.5).
BMP ligands are differentiated from TGF-β molecules based on the number of cystine 
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residues within a conserved region of the mature ligand [170, 172]. Structural differences between 
TGF-β and BMP type I receptors also help to prevent cross-activation and this signaling specificity 
is assisted by TGF-β ligands exhibiting higher avidity with their receptors than BMPs [172]. Thus, 
BMP signaling is generally more promiscuous. BMP molecules are regulated in a variety of ways 
including: ligand processing, ligand sequestration and gradient formation by Chordin, Noggin and 
extracellular matrix proteins [168, 170, 173]. Modulation of BMP signaling activity can occur 
at a variety of steps including: activation or inhibition of inhibitory Smads (Smad-6 or -7) [171, 
174], degradation of activated receptor Smad:co-Smad complexes [175] or through integration 
of signaling crosstalk with members of other pathways such as Hh, Wnt and MAPK (reviewed in 
[176]). 
BMP4, a member of the BMP signaling family, is expressed in mesenchymal cells 
surrounding the Wolffian duct in the developing urinary tract, and may act as an inhibitory factor to 
limit the sites of ureteral branch formation [163]. It is also expressed by the bladder mesenchyme 
underlying the urothelium as early as embryonic day 11.5 [177]. This expression is maintained in 
adult bladders and is modulated by infection, as BMP4 mRNA levels rapidly decline during the 
early phases of UPEC infection [7]. There are multiple flavors of BMP receptors and BMP4 can 
bind to and signal through either type I receptor, BmpR1a or BmpR1b [178] but only BmpR1a is 
expressed in the urothelium and expression is unaffected by injury [7]. 
Previous investigations into the effects of abrogated BMP4 signaling on urothelial injury 
response from UPEC infection have identified a reduced yet sustained proliferative response 
of P3 cells, aberrant proliferation of P1 cells, and a delay of terminal differentiation within the 
renewing urothelium [32]. Terminal differentiation defects were attributed to BmpR1a mediated 
dysregulation of p27kip1, a cyclin-dependent kinase inhibitor important for cell cycle arrest [179]. 
BMP4 is also a known downstream target of Hedgehog signaling [176, 180] which may result in 
epithelial-mesenchymal crosstalk between the two pathways [176, 177]. 
Activated Hedgehog (Hh) signaling occurs upon ligand binding that allows de-repression 
of the receptor patched by smoothened, to permit downstream signaling mediated by Gli proteins 
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Figure 1.5: BMP signaling through activation of receptor and co-smads.
Homodimerized BMP ligands induce heteromeric type I and type II receptor complex formation and phosphorylation 
activation. Intracellular receptor smads (R-Smad 1/5/8) are phosphorylated and form heteromeric complexes with Co-
Smad 4. This receptor complex translocates to the nucleus and binds to BMP response elements to control target gene 
expression in a cell specific manner. Transcriptional regulation requires various co-factors, such as other interacting 
transcription factors or co-activators like p300/CBP. Adapted from Itoh et al., 2000.
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[181]. The ligand, Shh, is expressed by the urothelium and Gli1 expression is found in the 
mesenchymal and muscle layers [33]. Investigations into the molecular mechanism governing 
bladder regenerative response to infection identified that after injury Shh expression by P3 cells 
increased leading to enhanced mesenchymal Gli1 activation and indirectly impacted urothelial 
regeneration by downstream activation of Wnt signaling [33].
 Canonical Wnt signaling, which is mediated by β-catenin, is an important regulator in 
limb development and can act downstream of BmpR1a signaling [182]. These signaling pathways 
(BMP, Hh, Wnt) work in concert to modulate P3 cell mediated urothelial and bladder renewal. 
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Interestingly, growth factor signaling dependence was only observed with infectious injury, as 
SDPS injury did not require BMP, Wnt or Hh signaling for proliferation nor BMP signaling for 
proper differentiation of P2 cells [32, 33]. I have included a study where I collaborated with Dr. 
Congxing Lin on examining the role of overexpression of Wnt pathway activity on the development 
of urothelial carcinoma, which is sex dependent (see appendix).
Together these results suggest an important role for growth factor signaling in mediating 
stem cell-like urothelial regeneration and cellular differentiation in response to infectious injury. 
Clues from SDPS injury suggest that the urothelium has distinctive regeneration responses. It 
remains unknown how the various aspects of infectious injury lead to activation of the P3 cells.
iii) Regeneration of the Barrier: A Role for Glycosaminoglycans, Estrogen and the 
Extracellular Matrix
The apical surface of the urothelium not only includes the AUM, but secretes a highly 
negatively charged glycosaminoglycan (GAG) layer whose nonspecific anti-adherence effect 
protects the bladder from infection by potentially inhibiting UPEC from binding to and invading 
P1 cells [183]. Normal physiological changes in GAG composition or thickness may render the 
bladder more vulnerable to invasion by bacteria by impacting the level of their anti-microbial 
adherence activity [184]. In healthy women, AUM GAG levels can vary during the normal 
menstrual cycle and may be under hormonal regulation [185-187]. 
GAGs are not only present at the AUM but are major components of the extracellular 
matrix [188]. Changes to the composition of the GAG layer, through sulfation or elongation, can 
change the way the GAGs interact with various components of the extracellular milieu. Various 
GAGs, such as heparin sulfate proteoglycans, are known to regulate growth factor signaling [189-
191]. Our lab has recently identified a role for estrogen in regulating the thickness and composition 
of the AUM GAG layer both before and after UPEC infection [192]. Further work also identified 
that estrogen signaling can regulate the BMP-mediated urothelial response, possibly through 
extracellular matrix GAG-mediated regulation of BMP4 [101] suggesting that GAG composition 
can greatly impact the regeneration of the urothelium. A structural component of the bladder 
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extracellular matrix, β1-integrin, was found to be important in regulating bladder function. Mice 
deficient for β1-integrin displayed a mechanosensory phenotype characterized by over-active 
bladder and incontinence without disruption of urothelial architecture [193]. These results suggest 
that extracellular matrix components, and in particularly GAGs, can regulate the physiology and 
regeneration of the bladder. 
The negative AUM GAG layer is targeted for ionic inactivation by the cationic SDPS, 
thereby allowing increased permeability of ions to the underlying tissues [130, 131]. GAGs are also 
shed into urine at significantly higher levels in BPS/IC patients (n=34 patients, p<0.01) as compared 
to healthy subjects [194-196]. Multiple therapies have been tried to re-establish the GAG layer 
including heparin (a sulfated glycosaminoglycan [197]), pentosan polysulphate (a polysulfated 
polysaccharide with GAG-like qualities [198]) and hyaluronic acid (a soluble component of the 
GAG layer [199]). These treatments have proved to be minimally effective [49]. Not only are 
GAGs shed by BPS/IC patients, but their urine also contains an antiproliferative factor that inhibits 
the regeneration of urothelial cells in culture [200]. Thus, disruption of GAGs and cellular renewal 
may lead to sustained tissue injury and pain sensitization [133]. 
 Urothelial regeneration from infectious injury requires tightly regulated growth factor 
signaling. GAGs can regulate availability of growth factors and thereby regulate renewal. Recent 
investigations into the impact of infection on GAG regulation show that GAGs can influence 
infection –related sequelae but how changes in GAG composition impacts non-infectious injury 
renewal is still to be determined. This introduction will become part of the book chapter, “Infectious 
diseases – Urinary Tract Infections (bacterial)” in Pathobiology of Human Disease: A Dynamic 
Encyclopedia of Disease Mechanisms to be published by Elsevier in 2013.
VI. Key Questions Addressed in This Thesis
The goal of this thesis is to elucidate the host responses to different bladder injuries, 
focusing on bladder pain and urothelial regeneration as outcomes. To investigate the interplay 
between pain, damage and regeneration induced during UTIs, this thesis will dissect each injury 
modality into its component parts of cellular damage and inflammation. I will investigate the P2 
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and P3 cell-mediated mechanisms of urothelial renewal following cellular or inflammatory injury 
in the bladder. Secondly, I will identify the various bladder injuries that differentially modulate 
the nociceptive response to bladder distention. This thesis will work to understand how the host 
copes with bladder injury by investigating exfoliation, proliferation, inflammation and nociception 
responses.
The murine models of UTI, SDPS and LPS were used in Chapter 2 of this thesis to increase 
our understanding of how various injuries, which target different layers of the urothelium, affect 
nociception (pain) response in mice utilizing VMR. These profiles can be used to validate these 
injury models as painful stimuli and assist in future investigations to identify biomarkers of bladder 
injury and pain. In Chapter 3 we analyzed the role of mGluR5, a potential bladder pain mediator, 
through genetic and pharmacological manipulations. We wanted to identify the role for this receptor, 
expressed in the central nervous system, on inflammatory and non-inflammatory bladder pain. In 
Chapter 4 of this thesis we separated UPEC injury into its component parts to investigate whether 
increased levels of physical damage or solitary inflammation of the mesenchyme were sufficient 
to fully activate P3 cell layer proliferation. We also investigated if these various modes of injury 
would display a dependence on growth factor signaling, similar to UPEC injury, by utilizing a 
conditional knockout of BmpR1a signaling in the urothelium. Together, my thesis research has 
led to a new understanding of how the bladder reacts to injury in order to regenerate and also how 
injuries impact bladder pain. It extends our understanding of the pain, damage, and regeneration 
induced by uropathogenic Escherichia coli infection, and begins to tease apart which components 
of bacteria-induced injury are most important for each of the subsequent host responses.
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Abstract
Purpose: Bladder pain is a debilitating symptom of many urologic conditions, and there is no 
generally effective treatment. Abnormal urothelial turnover is common to multiple disease states, 
but the specific components of urothelial injury and the resulting molecular signals that lead to 
bladder pain are unknown. We examined mouse models of bladder injury induced by uropathogenic 
E. coli (UPEC), protamine sulfate (PS), and bacterial lipopolysaccharide (LPS) to identify cellular 
and molecular correlates underlying pain sensitization in response to the stimuli.
Materials and Methods: C57BL/6 female mice were given intravesicular PS, LPS or UPEC, and 
the impact of each on nociception was determined by measuring the evoked visceromotor response 
to bladder distention at 24 hours post inoculation. Levels of pyuria and tissue inflammation were 
examined by urinary cytology and tissue histology. Quantitative PCR and gene expression analysis 
were used to identify injury profiles associated with nociception.
Results: PS treatment was significantly analgesic upon bladder distention. PS-treated bladders did 
not exhibit pyuria or extensive tissue damage. PS injury was associated with a global decrease in 
expression of inflammation-associated genes. In contrast, UPEC injury significantly increased the 
nociceptive response to bladder distention. LPS treatment did not affect nociception. Finally, injury-
induced expression of inflammation-associated genes correlated with nociceptive responses.
Conclusion: PS treatment of the bladder is analgesic, tissue protective, and suppresses inflammatory 
cytokine expression normally associated with nociception. Additionally, the injury modalities that 
result in differential tissue response patterns provide an innovative method for identification of 
mediators of visceral pain.
Introduction
The bladder is the site of several urologic conditions, and abnormal urothelial turnover 
is common to multiple painful disease states including bladder pain syndrome/interstitial cystitis 
(BPS/IC) and urinary tract infections (UTIs). BPS/IC and UTIs share the common clinical feature 
of increasing pelvic pain upon bladder filling (distention) leading to urinary frequency and urgency, 
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with bladder pain being the most frequent reason for physician visits [1]. BPS/IC affects 3-6% of 
women in the US [2]. UTIs, caused primarily by uropathogenic E. coli (UPEC), affect 13 million 
women each year [3].
 Urothelial cell sloughing and defective urothelial barriers characterize patients with 
recurrent/chronic UTIs and BPS/IC. Disruption of the normally impermeable urothelial barrier leads 
to tissue injury and pain sensitization [4]. Although the urothelium is recognized as a nociceptive 
(pain)-sensing structure that modulates and transmits noxious stimuli through mediators such as 
cytokines and ATP [5, 6], it is unclear how damage to each tissue layer of the bladder affects pain, 
and the specific molecular components generated by urothelial tissue injury that lead to bladder 
pain are unknown. 
The urothelium exhibits a remarkable ability to renew in response to environmental insults 
(e.g., pathogens and cytoinjurious factors). Intriguingly, the regenerative responses to injury 
modalities are distinct [7]. A murine model of bladder injury resulting from UPEC infection leads 
to urothelial barrier damage and inflammation within 24 h [7]. Urothelial regeneration following 
infection is fueled by a rapid activation of stem and early progenitor cells [7]. In contrast, 
intravesicular treatment with protamine sulfate (PS), a highly cationic peptide that causes increased 
ionic permeability of the urothelium and chemically exfoliates urothelial barrier cells within 12h 
of instillation, does not induce inflammation [7, 8]. Rather than activating urothelial stem cells, 
PS-induced injury appears to activate epithelial repair via transiently amplifying cells [7]. 
We used these two well-characterized models of urothelial damage to dissect the cellular 
and molecular mechanisms underlying pain sensitization in response to injury and inflammation. 
We report a striking protection from distention-induced bladder pain upon PS injury, which is 
in contrast to the nociceptive response triggered by UPEC infection. Urine cytology and tissue 
histology show that PS treatment protects against pyuria and distention-induced tissue damage. 
Finally, we identified a molecular profile of globally down-regulated inflammatory cytokines 
with an increase in transient amplifying cell signatures, thus providing novel insights into the 
mechanisms of nociception and PS-induced analgesia. 
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Materials and Methods
Mice
All animal experimental protocols were approved by the Washington University Institutional 
Animal Care and Use Committee. Female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME), 
9-13 weeks old were used for all experiments. Animals were housed on a 12-hour light/dark cycle 
and allowed ad libitum access to food and water. 
Intravesicular inoculations
UTI89, a pathogenic Escherichia coli strain, was grown statically in Luria-Bertani (LB) broth for 
17 h at 37 oC. 50 µl of PS (10 mg/ml in water; Sigma, St. Louis, MO) or 107 colony-forming units 
(CFU)/mL bacterial suspensions in saline were intravesicularly administered [7, 9]. Littermate 
controls received 50 µl of sterile 1x saline (Fisher, Waltham, MA). Inflammatory damage was 
induced with lipopolysaccharide (LPS) (50 µl, 100 µg/ml LPS from E. coli strain 055:B5, Sigma) 
by intravesicular inoculation once a day for four days [10]. Littermate controls received a four-
day administration of 50 µl of 1x sterile saline. After intravesicular administration, the catheter 
was removed, and all animals were maintained under isoflurane anesthesia for 10 minutes before 
spontaneous waking. 
Visceromotor Response (VMR) analysis
At 24 hours post last inoculation (hpi), animals were lightly anesthetized under isoflurane and the 
visceromotor response (VMR) of each animal was recorded. Visceral nociception was quantified 
by an electromyographic recording of the abdominal muscle response to bladder distention as 
described previously [11-13]. For each distention, the VMR signals were subtracted from the 
baseline, rectified, and integrated over 20 seconds to quantify the area under the curve. 
Tissue preparation and inflammation scoring 
Immediately following completion of VMR analysis, mice were sacrificed, and bladder and kidney 
tissues were aseptically removed. Tissues were fixed in methacarn (60% methanol, 30% chloroform, 
10% glacial acetic acid), embedded in paraffin, sectioned, and stained with hemotoxylin and eosin. 
Photomicrographs were taken using a Hamamatsu NanoZoomer HT (Hamamatsu Corporation) 
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and observed in a blinded fashion to score the level of tissue damage and inflammation using 
a modified semi-quantitative scoring system [14]: 0, normal; 1A, subepithelial edema without 
cellular infiltrate; 1B, subepithelial inflammatory infiltration (focal and multifocal); 2, edema and 
subepithelial inflammatory infiltration (diffuse); 3, marked subepithelial inflammatory cells with 
necrosis and polymorphonuclear neutrophils (PMNs) in and on bladder mucosal epithelium; 4, 
grade 3 criteria plus inflammatory infiltrate extends into muscle; 5, loss of surface epithelium 
(necrosis with full thickness inflammatory infiltration).
Urine collection, urine sediment, and bacterial titer analysis
Urines were collected prior to intravesicular treatment, at 6 hpi, 24 hpi, and twice during the VMR 
analysis. Urines collected prior to VMR were obtained as previously published [14]. During VMR 
rest periods, catheterized animals had gentle pressure applied to the skin just below the occiput, 
and voided urine was gathered by pipet and transferred to sterile tubes. “Non-noxious pressure” 
(<30 mmHg distention) and “noxious pressure” (>40 mmHg) urines were collected per mouse 
and pooled. Urine sediments were obtained as previously detailed [14], fixed for 15 minutes in 
acetic acid/alcohol, and Papanicolaou stained following manufacturer’s instructions (PROTOCOL 
brand, Fisher). Photomicrographs were taken using a Nikon Eclipse E800 microscope (Japan) and 
analyzed using Image J (NIH). Stained urine sediments were examined and scored in a blinded 
manner by light microscopy on a 0-4 scale, where 0 indicates <1 and 4 indicates >20 PMNs/high-
powered field as previously described [14]. Pre-treatment urines exhibited no evidence of superficial 
cell sloughing or pyuria prior to intravesicular instillations. Bladder infection was confirmed by 
spotting serial dilutions of urine on LB agar plates and quantifying CFUs after overnight growth 
at 37 ºC.
DNA Microarray inflammatory gene profiling
Total cellular RNA was isolated (RNeasy kit, Qiagen) from whole mouse bladders at 3 hpi, 6 hpi 
(for UPEC), and 3 hpi, 6 hpi, 24 hpi, and 48 hpi (for PS); (8-12 week old female mice, 10 animals/
injury/time point, n=2 independent experiments). cRNAs were generated from pooled RNAs 
and used to interrogate U74 (UPEC) and 430 2.0 whole mouse genome GeneChips (Affymetrix) 
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were determined. All such GO terms were plotted in Figure 2.5C-E.
Real time quantitative RT-PCR (qPCR)
Total cellular bladder RNA (TRIzol isolated following manufacturer’s protocols) was pooled (5-7 
animals, 6-11 week old females) from mice at 3.5 hpi, 6 hpi and 24 hpi. cDNAs were reverse 
transcribed, assayed in triplicate, and gene expression changes were determined using the ΔΔCt 
method (normalized to 18s rRNA, and then to saline treated mice) as described [7, 16]. Primer 
sequences (listed in Table 1) were obtained from the qPCR PrimerBank public database [17]. 
Statistical analysis
VMR measurements (mean ±SEM) were analyzed by 2-way ANOVA with Bonferroni post-hoc 
analysis. Inflammation scores were analyzed using two-tailed Mann-Whitney U-tests (where 
appropriate) comparing injuries to their respective controls.
Results
PS is analgesic on distention VMR assay
We hypothesized that various injuries to the bladder architecture and the respective 
renewal responses may have differential effects on the pain-like response to bladder distention. 
We have previously used the visceromotor response (VMR) to reliably measure hypersensitivity in 
a chemically-induced bladder inflammation model, demonstrating that the VMR is potentiated by 
inflammation (mustard oil, cyclophosphamide, and zymosan) and inhibited by analgesics (morphine 
and intravesicular lidocaine) [11-13]. The abdominal VMR is measured as the electromyographic 
signals of the external oblique muscle. Behaviorally, it corresponds to abdominal withdrawal and 
nocifensive guarding when an animal experiences pain while its bladder is distended. Therefore, 
the VMR is a surrogate measure of distension-evoked visceral nociception and represents a useful 
model for examining how different injuries to the bladder affect distention-induced bladder pain. 
24 hours prior to VMR testing, mice were given intravesicular UPEC, PS or saline (control). 
As expected, UPEC infection significantly increased the evoked response to bladder distention 
when compared to controls (Figure 2.1A). In contrast, PS treatment resulted in a significantly 
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as previously published [7]. Genes and Gene 
Ontology (GO) terms that were enriched in each 
treatment were determined using dChip and 
GOurmet software [15]. To identify GO terms 
increased following PS treatment, enriched 
genes were associated with GO terms. GO terms 
that increased by >25%, and represented >3% of 
the genes expressed at one or more time points 
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FIGURE 2.1: PS injury was analgesic for bladder 
distention in female mice. 
A. Female mice were administered saline, PS, or UPEC 
intravesicularly prior to VMR. PS-treated animals 
showed a significantly blunted VMR curve (+++p<0.0001) 
compared to saline controls with 70 and 80mmHg pressures 
(###p<0.0001) eliciting statistically significantly decreased 
VMRs. UPEC-infected animals had a significantly higher 
VMR curve (***p<0.0001) compared to saline controls, 
and sensitization was seen at the highest pressures of 
distention (70 and 80mmHg, **p<0.001). B. Female mice 
administered LPS or saline four times over four days had 
no significantly different VMR. The data is presented 
in arbitrary units as mean ±SEM, and p-values were 
determined by 2-way ANOVA with Bonferroni’s post-hoc 
test. VMR experiments and analysis were performed by 
L.W.C.
decreased VMR when compared to controls (Figure 2.1A). To determine whether the differential 
effect was due to the absence of an inflammatory response in PS injury, we treated a separate 
cohort of mice with intravesicular LPS every 24 hours for 4 days, a regimen previously shown to 
elicit an inflammatory response [10]. Multi-dose LPS injury did not significantly alter the VMR 
when compared to mice similarly treated with saline (Figure 2.1B).
PS does not induce pyuria
To track urothelial injury and the impact of distention on injury profiles, urine was 
collected for sediment analysis. Saline treatment did not induce injury as measured by cytology 
(Figure 2.2A-B, G-H). UPEC injury has been shown to result in formation of intracellular bacterial 
communities (IBCs) by 6 hpi. These are shed into the urine along with neutrophils (PMNs) as part of 
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FIGURE 2.2: Representative urine cytology images of PAP stained urine sediments of control, and PS, UPEC or 
LPS injured mice show that pyuria was not induced by PS treatment. 
A-B & G-H. Saline-treated controls showed minimal urothelial cell sloughing (highly kertanized vaginal cells are 
brown). By 6 hpi, both UPEC (E) and LPS (I) injuries displayed pyuria whereas PS (C) did not. IBCs were found 
throughout UPEC urines (E&F). Black arrows depict PMNs and white arrows demark IBCs. K. Urinary inflammation 
scores from PS- (n=6), UPEC- (n=10), saline- (n=8), x4 LPS- (n=6), and x4 saline- (n=4) treated animals. Bars 
represent median score values.
the host response [14]. Accordingly, we identified IBCs and PMNs in urines from UPEC-infected 
mice (Figure 2.2E-F). Analysis of urines from PS-treated mice showed minor cell sloughing prior 
to distention (Figure 2.2C-D). LPS injury resulted in PMN recruitment by 6 hpi without associated 
loss of superficial cells (Figure 2.2I-J). Urine sediments scored for inflammation at time points 
post injury revealed that UPEC injury lead to sustained pyuria (urinary inflammation), whereas PS 
treatment did not (Figure 2.2K). LPS injury resulted in acute pyuria, which was resolved prior to 
VMR (Figure 2.2K).
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PS induces hematuria at noxious pressure
Hemorrhagic cystitis is frequently induced upon toxic chemical or infectious instillation 
into the bladder [18]. We observed gross and microhematuria in urines and sediments from the 
majority of PS-injured animals (Figure 2.3D, 4/5, 80%), which was not evident in urines prior to 
pathologic bladder distention (Figure 2.3C). The incidence of hematuria from infectious injury 
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FIGURE 2.3: Representative urine cytology images of PAP stained urine sediments from control and injured mice 
reveal that noxious distention induced hematuria in PS injured mice. 
A, C, E. Distention-induced sloughing of superficial cells from all animals. At noxious distention pressures (>40 
mmHg), hematuria was induced in control (B) and PS (D) treated animals. G. Individual PS- (left) or UPEC- (right) 
treated animals showed an inverse correlation between the levels of pyuria (urine inflammation score) and hematuria 
(urine RBC score). Dotted lines partition individual animals’ scores from one another. L.W.C. collected all noxious 
urines.
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FIGURE 2.4: Histological analysis demonstrated that 
PS injury protected against distention induced damage. 
A. H&E of normal bladder histology without injury 
or distention. B. Saline treated bladder after distention 
showed edema and superficial cell disruption (inset). 
C. PS treatment prevented exacerbated superficial cell 
loss or edema due to distention. The urothelium and 
stromal compartment appeared almost normal, with no 
infiltration of immune cells (inset). D. Edema and major 
urothelial barrier disruption occurred in UPEC-infected 
bladders after distention. Immune cells were evident 
in the stromal and urothelial layers (black arrowheads, 
inset). Dotted boxes denote area depicted in insets. E. 
Tissue inflammation scores from control (saline n=12; 
x4 saline n=4) and injured (PS n=6; UPEC n=9; x4 
LPS n=5) animals after distention. Bars represent 
median score values. ***p<0.0001. Two-tailed Mann-
Whitney U-test comparing to saline controls. N.S. = Not 
Significant.
was far less prevalent (Figure 2.3E-F, 5/10, 50%). Saline treated animals exhibited hallmarks of 
distention-induced microhematuria (Figure 2.3A-B, 4/7, 57%). Moreover, we found that levels of 
hematuria and pyuria were inversely correlated in PS and UPEC injuries (Figure 2.3G). 
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PS protects against distention induced exacerbation of injury
To track architectural changes as a result of both distention and injury, bladders were 
collected immediately following completion of the VMR recordings. We found that control 
animals displayed superficial cell loss and edema of the lamina propria upon distention (Figure 
2.4A-B). Interestingly, PS injury was not associated with extensive urothelial or stromal damage 
(Figure 2.4C) and displayed a relative lack of tissue inflammation (Figure 2.4E). In contrast, 
histological characterization of UPEC-injured bladders after distention revealed stromal edema, 
urothelial damage, and PMN influx (Figure 2.4D, inset) associated with significantly higher tissue 
inflammation scores (Figure 2.4E) when compared to saline-treated controls. 
PS suppresses proinflammatory response
The bladder and urothelium produce distinct pro-inflammatory cytokines and chemokines 
in response to inflammatory (e.g., CPX, LPS, substance P) and infectious injury [10, 14, 19, 
20]. Pro-inflammatory cytokines (e.g., IL-6, IL-1β) can also lead to pain hypersensitivity [21, 
22]. To determine how PS treatment regulates inflammation, we compared gene expression in 
bladders from mice treated with PS to mice infected with UPEC. UPEC infection lead to increased 
expression of genes with ‘inflammation/immune response’ GO terms, whereas PS down-regulated 
the expression of those genes (Figure 2.5A-B) [15]. Nearly 10 % of all genes enriched by UPEC 
at 6 hpi were characterized by the GO term ‘inflammatory response’, whereas only about 0.1 % of 
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those enriched in the PS at 48 hpi were characterized as having ‘chemokine activity’, indicating 
that the molecular signatures of bladder responses to PS were distinct from those induced by 
UPEC infection. 
Microarray analysis following PS injury revealed an increase in expression of genes that 
function in tissue renewal mechanisms (Figure 2.5C-E). At early time points (6 h and before, 
Figure 2.5C), genes related to signaling and cell adhesion were elevated, and by 12 h, GO terms 
like ‘DNA replication’ and ‘cell cycle’, which characterize transient amplifying cells but not stem 
cells, were induced (Figure 2.5D). 
We further confirmed these results by identifying multiple gene expression profiles that 
correlated between injury and its respective nociception response by qPCR (Figure 2.5F-I and 
Table 2.1). UPEC injury triggered an up-regulation of the early pro-inflammatory cytokines, IL-1β 
and IL-6, and of Socs3, a negative regulator of IL-6. Furthermore, infection with UPEC resulted in 
down-regulation of the anti-inflammatory cytokine, IL-4, but PS treatment correlated with an up-
regulation of this cytokine. In contrast, PS injury resulted in down-regulation of IL-1β, IL-6, and 
Socs3 (Figure 2.5F-I). We have also identified molecular markers that were up-regulated by both 
UPEC and PS treatments or only regulated by UPEC or PS injury (Table 2.1).
Discussion
Here we report that different bladder injuries result in distinct alterations in nociception and 
provide several lines of evidence that this is due to differential effects on inflammation. We find 
that although UPEC infection causes increases in distension-induced pain responses, PS treatment 
reduces these responses. Our urine and tissue inflammation assays and gene expression analyses 
FIGURE 2.5: Global gene expression profiles after UPEC or PS injury reflected nociception trends. 
A. UPEC infection lead to a rapid global increase in gene expression associated with an inflammatory state by 6 hpi. B. 
PS injury resulted in a global decrease in pro-inflammatory gene expression by 24 hpi maintained through 48 hpi. C-E. 
PS treatment induced increases in various GO terms that peaked at 6 h (C, early), 12 h (D, mid), or 24 h (E, late). The 
genes peaking at 6 h were associated with cell cycling, whereas those at 12 h had to do with transiently amplifying cell 
populations. F-I. qPCR analysis confirms inflammatory profiles of UPEC and PS injuries, where the pro-inflammatory, 
pro-nociceptive cytokines IL-1β (F) and IL-6 (G) were up-regulated by UPEC and down regulated by PS injury 
relative to untreated bladder. Socs3 was also up-regulated by UPEC and down-regulated by PS injury (H). Infection 
decreased mRNA expression levels of the anti-inflammatory cytokine, IL-4 (I) and PS injury up-regulated it by 24 hpi. 
Significant fold changes indicated by dotted line at ±2 fold. J.C.M. performed GO-term analysis. 
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all indicate that the pain modulation correlates with inflammation as a result of UPEC infection 
and suppression of inflammation by PS treatment.
 Chronic bladder pain is a debilitating condition that is often unresponsive to conventional 
pain medications. Injury-induced sensitization can result in acute pain that resolves, but in some 
instances can transition to chronic pain that persists even in the absence of ongoing injury [21]. 
Renewal after injury typically requires barrier restoration and resolution of inflammation [7]. The 
pathophysiology of conditions such as BPS/IC remains poorly understood. Underlying mechanisms 
include occult UTI, non-infectious idiopathic inflammatory changes of the bladder, or urothelial 
cell sloughing and regeneration. Patients can be divided into subsets based on these underlying 
mechanisms. BPS/IC symptom exacerbation (“flare up”) bears remarkable resemblance to recurrent 
UTI, with increasing bladder pain and urinary urgency, and in some cases, may be associated with 
subclinical UTI [23]. IC urine contains an antiproliferative factor that inhibits the regeneration of 
bladder epithelial cells in culture [6]. In BPS/IC and UTIs, disruption of the normally impermeable 
urothelial barrier by continued cell sloughing may further impede renewal and lead to exacerbated 
tissue injury and pain sensitization [4, 6]. 
The differential pain response to UPEC, LPS and PS stimuli could in part be explained 
by type of urothelial damage. Consistent with previous findings [11-13, 24], we find that UPEC 
infection results in visceral hyperalgesia and sensitization of nociceptive responses. UPEC infection 
appears to activate the nociceptive signals transmitted to the central nervous system; inhibition of 
a key receptor (mGluR5) in this pathway results in a blunted VMR to UPEC infection [13]. One 
explanation for this activation could be the potent inflammatory response induced upon infection. 
To better study the effect of inflammation on VMR activation, we simplified the complex 
host-pathogen interaction in infection by focusing on inflammation induced by the surface antigen 
LPS. Although adjuvant pre-treatment has been used to increase levels of inflammation [10, 20], 
we treated with LPS alone to mimic the naïve bladder’s response to bacterial products. In contrast 
to adjuvant administration, we found that LPS treatment, although displaying acute pyuria, is 
insufficient to induce changes in VMR. Our findings suggest that acute inflammation alone is 
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not critical to evoke bladder pain. Future work should focus on identifying how urothelial status 
affects the integration of signals important for nociception sensitization.
Although the presence of a foreign body within the bladder and other PS injury models 
have been shown to result in cystitis-like inflammation [25, 26], our PS injury model uses short 
catheterization and incubation periods and does not result in inflammatory cystitis [7]. We found 
that PS injury was analgesic upon distention and had improved bladder histology when compared 
to distended infectious injury and controls. This is the first report of urothelial injury eliciting 
analgesia, but the mechanism by which PS treatment is protective is unknown. 
Our microarray analysis revealed contrasting expression profiles in UPEC- and PS-treated 
bladders, consistent with the differential effects of UPEC and PS injury on VMR. UPEC infection 
resulted in increased pro-inflammatory gene expression changes within 3-6 hours, consistent with 
molecular changes preceding urothelial stem cell (USC) activation [7, 16]. In contrast, we detected 
decreased expression of inflammatory-related genes 24 hours after PS injury. We confirmed the 
suppressed immune response after PS injury by qPCR, focusing on multiple pro-inflammatory 
and pro-nociceptive cytokines. Expression of IL-1β, a pro-inflammatory, pro-nociceptive cytokine 
that regulates the expression of other inflammatory cytokines, and is produced by the bladder in 
response to inflammatory injury [19, 22], was decreased in PS injury, but increased following 
UPEC infection. Expression of the pro-inflammatory cytokine IL-6 was similarly affected [14, 
21, 27]. Conversely, we observed decreased expression of IL-4, a prototypical anti-inflammatory 
cytokine, in UPEC-infected mice but increased expression following PS injury.
PS injury revealed an increase in renewal mechanisms initiating from transient amplifying 
regulation rather than USC activation [7].  It is possible that injuries, such as UPEC infection, that 
activate stem cell-mediated renewal might amplify a feed-forward loop that leads to enhanced 
nociception, whereas injuries like PS that do not activate stem cell-mediated renewal do not 
contribute to increased nociception. Therefore, this combination of suppressed immune response 
and transient amplifying renewal could be contributing to the mode of PS injury-induced analgesic 
action. 
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Conclusions
We report that various injuries to the bladder lead to differential effects on distention-
induced nociception. PS injury leads to a decrease in global inflammatory profile expression, is 
analgesic in a model of bladder distention, and decreases the level of injury from distention as 
compared to controls. Our PS injury model provides a new avenue to understand analgesia and 
how pain is sensed in the bladder. 
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Abstract
Background: Bladder pain syndrome/interstitial cystitis (BPS/IC), is a severely debilitating 
chronic condition that is frequently unresponsive to conventional pain medications. The etiology 
is unknown, however evidence suggests that nervous system sensitization contributes to enhanced 
pain in BPS/IC. In particular, central nervous system plasticity of glutamatergic signaling involving 
NMDA and metabotropic glutamate receptors (mGluRs) has been implicated in a variety of chronic 
pain conditions. Here, we test the hypothesis that mGluR5 mediates both non-inflammatory and 
inflammatory bladder pain or nociception in a mouse model by monitoring the visceromotor 
response (VMR) during graded bladder distentions. 
Results: Using a combination of genetic and pharmacologic approaches, we provide evidence 
indicating that mGluR5 is necessary for the full expression of VMR in response to bladder distention 
in the absence of inflammation. Furthermore, we observed that mice infected with a uropathogenic 
strain of Escherichia coli (UPEC) develop inflammatory hyperalgesia to bladder distention, and 
that the selective mGluR5 antagonist fenobam [N-(3-chlorophenyl)-N’-(4,5-dihydro-1-methyl-4-
oxo-1H-imidazole-2-yl) urea], reduces the VMR to bladder distention in UPEC-infected mice. 
Conclusions: Taken together, these data suggest that mGluR5 modulates both inflammatory 
and non-inflammatory bladder nociception, and highlight the therapeutic potential for mGluR5 
antagonists in the alleviation of bladder pain. 
Introduction
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a serious and painful condition of 
unknown etiology that affects 3-6% of women in the United States [1, 2]. The major clinical 
symptom of BPS/IC is pain upon bladder filling (distention) leading to urinary frequency and 
urinary urgency [3]. The current available treatments are often ineffective and do not treat the 
underlying pathology. Rodent bladder-injury models that induce some of the symptoms observed 
in BPS/IC have been used to evaluate potential treatments for BPS/IC [4-9]. One injury model, 
bacterial cystitis (urinary tract infection, UTI) is known to cause a similar constellation of symptoms 
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as observed in BPS/IC (i.e. urinary frequency and urgency [10-12]). In addition, bacterial cystitis 
can be modeled in rodents through bladder exposure to uropathogenic Escherichia Coli (UPEC) 
[13, 14]. Bladder infections due to UPEC are responsible for approximately 80% of UTIs in 
otherwise healthy women [15, 16]. Understanding the underlying molecular mechanisms of both 
non-inflammatory bladder pain and inflammatory bladder pain due to UPEC infection could lead 
to the development of novel treatments for painful bladder infections as well as for BPS/IC and 
possibly other visceral pain conditions. 
Glutamate is the predominant excitatory neurotransmitter in the mammalian nervous system 
[17-19]. Glutamate mediates its effects through two major classes of glutamate receptors: ligand-
gated ionotropic receptors (iGluRs) and G protein-coupled metabotropic glutamate receptors 
(mGluRs). Among the metabotropic glutamate receptors, one subtype, mGluR5, is of particular 
interest in the context of pain conditions. mGluR5 is expressed throughout the peripheral and 
central nervous system [20] and has previously been shown to have a pro-nociceptive role in a 
variety of somatic pain models [20-25] and some visceral pain models [26-28]. Specific to visceral 
pain models, mGluR5 was found to modulate gastroesophogeal and colorectal afferent sensitivity 
[26, 27, 29]. Based on this prior information, a previous study examined the ability of the mGluR5 
antagonist, MPEP (2-methyl-6-(phenylethynyl)-pyridine), to reduce bladder pain responses in 
naïve (uninjured) rats [30]. While this study suggests a potential role for mGluR5 in bladder pain, 
the evidence is based exclusively on the use of MPEP, which has recently been shown to act non-
selectively in vivo [31]. Thus, these intriguing initial findings are in need of validation. Furthermore, 
the role of mGluR5 in inflammatory bladder pain is unknown. Here, using a combination of 
genetic and pharmacological approaches we demonstrate that mGluR5 regulates both bladder 
nociception and normal bladder function in naïve mice. Furthermore, we observed an increased 
VMR to bladder distention in mice infected with UPEC. Finally, UPEC-induced hyperalgesia is 
reduced by treatment with the specific mGluR5 antagonist, fenobam. Together these data strongly 
support the hypothesis that mGluR5 is necessary for the full expression of inflammatory and non-
inflammatory bladder nociception and may be a relevant target for the treatment of bladder pain 
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arising from multiple pathologies, including BPS/IC. 
Materials and Methods
Subjects and ethical approval
All animal experiments were performed in accordance with the guidelines of the Committee for 
research and Ethical Issues of International Association for the Study of Pain [61]. The experimental 
protocol was approved by the Washington University Institutional Animal Care and Use Committee 
(St. Louis, MO). All experiments were performed on female mice aged 10-13 weeks. All mice 
were humanely euthanized at the end of the experiments by decapitation under deep isoflurane 
(5%) anesthesia. Female C57BL/6 mice used in UPEC experiments were purchased from The 
Jackson Laboratory (Bar Harbor, ME). For experiments involving mice lacking mGluR5 (mGluR5 
KO), animals were bred in-house on a C57BL/6 background and compared with wildtype (WT) 
littermates [50]. Unless otherwise indicated, all mice were group housed in cages of 3-5. All mice 
were kept on a 12:12-h light/dark schedule with ad libitum access to food and water. 
Drugs and other agents
Fenobam was purchased from Tocris Bioscience (Ellisville, MO), and is a specific negative 
allosteric modulator of mGluR5 [31, 38]. The dosage (30mg/kg, intraperitoneal) of fenobam 
was chosen because it was the lowest effective dose to induce analgesia in two mouse models 
of inflammatory pain, and had no effect on mGluR5 KO mice [31]. Fenobam was dissolved in 
100% dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO) on the day of the experiment. 
All intraperitoneal injections were 20µl. Throughout all experiments and analysis, the investigator 
performing the VMR was blinded to pharmacological treatment. 
Phasic bladder distentions and VMR measurements
Visceral nociception was quantified using VMR, an electromyographic (EMG) recording of the 
abdominal muscle response to bladder distention that has previously been validated as a measure of 
nociception [34, 62]. An example of the bladder-distention induced VMR of WT mice can be seen in 
Figure 1. Abdominal VMRs to urinary bladder distention were performed as described previously 
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[5]. The mice were anesthetized with 2% isoflurane, and chlorinated silver wire electrodes were 
placed on the superior oblique abdominal muscle. One was placed subcutaneously across the 
abdominal wall (as a ground) to allow differential amplification of the abdominal VMR signals. A 
lubricated 24G angiocatheter was inserted into the bladder via the urethra for bladder distention. 
After completion of the surgical preparation, isoflurane anesthesia was reduced to approximately 
0.9% until a flexion reflex response was present (evoked by pinching the paw) but spontaneous 
escape behavior and righting reflex were absent. Once a stable depth of anesthesia was obtained, 
the level was not changed for the duration of the experiment. The animals were not restrained in 
any fashion. Body temperature was monitored throughout the experiment and maintained using 
an overhead radiant light. Phasic bladder distention with compressed air was then used to evoke a 
VMR. The air pressure was controlled by an automated distention control device custom made in 
the Washington University School of Medicine Electronics Shop. The distention stimulus applied 
20 to 80 mm Hg pressure (10mmHg steps) for 20 seconds every 2 minutes. The VMR signal was 
relayed in real time using a Grass CP511 preamplifier (Grass Technologies, West Warwick, RI) to 
a PC via WinDaq DI-720 module (Dataq Instruments, Arkon, OH). These data were exported to 
Igor Pro 6.05 software (Wavemetrics, Portland, OR). Using a custom script, the VMR signals were 
subtracted from the baseline, rectified, and integrated over 20 seconds to quantify the area under 
the curve (see Figure 1). The VMR is presented in arbitrary units. 
After baseline responses to distensions 20mmHg-80mmHG (10mmHg steps) were recorded, 
the mouse was allowed to recover for at least 30 min (level of anesthesia remained unchanged). 
Following baseline recordings, the mice were given a 20ul IP injection of either fenobam (30mg/
kg, dissolved in 100% DMSO) or 100% DMSO (vehicle). A second set of bladder distentions 
(20mmHg-80mmHg, 10mmHg steps) was started 5 minutes following administration of fenobam 
or vehicle and completed within 45 minutes. The investigator who tested, processed and quantified 
the VMR was blinded to the drug treatment and genotype.
Infection with UPEC
Infection with a clinical UPEC isolate, UTI89, was performed as previously described [63]. Briefly, 
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mice were anesthetized with isoflurane and inoculated via transurethral catheterization with 50 
µl of 2-8x107 colony-forming units/mL of bacteria in phosphate buffered saline (PBS). Control 
mice (mock-infection) received 50ul of intravesicular PBS. Following intravesicular instillation of 
either PBS or UPEC, the mice were individually housed. Urine was collected at 6 and 24 hours, and 
infection was confirmed. At 24 hours post infection, the VMR response to bladder distention was 
recorded as previously described [5]. Following the VMR, isoflurane anesthesia was increased and 
the mice were euthanized by cervical dislocation. Bladder tissue was quickly removed and fixed in 
methacarn (60% methanol, 30% chloroform, 10% glacial acetic acid) [13]. The bladder tissue was 
then embedded in paraffin, sectioned and stained with hemotoxylin and eosin. Photomicrographs 
were taken using a Hamamatsu NanoZoomer HT (Hamamatsu Corporation). 
Urodynamics
Urodynamic recordings were performed as described previously [64]. Briefly, mice were 
anesthetized with subcutaneous urethane (1.2g/kg). A midline laparotomy incision was made, and 
the dome of the urinary bladder was exposed. The bladder dome was punctured with a 25-gauge 
needle. Intravesicular pressure was monitored continuously in vivo while the bladder was filled 
with room temperature saline at a rate of 0.04 mL per minute using a syringe pump (KD Scientific, 
New Hope, PA). Voiding was allowed to occur spontaneously via the urethra. The intravesicular 
pressure was recorded in real time using WINDAQ data acquisition program (DataQ Instruments, 
Akron, OH) at a sampling rate of 20 Hz. The intermicturition interval (IMI) was calculated as the 
average time (seconds) between peaks. The amplitude of contraction was the value (cmHg) of the 
peak. 
Results
mGluR5 is necessary for the full expression of noninflammatory bladder nociception
To assess bladder nociception in response to distension, we utilized the distension-evoked 
visceromotor response (VMR). The VMR is a spinobulbospinal reflex to bladder distention, 
increased in decerebrate mice/rats and absent in mice/rats with an acute mid thoracic spinal cord 
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FIGURE 3.1: Reduced 
visceromotor response to 
bladder distension in mGluR5 
knockout mice compared to 
wild type littermates. 
A. Representative VMR tracings 
from a WT and mGluR5 KO 
mice. As the intravesicular 
pressure is increased (20-
80mmHg), the EMG activity 
of the abdominal muscle 
(VMR) is also increased. The 
total amount of activity (area 
under the curve) during the 20 
second distention is calculated 
to determine the evoked 
response at each pressure. 
B. mGluR5 KO (n=18) mice 
have a significantly blunted 
VMR when compared to WT 
littermates (n=15) +/- SEM,* 
p<0.05, **p<0.01, ***p<0.001. 
2-way ANOVA with Bonferroni 
post-hoc test. There were no 
obvious histological differences 
observed between mGluR5 
KO mice (1D) and their WT 
littermates (1C). In both, the 
urothelium (above dashed 
line) has normal layers of 
superficial facet cells (arrows), 
intermediate cells (black 
arrowhead) and basal cells 
(white arrowhead). L.W.C. 
performed VMR measurements 
and analysis.
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FIGURE 3.2: The selective mGluR5 antagonist, fenobam, is analgesic in distention-induced bladder pain model. 
A. Treatment with the vehicle used to dissolve fenobam (100% DMSO) has no effect on the response to bladder 
distention. B. Treatment with an mGluR5 antagonist, fenobam, is analgesic in a bladder distention-evoked pain 
model. C&D. Fenobam and DMSO reduce the evoked response in mGluR5 KO mice. +/- SEM,* p<0.05, **p<0.01, 
***p<0.001. 2-way ANOVA with Bonferroni post-hoc test. L.W.C. performed VMR measurements and analysis.
transection [32-34]. Bladder distention reliably produces pain and/or discomfort in humans [35], 
and is frequently used in rodents as a visceral pain model [5, 30, 33]. To provide genetic evidence 
supporting a role for mGluR5 in bladder nociception, we tested the VMR to bladder distention in 
mGluR5 knockout mice (mGluR5 KO) compared to their WT littermates. Stepwise increases in 
bladder distension resulted in progressively larger VMR in wild type mice, as shown in Figure 
3.1B. Furthermore, mGluR5 KO mice showed a statistically significant decrease in the evoked 
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response to bladder distention (VMR) in the noxious range of pressures when compared to the 
VMR of WT littermates (p< 0.0001). 
There are several possible reasons that genetic ablation of mGluR5 could lead to the 
observed suppression of the VMR. Recent work has implicated the urothelium in the sensation 
of physical and chemical stimuli [36]. One possibility is that loss of mGluR5 could lead to 
anatomical changes in the bladder lining, thus altering the response to distension. We therefore 
examined histological sections from mGluR5 KO mice and their WT littermates. The absence of 
mGluR5 does not appear to impact bladder architecture, as the bladders from mGluR5 KO mice 
are histologically indistinguishable from WT littermates. The superficial, intermediate and basal 
epithelial cells are present (see Figure 3.1C and D) and the underlying mesenchyme and muscle 
layers also remain intact. Furthermore, the barrier formed by the superficial cells is normal as 
evidenced by Uroplakin III staining (data not shown) in both the WT and mGluR5 KO mice. 
Therefore, the absence of mGluR5 affects the response to noxious bladder distention but does not 
alter gross urothelial architecture. 
Compensatory changes in gene expression represent a potential confound to any experiment 
utilizing genetic manipulation. Thus, the robust phenotype observed in the mGluR5 KO mice 
could be the result of compensatory expression changes in other genes that have a role in bladder 
nociception. An acute pharmacological blockade of the receptor represents a potentially powerful 
approach to complement these findings from genetically modified mice. However, as mentioned 
above, the pharmacologic agent (MPEP) used in prior studies shows a clear lack of specificity in 
vivo [31]. To ask whether mGluR5 activation is acutely involved in distention-induced bladder 
nociception, we tested whether specific pharmacologic inhibition of mGluR5 with the selective 
antagonist fenobam [31, 37, 38], would suppress the VMR to urinary bladder distention. Systemic 
(intraperitoneal (IP)) administration of fenobam to WT mice resulted in a statistically significant 
reduction in the response to bladder distention compared to pretreatment baseline responses 
(Figure 3.2B, p< 0.0001), whereas treatment with vehicle had no statistically significant effect 
on VMR compared to baseline (Figure 3.2A). Thus, pretreatment with fenobam mimicked the 
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reduced nociceptive response to bladder distention that was observed in mGluR5 KO mice relative 
to their WT littermates (compare Figure 3.1A and 3.2A). We next evaluated the effect of fenobam 
on the VMR of mGluR5 KO mice. Surprisingly, treatment with either vehicle (DMSO) or fenobam 
caused a small but statistically significant decrease in the VMR evoked by bladder distention 
compared to baseline responses in mGluR5 KO mice (Figure 3.2C and D, p<0.001 and p=0.007). 
mGluR5 regulates intermicturition interval (IMI)
To test the role of mGluR5 in urodynamics, we compared the cystometry profile of mGluR5 
KO mice and their WT littermates. mGluR5 KO mice had a significantly increased IMI (212.3 
seconds versus 471.5 seconds, for WT and KO, respectively, p=0.0006) (Figure 3.3A-C). Despite 
the difference in IMI, the average amplitude of bladder contractions was not significantly different 
in mGluR5 KO mice relative to their WT littermates (Figure 3.3D, p=0.9215). 
To determine if the voiding behavior we observed in mGluR5 KO mice was the result of 
genetic ablation of mGluR5 or the result of compensatory changes, we acutely treated WT mice 
with fenobam or vehicle and measured the effect on urodynamics. While vehicle treatment had no 
effect on IMI (160.2 seconds versus 177.1 seconds, for baseline and vehicle (DMSO) respectively, 
p=0.66, Figure 3.4D), fenobam treatment increased the IMI when compared to the baseline IMI. 
The IMI before fenobam treatment was 182 seconds (n=8). After IP fenobam treatment, four of 
the eight mice stopped bladder cycling and micturition immediately (Figure 3.4C), while four of 
the mice had significantly increased IMI (481.3 seconds, p=0.031, Figure 3.4D and E). The mean 
time to resume bladder cycling and micturition after systemic fenobam administration was 18.6 
minutes. This suggests a tight coupling between mGluR5 activation and micturition cycling. The 
acute effect of the mGluR5 antagonist also suggests that the increased IMI observed in mGluR5 
KO mice is not likely due to developmental changes as a result of genetic ablation of mGluR5. 
UPEC infection results in changes in bladder histology and an increased VMR
Our results, together with previous studies [30, 39, 40] suggest that mGluR5 is involved 
in the mediation of micturition cycling and controls nociceptive responses during noxious bladder 
distention; however, the role of mGluR5 in inflammatory bladder nociception is unexplored. 
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FIGURE 3.3: mGluR5 KO mice have an increased intermicturition interval. 
A. Representative urodynamic profile of a WT mouse. B. Representative urodynamic profile of a mGluR5 KO mouse. 
A-C. The IMI in WT mice was significantly smaller when compared to mGluR5 KO mice (WT baseline IMI 212.3 
± 12.94 N=3, mGluR5 KO IMI baseline 471.5 ± 29.14 N=5). D. However, there was no difference in the bladder 
contraction amplitude. ***P<0.001 unpaired Student’s t-test compared to WT IMI. Data were collected by D.G.S. and 
analyzed by L.W.C.
We therefore used the UPEC model of bladder inflammation to examine the role of mGluR5 in 
inflammatory bladder nociception. We found that UPEC infection resulted in an increased VMR 
to noxious bladder distention when compared to mock-infected littermate controls (Figure 3.5A, 
p< 0.0001). Furthermore, in mice whose bladders had been distended, UPEC infection produced 
an increased infiltration of polymorphonuclear leukocytes observed throughout the full thickness 
of the bladder tissue (Figure 3.5B, arrowheads), as well as an increased tissue thickness of both 
the urothelium and mesenchyme compared to distended mock-infected mice (Figure 3.5C). 
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FIGURE 3.4: Fenobam treatment increases the intermicturition interval. 
A-C. Representative urodynamic profile of WT mice before and after treatment. An intraperitoneal (IP) injection with 
fenobam significantly increased the IMI in 4/8 mice treated (B,E), while 4/8 mice stopped cycling (C). In the mice 
that stopped cycling, the mean time to resume bladder cycling and micturition after IP fenobam administration was 
18.6 ± 5.0 minutes. The IMI was not significantly affected by IP DMSO (n=7) (A,D). *P<0.05 paired Student’s t-test 
compared to baseline. These data were collected by P.A. and analyzed by L.W.C. 
63
Noxious bladder distention combined with UPEC infection resulted in greater histological damage 
as measured by tissue inflammation scores when compared to mock-infected mice with noxious 
distention (data not shown) [41]. UPEC infection (alone and with distention) resulted in barrier 
disruption through a loss of superficial facet cells, while noxious distention alone had no effect on 
these cells and the barrier remained intact (arrows, Figure 3.5C). 
mGluR5 is necessary for the full expression of inflammatory bladder nociception
In mice with a UPEC-induced UTI, mice treated with vehicle had an increased VMR 
when compared to baseline (Figure 3.6A, p=0.0007). While vehicle treatment increased the VMR, 
treatment with fenobam resulted in a significantly reduced VMR when compared to pre-fenobam 
measurements (Figure 3.6B, p=0.0006). In contrast, vehicle had no effect on the VMR in mice 
mock infected (with PBS instead of UPEC, Figure 3.6C). In these control mice (mock infected), 
treatment with fenobam significantly reduced the VMR when compared to pre-treatment VMR 
measurements (Figure 3.6D). These results are consistent with those observed in WT mice (not 
mock-infected, Figures 3.2A and 3.2B). 
Discussion
Clinically, visceral pain is often treated as a variant of somatic pain under the assumption 
that one neurological mechanism may be responsible for both visceral and somatic pain [42]. 
However, conventional treatments for somatic pain are often ineffective in treating visceral pain, 
indicating significant differences between visceral and somatic pain [42, 43]. This is likely due, in 
part, to intrinsic differences between visceral nociceptors and non-visceral nociceptors (Reviewed 
in: [43-45]). Our results support this difference as we found that blocking mGluR5 activation 
resulted in a decreased VMR in the absence of injury. Whereas previous work has demonstrated 
that blocking mGluR5 activation has no effect on somatic pain in the absence of injury [31, 46]. 
 Although the role of mGluR5 in inflammatory bladder pain is unclear, a few reports have 
shown that mGluR5 antagonism can lead to analgesia in visceral pain models (acetic acid writhing 
and colonic distention) [23, 24, 27, 30, 37, 47-49]. A recent publication reported that an mGluR5 
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FIGURE 3.5: UPEC Infection results in 
histological changes and bladder hyperalgesia. 
A. 24 hour infection with uropathogenic E. coli 
(UPEC) increases the VMR to bladder distention 
when compared to mock-infected (PBS) 
littermates. B. Infection with UPEC results in 
an increased infiltration of polymorphonuclear 
leukocytes (arrowheads), and a sloughing of 
the superficial facet cells. C. Distention alone 
does not result in the loss of superficial facet 
cells (arrows,). +/- SEM *p<0.05, **p<0.01, 
***p<0.001. Unpaired 2-way ANOVA with 
Bonferroni post-hoc test. VMR measurements 
and analysis by L.W.C.
antagonist, MPEP, effectively reduced 
the nociceptive VMR to noxious 
distention of non-inflamed bladders in 
rats [30]. However, MPEP, has since 
been shown to have off-target effects, as 
it retains analgesic efficacy in mGluR5 
KO mice [31]. Thus, the precise role of 
mGluR5 in bladder distention-induced 
nociception remains unclear. Further, it 
is unknown whether mGluR5 activation 
has a role in the more clinically relevant 
condition of inflammatory bladder pain. 
In the present study, we demonstrate 
that mGluR5 is necessary for the full 
expression of distention-induced 
bladder nociception in naïve as well as 
UPEC-infected mice.
 Here, we demonstrate the importance of mGluR5 in non-inflammatory bladder nociception 
using both genetic and pharmacologic techniques. First, mice lacking mGluR5 have a significantly 
reduced response to noxious bladder distention when compared to their WT littermates. Despite 
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this dramatic effect, mGluR5 KO mice have no baseline motor deficiencies [50]. However, genetic 
deletion of mGluR5 could result in unpredictable upregulation or compensation of other genes 
involved in bladder function. Acute systemic treatment with a selective mGluR5 antagonist 
(fenobam) mimicks the blunted VMR observed in the mGluR5 KO mice, suggesting that the 
absence of mGluR5 activity accounts for the differences in VMR as well as the cystometric profile 
observed in mGluR5 KO mice. Together these data suggest that mGluR5 is necessary for the full 
expression of distention-induced bladder pain in naïve mice and highlight the therapeutic potential 
for mGluR5 antagonists in the treatment of bladder pain. 
Surprisingly, both fenobam and vehicle (DMSO) induced a small but statistically significant 
reduction in the distention induced VMR in mGluR5 KO mice. Fenobam at the dose used in this 
study was previously demonstrated to be specific to mGluR5 in vivo [31], and we do not believe 
that these results challenge that finding because fenobam but not DMSO, had an effect on the VMR 
of WT mice. Because both fenobam and vehicle significantly reduced the VMR in mGluR5 KO 
mice, we conclude that the vehicle is having effects in the KO that are not observed in WT mice. 
A possible explanation for the effects of the DMSO in KO but not in WT mice is that mGluR5 
KO mice are significantly smaller than their WT littermates [51]. DMSO has been shown to block 
peripheral C-fiber nerve conduction [52]. It is possible that the volume (20µl) delivered in relation 
to the weight of the mGluR5 KO mice leads to such a conduction block. 
The dramatic phenotype of mGluR5 KO mice as well as the significantly reduced pain 
response in fenobam-treated WT mice suggests that mGluR5 regulates bladder nociception. It is 
also possible that mGluR5 could regulate normal bladder function such as micturition. To examine 
the role of mGluR5 in normal bladder function, we examined the cystometric profiles of mGluR5 
KO mice compared to their WT littermates. Genetic disruption of mGluR5 significantly increased 
the IMI, but had no effect on the bladder contraction amplitude (pressure at which voiding occurred). 
An increased IMI suggests that mice lacking mGluR5 are able to urinate, but they tolerate higher 
bladder volumes (i.e. higher bladder distension) before voiding. Our results are consistent with 
previous work demonstrating a role for mGluR5 in the micturition reflex [30, 39, 40]. Importantly, 
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FIGURE 3.6: Treatment with an mGluR5 antagonist, fenobam, is analgesic in a UPEC infection-induced 
inflammatory bladder distention evoked pain model.
A. Treatment with the vehicle used to dissolve fenobam (100% DMSO) increases the evoked response to bladder 
distention (n=5) B. Treatment with fenobam significantly reduced the evoked response to bladder distention (n=7). 
C. Fenobam is analgesic in mice given intravesicular PBS (control) 24 hr prior to VMR testing (n=6). D. Treatment 
with the vehicle used to dissolve fenobam (100% DMSO) had no effect on mice treated with intravesicular PBS 
(control, n=6), +/- SEM,* p<0.05, **p<0.01, ***p<0.001. Paired 2-way ANOVA with Bonferroni post-hoc test. 
L.W.C. conducted VMR measurements and analysis.
mGluR5 does not appear to be involved in bladder development, as bladders of mGluR5 KO mice 
were indistinguishable from their WT littermates upon gross inspection. These results suggest that 
mGluR5 has a role in bladder sensation in naïve mice. 
Bladder infections due to UPEC are the most common reason that women see a doctor 
[11, 53]. This is the first evidence that infection with UPEC sensitizes mice to noxious bladder 
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distention. WT mice infected with UPEC had a greater VMR to bladder distention when compared 
to mock-infected littermate controls. These data are consistent with the finding that mice with a UTI 
have increased referred abdominal pain [54]. Furthermore, our results indicate that pharmacologic 
blockade of mGluR5 activation can reduce the VMR to bladder distention in UPEC-infected mice. 
The reduction in the distention-evoked VMR after fenobam treatment in mice infected with UPEC 
may be even larger than is apparent in Figure 3.6B, as the VMR is actually increased in vehicle-
treated mice (see Fig 3.6A). Because distention in combination with UPEC infection was more 
damaging to bladder histology than distention in mock infected mice, the increased VMR after 
vehicle is likely the result of injury induced by bladder infection in combination with repeated 
noxious bladder distention. Another, yet unlikely, explanation is that systemic DMSO might lead 
to bladder sensitization in mice with UPEC infection. 
Conclusions
Up to 85% of community-acquired UTIs are due to infection with UPEC [55, 56]. Standard-
of-care for a UTI is antibiotic treatment. However, in women with normal urological anatomy 
(uncomplicated UTI), UTIs are self-limiting [16]. Therefore, uncomplicated UTIs will resolve 
without antibiotic treatment. Despite this, the pain due to a UTI necessitates antibiotic treatment for 
symptomatic relief. Antibiotic use can lead to UTI recurrence by selecting for antibiotic resistant 
bacteria [16]. By treating the pain of a UTI rather than the infection, it may be possible to allow the 
UTI to take its natural course and become self-limited and reduce antibiotic-resistant reoccurrence. 
Based on our findings, we suggest that mGluR5 antagonists could be a useful for therapy for 
symptomology in UTI that could reduce antibiotic use.
Although less common, bladder pain in the form of BPS/IC is a serious and debilitating medical 
condition. Unfortunately for patients, no reliably effective treatment options exist. Previous work 
has suggested a role for mGluR5 in the CNS in distention-induced bladder pain [30]. However, 
the mGluR5 antagonist used in this study (MPEP) is analgesic in mGluR5 KO mice, suggesting 
off-target effects [31]. Here, using a combination of genetics and pharmacology, we demonstrate 
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that mGluR5 has a crucial role in the modulation of distention induced bladder nociceptive 
responses. Because in these studies mGluR5 was blocked systemically and knocked out globally, 
the anatomical localization where mGluR5 modulates bladder pain is undefined. In addition, 
mGluR5 is expressed throughout the peripheral and central nervous system [20, 21, 46, 57-60]. 
However, it should be noted that the mGluR5 antagonist, fenobam, readily and rapidly crosses 
the blood brain barrier [31]. Although it is undertermined if or where mGluR5 is upregulated in 
visceral pain, previous work has demonstrated a role for mGluR5 in the CNS and PNS in somatic 
inflammatory and neuropathic pain models [20, 31, 46]. Previous work has demonstrated that 
mGluR5 expression is upregulated in the CNS (specifically the central nucleus of the amygdala 
and the spinal cord) following peripheral inflammation [65, 66] and in the CNS PNS following a 
neuropathic pain model [67]. If the chronic pain experienced due to BPS/IC is also mediated by 
mGluR5, then antagonists of mGluR5 such as fenobam may be useful in treating chronic bladder 
pain. Antagonists of mGluR5 may have clinical potential for the treatment of both acute and 
chronic bladder pain. 
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CHAPTER 4: Cellular damage and inflammation are required to activate epithelial progenitor 
cell-mediated regenerative response in the urinary bladder
This chapter is in preparation for publication.
Stemler KM, and Mysorekar IU
K.M.S. performed all following experiments within this chapter.
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Abstract
Pathologic conditions of the bladder, such as urinary tract infections and bladder pain 
syndrome, are common and costly. Systematic damage to the various layers of the bladder and 
therefore models of the various aspects of these injury conditions are lacking. We have developed 
a progressive step wise injury model to the bladder which utilizes multiple doses of protamine 
sulfate (DDPS) to strip layers of the urothelium in order to assess mechanisms of bladder tissue 
renewal.
We found that DDPS injuries are capable of activating the basal urothelial cells to mediate 
regeneration of the damaged tissue. Furthermore, these injuries display cytokine profiles of an 
intermediate nature from other previously established bladder injury models. These results suggest 
that the bladder has a progressive renewal response to injury depending on severity, inflammation 
and duration. 
Introduction
The bladder, is the target of one of the most common infectious diseases, urinary tract 
infection (UTI), which affects 15 million women each year [1-3]. Chronic complex diseases such 
as bladder pain syndrome and interstitial cystitis also predominately afflict women [4-6]. These 
conditions have a high cost of treatment and negatively impact the quality of life [7-10]. UTIs 
alone cost $1.6 billion in treatment/physician visits in 1995 [11]. 
 Many conditions target the epithelial tissue lining the bladder (urothelium) leading to cellular 
damage and underlying tissue inflammation comprising of innate immune cell recruitment and edema 
[12-14]. The bladder is not without regenerative potential. Homeostatic turnover of the urothelium 
is at an almost imperceptible rate [15, 16], yet environmental insults, like UTIs, rapidly activate 
the basal layer containing long-term label-retaining cells to restore damaged tissue [17-19]. This 
layer of basal cells are mononucleated, undifferentiated, cytokeratin5+ Sonic hedgehog+Uroplakin- 
(P3 layer) and are capable of forming bladder spheres and organoids in vitro [17]. Above these 
reside mononucleated cells of intermediate differentiation expressing Uroplakin+P63+cytokeratin5- 
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markers (P2 layer). Finally, the P1 layer (Uroplakin+P63-cytokeratin5-) consists of differentiated 
multinucleated barrier cells that confer the high transepithelial resistance characteristic of this 
tissue [20, 21]. These disparate urothelial layers potentially have different functions within the 
context of bladder regeneration.
Previous work has shown that the bladder contains multiple renewal mechanisms depending 
on mode and severity of bladder injury [17, 22, 23]. Urothelial cells from the various layers were 
recruited to proliferate depending on the extent of barrier damage from cellular exfoliation and the 
presence of inflammation. A murine model of UTI utilizing a cystitis strain of uropathogenic E. 
coli (UPEC) activated P3 cells, whereas P2 cells proliferate after a non-inflammatory, cell damage 
injury induced by low dose protamine sulfate [23]. This injury stimulus was also identified to have 
a suppressive effect on cytokine induction [23, 24]. 
Multiple signaling pathways have been implicated in modulating the renewal response to 
injury including: BMP, Hh, Wnt and inflammatory cytokines [17, 23, 25]. Many of these were 
found to play a prominent role for regeneration in the infection model but not in the cellular damage 
model. Therefore we sought to determine why infection-induced injury uniquely leads to this 
distinct renewal profile and propensity to require stem cell associated signaling pathways for tissue 
regeneration. We developed dual dose protamine sulfate models, administering doses targeting 
various layers of the urothelium, to assess if extensive cellular damage without inflammation is 
sufficient for P3 proliferation. We also utilized bacterial endotoxin (lipopolysaccharide, LPS) that 
induces a mesenchymal inflammatory process without urothelial cell damage [26, 27] to evaluate 
if inflammation alone is sufficient for P3 activation. Lastly we assessed for a requirement in BMP 
signaling to mediate regeneration following these injuries. We hypothesized that P3 activation 
would require both cellular damage to the urothelium and an induction of inflammatory processes 
and that these injuries combined may explain why infection results in maximal P3 cell activation.
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Materials and methods
Mice 
All animal experimental protocols were approved by the Washington University Institutional 
Animal Care and Use Committee (Animal Welfare Assurance #A-3381-01). Animals were housed 
on a 12 hr light/dark cycle and allowed ad libitum access to food and water in a pathogen free 
facility. Female Bmpr1a conditional knockout and control mice were used for all experiments [28, 
29]. 
Induction of Bmpr1a CKO
Animals of the Bmpr1afx/fx;β-Actin-CreERT+ (CKO) and Bmpr1afx/fx;β-Actin-CreERT- (WT) genotypes 
were bred in house [23]. Conditional gene knockout (CKO) of the bladder was performed by 
instilling an emulsion of 4-hydroxy-tamoxifen (tamoxifen, TMX, Sigma-Aldrich, St. Louis, MO) 
in absolute ethanol:sunflower oil (Sigma). Three intravesical treatments of 50 µl of TMX were 
given to adult wild type (Bmpr1afx/fx; β-Actin-CreERT-) and CKO (Bmpr1afx/fx; β-Actin-Cre-ERT+) 
bitransgenic mice and allowed to rest one week prior to injury induction. 
Intravesicular injury inoculations
Bladder urothelial damage was stimulated by administration of two doses of the polycationic 
chemical protamine sulfate (PS, Sigma) twelve hours apart. 50 µl of 50 mg/ml followed by 50 µl 
of 50 mg/ml PS (DDPSlo) while 50 µl of 50 mg/ml followed by 50 µl of 200 mg/ml PS (DDPShi) 
injuries were administered in water intravesicularly to anesthetized animals. Littermate controls 
received two inoculations of 50 µl sterile 1x phosphate buffered saline (PBS, Fisher, Waltham, 
MA). Control and lipopolysaccharide (LPS, strain 055:B5, Sigma) injuries were induced as 
previously published [24]. Animals were culled at 3, 6, 24 hours post injury (hpi) or 2 weeks post 
injury (wpi).
Immunofluorescence analysis
Culled animals had bladders aseptically removed and fixed in methacarn (60% methanol, 30% 
chloroform, 10% glacial acetic acid). Bladders were paraffin processed as previously published 
[23]. 5 µm tissue sections were deparaffinized, rehydrated, and underwent sodium citrate antigen 
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retrieval prior to overnight incubation with primary antibodies. The following primary antibodies 
were used: mouse mAb to anti-human E-cadherin (1:500, BD Transduction Labs; San Jose, CA), 
rabbit pAb to anti-human Cytokeratin 5 (K5) (1:500, Abcam; Cambridge, MA), mouse mAb to 
anti-human Ki67 (1:500, BD Pharmingen; San Jose, CA), rabbit pAb to anti-human p27kip1 
(1:500, Sigma), mouse mAb to anti-bovine Uroplakin III (1:100, Fitzgerald; Acton, MA). Antigen-
antibody complexes were visualized using a panel of species specific secondary antibodies with 
AlexaFluor™ 488-, 594-, and 647-conjugated fluorophores (1:500, Invitrogen; Carlsbad, CA). 
Nuclei were counterstained with Hoechst 33358.
Proliferation analysis
Bladder sections from injuries and controls at each time point were co-stained with Ki67 and K5 
and imaged using a Zeiss Apotome microscope. 10 images per bladder were taken and enumerated 
with Image J (http://rsb.info.nih.gov/ij/) to quantify total Ki67+K5+ and Ki67+K5- cell populations 
per bladder.
Histologic tissue inflammation scoring 
5 um paraffin embedded tissue sections were stained with Hematoxylin & Eosin and imaged using 
a Hamamatsu NanoZoomer HT (Hamamatsu, Bridgewater, New Jersey). Micrographs were scored 
in a blinded fashion utilizing a semi-quantitative scoring system, where 0-normal and 5-loss of 
surface epithelium due to inflammatory mediated necrosis [30].
Immunoblotting 
Bladders from injured and control animals were isolated and total proteins extracted using RIPA 
buffer supplemented with 1 mM Sodium Vanadate (NaVO4, Sigma), 1 mM Sodium Fluoride 
(NaF, Sigma) and 1x Protease Inhibitor cocktail (Roche, Indianapolis, IN). Bladder lysates 
were quantified and loaded into 4-20% PAGE gels (Pierce Biotechnology, Rockford, IL) then 
transferred to nitrocellulose or PVDF membranes. Membranes were immunoblotted using the 
following primary antibodies: goat pAb anti-human BMPR-1A/ALK-3 (1:500; R&D Systems; 
Minneapolis, MN), mouse mAb anti-human Cytokeratin 5/6 (1:1000; Millipore; Billerica, MA), 
mouse mAb anti-mouse p27Kip1 (1:1000, BD Transduction Laboratories; San Jose, CA), rabbit 
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mAb anti-human Gapdh (1:1000, Cell Signaling; Boston, MA), mouse mAb anti-human BMP-4 
(1:500, R&D Systems; Minneapolis, MN), goat pAb anti-human UP1a (1:1000, Santa Cruz 
Biotechnology; Dallas, TX) and followed by secondary antibodies: donkey anti-goat IgG HRP 
(Santa Cruz; Dallas, TX), goat anti-Mouse IgG HRP (Santa Cruz), goat anti-Rabbit IgG HRP 
(Santa Cruz). Protein bands were developed using SuperSignal West Dura Extended Duration 
Substrate (Thermo Scientific, Waltham, MA) and quantified by Image J (http://rsb.info.nih.gov/ij/) 
relative to loading control and noninjured animals.
Real time quantitative RT-PCR (qPCR) 
Bladders from WT and Bmpr1afx/fx;β-Actin-CreERT+ (CKO) mice treated with LPS or DDPShi 
(2-3 animals per group) were removed at 6hpi. The urothelium was physically removed from 
the underlying laminia propria using fine forceps to generate urothelium and mesenchyme preps. 
Total RNA from urothelium or mesenchyme was isolated using the RNeasy Mini Kit (Qiagen; 
Germantown, MD) and was followed by DNaseI (Ambion; Austin, TX) treatment to remove 
genomic DNA. cDNA synthesis was performed using Superscript II RNase H reverse transcriptase 
(Invitrogen) with 1ug total RNA. Expression of BMP, GAG and immune related genes were 
detected by quantitative real-time PCR using a CFX96 Touch Real-Time PCR Detection System 
(BioRad; Hercules, CA) and SsoAdvanced SYBR Green Supermix (BioRad; Hercules, CA) 
according to manufacturer’s instructions. Changes in gene expression were determined using the 
ΔΔCt method, by normalizing each sample to 18s ribosomal RNA (control gene) and then to levels 
of the queried transcript in urothelium or mesenchyme RNA prepared from mock injured mice 
(control treatment). Primer sequences were obtained from the qPCR PrimerBank public database 
(http://pga.mgh.harvard.edu/primerbank/index.html)[31].
Statistical Analysis 
2-tailed Mann-Whitney U-tests were performed where appropriate utilizing GraphPad Prism 5. 
P-values  below 0.05 were considered significant.
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Figure 4.1: DDPS injuries resemble SDPS injury.
A. 24 hpi histology shows DDPS injuries lead to urothelial damage with minimal innate immune cell influx. 
B. Tissue inflammation scores of non-injured PBS treated and DDPSlo and DDPShi injured animals. Median levels of 
inflammation for each injury indicated. n = 2-3 animals per group/ time point. Scale bar = 100 µm.
Results
DDPS injury does not induce tissue inflammation
Previous work has shown that a single dose of protamine sulfate (SDPS) intravesically injures 
the bladder barrier by disrupting the terminally differentiated (P1) cells on the urothelium [23, 
32-36]. In contrast, UPEC injury damages the urothelium and through inflammatory processes, 
the underlying lamina propria and mesenchyme [23, 35, 37, 38]. Therefore, we wanted to develop 
injuries that could individually target different layers within the bladder. Utilizing dual dose 
protamine sulfate (DDPS) models (for more information see Material and Methods) we identified 
that a second course of PS treatment enhances damage to the urothelial barrier as evidenced by 
areas of urothelial detachment with DDPShi exhibiting the greatest levels of urothelial damage 
(Figure 4.1A). By 24hpi, DDPS results in large swaths of P1 cell removal, but also results in 
areas where the urothelium is detaching from the underlying mesenchyme (Figure 4.1A). Blinded 
tissue inflammation scores show that injured bladders experience minor inflammation upon DDPS 
instillation but the level is not different from saline treatment (Figure 4.1B) and supports previous 
observations of SDPS injury vs. saline [24]. These results suggest that DDPS injuries do not 
lead to a hyper-immune state, which is in contrast to UPEC injury, and therefore DDPS injury is 
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histologically similar to SDPS injury although with more severe urothelial damage.
Proliferation by injury: DDPSlo mimics SDPS and DDPShi partially mimics UPEC injury 
UPEC and SDPS injury recruit different cellular pools for urothelial regeneration [23]. We 
investigated proliferative activation of the cytokeratin 5+ (K5+) or cytokeratin 5- (K5-) cellular 
populations after DDPS injury by immunofluorescence. K5 is a marker of P3 cells in the urothelium 
and lie adjacent to the basement membrane [17, 23]. By 24 hpi, both DDPS injuries activate the 
K5+ and K5- layers of the urothelium (Figure 4.2A). However, proliferation indices show DDPShi 
results in an increased recruitment of K5+ cells to regeneration, more closely resembling a UPEC 
level of recruitment (Figure 4.2B). As SDPS injury initially targets P2 cell activation [23], we 
clearly identified that DDPSlo injury preferentially activates the K5- cell population (Figure 4.2C). 
Activation and regeneration of the bladder urothelium by 24 hpi in the K5+ or K5- layers occur 
concomitantly with an increase in the total number of nuclei per layer as compared to saline treated 
animals (Figure 4.2D-E), with the total number of K5+ cells from DDPSlo reflecting the SDPS 
model and DDPShi injury reflecting UPEC injury trends. It is possible that the DDPS induced low 
level of inflammation could impact the proliferation, but we do not see any correlation between 
low levels of inflammation and P2 or P3 cell layer activation (Figure 4.2F-G). These data suggest 
DDPSlo injury activates the urothelium in a similar pattern to SDPS, by predominantly targeting 
the K5- cell population, while DDPShi injury overcomes a reliance on K5- cell activation in order 
to recruit the K5+ population in a similar fashion to UPEC injury. These results also suggest that 
extensive urothelial damage without drastic inflammatory cell recruitment is sufficient to activate 
the K5+ cells of the urothelium. Therefore, we have injuries that titrates damage to the urothelium in 
order to assess the impact of urothelial damage and layer activation on molecular requirements. 
Naïve mice sustain low level inflammation from nonpathogenic LPS injury
Bladder instillation with nonpathogenic derived LPS does not result in a hyper-immune response 
[24]. We further investigated levels of tissue damage and activation from LPS injury extending 
to later time points. These animals displayed minimal to no damage to the urothelial barrier but 
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Figure 4.2: DDPShi injury is sufficient for P3 cell proliferation. 
A. Representative immunofluorescent micrographs of control and DDPS injured animals co-stained for Ki67 and K5 
at 24 hpi. B-C. DDPS proliferation indices at multiple time points of P3 (A) and P2 (B) cell layers in comparison to 
SDPS and UPEC at 24 hpi. D-E. Total nuclei counts within P3 (D) and P2 (E) cell layers showing DDPSlo similarities 
to SDPS and DDPShi similarities to UEPC at 24 hpi. F-G. Cell layer activation by inflammation score. Neither DDPS 
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injury displays a correlation between level of mesenchymal inflammation and proliferation of either P3 (F) or P2 (G) 
urothelial tissue layers. All time points were pooled for urothelial activation by inflammation score. Graphs plotted 
as mean ± SEM. Arrowheads indicate Ki67+K5- cells and arrows indicate Ki67+K5+ cells. Dotted line demarcates 
basement membrane. Scale bar = 50 µm. n = 2-3 animals per group/ time point.
instead exhibited acute edema and inflammation in the adjacent mesenchymal and lamina propria 
layers (Figure 4.3A) as previously identified [24]. Inflammation scores display multiple rounds of 
nonpathogenic LPS injury does not result in severe inflammation, but low levels of inflammation 
are sustained over 2 wpi (Figure 4.3B). Proliferation indices show LPS injury is sufficient to only 
moderately activate the urothelial layers (Figure 4.3D-E). This activation does not result in a major 
increase in the number of K5+ or K5- number of nuclei. Levels of inflammation from LPS injury 
again were not associated with ability to activate the urothelium (Figure 4.3H-I). Together these 
results suggest that although inflammation is sufficient to induce proliferation, such low levels are 
not a major driving force behind urothelial activation.
BMP signaling is not required for urothelial response to DDPS injury
BMP4 signaling was previously identified to be required for proliferation of K5+ cells by UPEC 
injury [23]. Utilizing the same conditional knock out (CKO) mouse model, we administered DDPS 
injuries to assess the role of BMP signaling in DDPS injury renewal.
We do not see any impact of BMP status on histology or inflammation of the tissue after injury 
(Figure 4.4A,F). Furthermore, we noticed no impact of BMP signaling loss on proliferation indices 
of either DDPS injury for P3 or P2 cell populations (Figure 4.4B-C). Removal of BMP signaling 
also does not impact total nuclei number per urothelial layer (Figure 4.4D-E). Similarly there is no 
correlation between inflammation score of the tissue and tissue layer activation from DDPS injury 
(Figure 4.4G-H). These results suggest that regeneration after extensive urothelial damage does 
not require BMP signaling. Although DDPShi has the capacity to activate the P3 layer in a way 
similar to UPEC injury, this deviation from a requirement of BMP signaling suggests that multiple 
molecular mechanisms govern urothelial regeneration.
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Figure 4.3: Repeated LPS injury results in low levels of tissue inflammation and minor activation of urothelial 
proliferation. 
A. Tissue histology indicates the presence of innate immune cell infiltrate within the mesenchyme in LPS injured 
animals. Immune cell aggregates can be found by 2 wpi in LPS animals. B. Tissue inflammation scores of control and 
LPS injured animals indicate localized mesenchymal inflammation. C. Representative immunofluorescent micrographs 
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of control and LPS injured animals co-stained for Ki67 and K5 at 24 hpi. D-E. Proliferation indices of P3 (D) and 
P2 (E) cell layers show very low levels of urothelial activation after mesenchymal injury. F-G. Total nuclei counts 
within P3 (F) and P2 (G) cell layers. H-I. Cell layer activation by inflammation score. All time points were pooled for 
urothelial activation by inflammation score. Graphs plotted as mean ± SEM. Arrowheads indicate Ki67+K5- cells and 
arrows indicate Ki67+K5+ cells. Dotted line demarcates basement membrane. Scale bars = 50 µm.
Urothelial response to low levels of inflammation from LPS does not require BMP signaling
To assess if BMP signaling modulated activation of the urothelium by LPS injury, we administered 
multiple doses of LPS to CKO animals and assessed tissue activation and histology. BMP status 
did not affect LPS injury histology or inflammation (Figure 4.5A-B). Proliferation indices nor cell 
number were also not susceptible to BMP signaling reduction in LPS injury (Figure 4.5C-F). BMP 
status further does not relate tissue inflammation levels with the ability to activate the urothelium 
(Figure 4.5G-H). These results imply that low levels of inflammatory damage, although sufficient 
to moderately activate the urothelium, do not reflect a molecular requirement for BMP signaling. 
DDPS injury down-regulates inflammatory mediators
UPEC and SDPS injuries are molecularly distinct at a global level within the bladder [23]. Recently 
we have identified that UPEC injury sensitized the bladder to distention but in contrast, SDPS injury 
lead to an analgesic response and we partially attributed this analgesic phenotype to the global 
down-regulation of inflammatory mediators [24]. Biomarkers for infection severity, chronicity 
and immunization are being targeted for diagnostic and therapeutic purposes [39-42]. Therefore, 
we sought to identify if either DDPS injury has molecular biomarkers that were more similar 
to infection or SDPS previously identified profiles. By qPCR we assessed DDPSlo and DDPShi 
bladders at 6 hpi and found that similar to SDPS, IL-6 and IL-1β were down regulated (Figure 
4.6J). Investigation of infection chronicity markers shows that KC, MIP2 and TNFα were all 
down-regulated by DDPS (Figure 4.6H). Intriguingly, KC, MIP2 and TNFα were not regulated by 
SDPS injury [24]. These results suggest that although DDPSlo or DDPShi have similar histological 
profiles to SDPS, they exhibit an intermediate molecular profile, seeming to impact inflammatory 
mediators not originally targeted by SDPS injury.
 To confirm immunofluorescent analyses, immunoblots of DDPShi at 24 hpi show a reduction 
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Figure 4.4: BMP signaling is not required for DDPS injury repair. 
A. There is no evident histological enhancement of DDPS injuries with loss of BMP signaling by 24hpi. B-C. 
Proliferation indices of P3 (B) and P2 (C) cell layers shows similar proliferation trends as WT DDPS injured animals. 
D-E. Total nuclei number of each urothelial layer is not impacted by loss of BMP signaling. F. Tissue inflammation 
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scores of CKO DDPS injured animals indicate no change in inflammatory tissue response with loss of BMP signaling. 
G-H. Cell layer activation by inflammation score shows no correlation between CKO injured animal inflammation 
score and proliferative activity of P3 (G) or P2 (H) tissue layers. All time points were pooled for urothelial activation 
by inflammation score. Graphs plotted as mean ± SEM. Scale bar = 100 µm. n = 2-3 animals per group/ time point. 
in the levels of BMPR1A (Figure 4.6A-B). A downstream target of BMP signaling, which is 
important in UPEC injury repair, is P27kip1[23]. Levels of P27kip1 were found to be unchanged by 
DDPS injury or BMP status after DDPS injury (Figure 4.6A,C). We were intrigued to see the large 
increase in P3 nuclei number after DDPShi injury; therefore we measured the levels of K5/6 and 
identified an injury related increase in K5/6 protein levels (Figure 4.6D-E). DDPS injury led to 
a moderate decrease in UP1a levels in WT animals (Figure 4.6D, F). These results confirm that 
DDPS injury increases the P3 cell layer while physically removing cells from the urothelial layer.
GAG modification is disrupted by DDPS injuries 
Estrogen status and infection can modulate glycosaminoglycan (GAG) thickness and modification 
in the bladder [22, 43]. The GAG layer is an important component of the extracellular matrix (ECM) 
and through changes in the extracellular milieu, it is possible to regulate growth factor binding, 
sequestration, and mobility [44-46]. We measured the expression levels of various GAG synthesis 
enzymes by qPCR that were previously identified to be regulated either by estrogen, infection or 
both [22] and found that DDPS injuries lead to general changes in regulation of GAG modification 
enzymes including Hs6st2 and Hs3st6 (Figure 4.6I,K), which are known to contribute to regulation 
of BMP signaling [47-49]. The differences between whole bladder and urothelial only expression 
of inflammatory cytokines or modulatory GAG enzymes (Figure 4.6J,K) indicate contribution 
from mesenchymal and muscle layers to whole bladder signaling after injury. These results suggest 
that extreme urothelial damage can change the composition of the ECM and therefore can impact 
multiple signaling pathways and multiple tissue layers involved in bladder renewal.
LPS injury impact on the urothelium
Pathogenic LPS injury leads to a large host of molecular changes to the bladder [26, 27]. We 
therefore assessed the bladder’s response to nonpathogenic LPS by qPCR and western blots. We 
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Figure 4.5: Urothelial response to LPS does not require BMP signaling. 
A. Histology indicates no exacerbation of inflammatory phenotype with loss of BMP signaling. Innate immune cell 
aggregates are still visible by 2 wpi in LPS injured animals. B. Tissue inflammation scores display no enhancement of 
inflammatory injury with loss of BMP signaling. C-D. Proliferation indices of P3 (C) and P2 (D) urothelial cell layers 
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in CKO animals after LPS injury show no change in tissue response. E-F. Total nuclei counts within P3 (E) and P2 
(F) cell layers show no differences between control and injured animals. H-I. Cell layer activation by inflammation 
score. All time points were pooled for urothelial activation by inflammation score. Graphs plotted as mean ± SEM. 
Scale bar = 50 µm.
confirmed a 40% knockdown of BMPR1A in LPS injured CKO animals (Figure 4.7A,B) along 
with a 50% reduction in P27kip1 levels (Figure 4.7A,C). LPS injury alone to naïve mice does not 
lead to changes in BMP receptor prevalence or downstream signaling (Figure 4.7A-C), which is 
unlike UPEC injury that directly regulates BMP signaling [23]. However, LPS injury does impact 
P3 and P2 cell layers, as we saw about a 50% reduction in K5/6 and a 75% increase in UP1a (Figure 
4.7D-F). These changes are confirmed to not have a significant impact from BMP signaling. As we 
identified DDPS injuries as regulating GAG modification enzymes, we also wanted to investigate 
the potential impact of a low level inflammatory injury on these enzymes as well. Interestingly, 
at 6 hpi we identified enzymes that are both up and down-regulated by LPS injury whereas by 24 
hpi the GAG enzymes were all down-regulated, including BMP signaling related Hs6st1/2 (Figure 
4.7G). These results are in contrast to UPEC profiles at 6 and 24hpi that mostly show up-regulation 
of GAG modifying enzymes. Nonpathogenic LPS injury may therefore only provide a minimal 
stimulus to the bladder that is quickly shut off in the absence of any other immune modulation.
Discussion
Tissue renewal choice
The bladder has multiple avenues to utilize in order to restore the urothelial barrier after 
different modes of injury. Under infectious conditions, P3 basal cells contribute the majority of 
the proliferative response, whereas under cellular damage conditions without inflammation from 
SDPS the P2 intermediate cells are quickly recruited [17, 23]. These diverse cellular reactions 
lead us to the basic question, how does a tissue with multiple renewal mechanisms initiate an 
individual renewal response? How does the bladder sense the differences to a variety of insults in 
order to repair inflammatory versus cellular damage? We hypothesized that cellular damage and 
inflammation in concert would be the greatest injury stimulus to the bladder and would initiate the 
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Figure 4.6: DDPS injuries display signaling profiles that are intermediate between SDPS and UPEC.
A-C. Western blots (A) and quantification of BMPR1A (B) and P27kip1 (C) from control and DDPShi injury in 
WT and CKO animals. D-F. Western blots (D) and quantification of cytokeratin 5/6 (K5/6, E) and UP1a (F) from 
control and DDPShi injury in WT and CKO animals. G-K. Quantitative real-time PCR from urothelial only (H-I) 
preps or whole bladder (G,J-K) preps with DDPSlo or DDPShi injuries at 6 hpi. G. BMP signaling components are 
differentially regulated by DDPS injury. H. Cytokine predictors of infection severity are down regulated by DDPS 
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injuries although these cytokines are not targeted by SDPS injury. I. Glycosoaminoglycan (GAG) modification 
enzymes are differentially regulated by DDPS injuries. J. SDPS suppressed and pain-related cytokines are also down-
regulated by DDPS injuries. K. The GAG modifying enzyme Hs6st2, which is important in BMP regulation, is down-
regulated by DDPS injuries. 
most potent response. We sought to identify the injury mechanisms that were sufficient to activate 
the renewal response.
Our DDPShi injury model is similar to SDPS in gross histology, but it is capable of 
activating a robust cellular proliferative response similar to infectious injury while DDPSlo injury 
preferentially activates P2 cells. These results suggest that P2 cells are the first responders to 
cellular damage, as even DDPShi injury induces their proliferation. Either through direct or indirect 
mechanisms, P3 cells are capable of sensing extensive physical barrier injury and are recruited to 
assist in wound healing. Recent work on partial bladder cystectomy shows that all tissue layers 
respond to this massive inflammatory and cellular insult and concordantly proliferate [50]. These 
results further support our observations that severe injuries recruit multiple tissue layers to try and 
mitigate the damage and begin wound repair.
Within the skin, both hair follicle stem cells and inter-follicular epidermis stem cells are 
recruited to repair extensive excisional wounds [51, 52]. This is in contrast to the esophagus 
epithelium, where a single progenitor cell population is utilized both for homeostasis and for local 
injury repair [53]. This wounding response was found to occur in the absence of active immune 
cell recruitment [53] while others such as the colonic epithelium require innate immune cell 
participation for proper wound healing [54]. Together with our results, this suggests that the bladder 
does not require an innate immune response in order to initiate wound healing, but we cannot fully 
rule out the innate immune response for P3 cell activation as low levels of inflammation present 
are present after DDPS injury. 
Importance of the BMP signaling pathway
UPEC injury requires BMP signaling for both proper proliferative response and 
differentiation [23]. Our investigations utilizing BMP CKO animals with DDPS injury show 
that the molecular signals important for UPEC renewal are dispensable for physical injury. This 
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Figure 4.7: Mesenchymal injury from LPS molecularly impacts the urothelium. 
A-C. Western blots (A) and quantification of BMPR1A (B) and P27kip1 (C) from control and LPS injury in WT and 
CKO animals. D-F. Western blots (D) and quantification of cytokeratin 5/6 (K5/6, E) and UP1a (F) from control and 
LPS injury in WT and CKO animals. G. Quantitative real-time PCR from LPS injured whole bladder preps at 6 or 
24 hpi of GAG modifying enzymes from pooled samples (n=5-7) show expression changes based on mesenchymal 
inflammation.
observation could be due to a variety of possibilities; one that these molecular signals are not 
required for the initiation of DDPS injury renewal but could be required for sustaining/ maintaining 
regeneration. This seems unlikely as SDPS leads to restoration of the urothelial barrier without 
requiring BMP or Hh signaling [17, 23]. Two, DDPS injury may activate a completely different 
set of molecular mediators that result in the same cellular response. Although we cannot rule out 
this possibility, it seems likely that as SDPS and DDPS injury both suppress inflammation [23, 
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24] we suggest that sustained inflammation, as in infectious injury, may be required for BMP 
dependent P3 cell activation. Our nonpathogenic LPS injury only leads to low levels of sustained 
inflammation; however, this inflammatory model did not exhibit a requirement for BMP signaling 
to induce minor P3 cell proliferation. 
Role of ECM in bladder renewal
ECM regulation of BMP signaling is complex but both ligands and receptors interact with 
various components such as heparan sulfate proteoglycan or collagen IV in order to spatially or 
temporally regulate BMP signaling (reviewed in [46]). For example, in zebrafish development, 
laminin and HSPGs are required to establish the proper pattern of BMP responsive cells for myotome 
development by regulating BMP ligand availability [55]. Furthermore Smads, the downstream 
components of the BMP signaling pathway, can in turn regulate ECM and GAG production [56] 
indicating a delicate integration of a variety of signaling pathways for tissue homeostasis and 
therefore injury repair.
We therefore wanted to take a broader approach to DDPS injury renewal. Previously we have 
identified that estrogen signaling regulates both tissue homeostasis and the bladder’s response to 
infection. Estrogen deficient mice displayed delayed differentiation alongside a disrupted regulation 
of the glycosoaminoglycan (GAG) layer [22]. Investigations into regulation of GAG modifications 
after DDPS injury show a disruption of enzymes important for BMP signaling pathway regulation. 
It is possible that although DDPS injuries do not require BMP signaling for early regeneration, this 
disruption of BMP signaling could delay tissue differentiation [22, 23].
 Interestingly, the extra cellular matrix (ECM) seems to play a large role in the speed and 
type of injury repair. Work by Seifert and colleagues showed that during skin regeneration in 
Acomys mice that an abundance of type III collagen leads to non-fibrotic injury repair capable 
of even repairing full excisional ear punch wounds [57]. This is in contrast to Mus mice where 
a predominance of type I collagen contributes to scar formation [57]. Tissue repair function has 
also been related to a balanced ECM makeup, where age- and disease-related deterioration and 
imbalance is associated with increased inflammation, increased matrix metalloproteinase activity, 
93
increased type I collagen disposition and scarring, and decreased stem cell function [58-60]. 
Together these observations suggest a major role for the ECM and its composition in injury repair. 
It is possible that injury to the bladder leads to composition changes of the GAG layer and ECM 
in order to modulate signaling pathways, which is then relayed through the tissue layers to mediate 
the various cellular responses to injury. Together our observations of DDPS and LPS injuries 
suggest that urothelial injury response is dynamic and wound healing and regeneration depends on 
the type of insult.
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CHAPTER 5: Conclusions and future directions
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Conclusions
The goal of my thesis has been to better understand how the host responds to different 
bladder injuries. I used a two pronged approach, focusing both on how different injuries affected 
bladder pain and on how those different injuries induced regenerative responses. UPEC-induced 
UTI damage of bladder takes the form of inflammation and urothelial cell exfoliation. We have 
studied previously and in this thesis have shown that infectious injury leads to pain sensitization 
and P3 basal urothelial cell proliferation. I used different models of injury to separate inflammatory 
from exfoliation injury to test if either injury independently could cause similar damage as UPEC 
or if UPEC’s injury is specific. 
In Chapter 2, we showed that exfoliation injury from SDPS is analgesic in a distension-
induced model of bladder pain. Furthermore, SDPS globally suppressed immune activation by 24 
hpi. Although the mechanism of action for SDPS suppressed immune gene expression is unknown, 
it is possible that PS-induced P1 exfoliation removes the ability of this cell type to signal to 
underlying tissues [1, 2] and therefore indirectly regulates inflammatory or painful signals and thus 
contribute to analgesia. Inflammation from LPS was not sufficient to alter the response to VMR, 
although recent research suggests that inflammatory pain from LPS may be antigen specific [3].
 Chapter 3 investigated if UTI injury-induced pain could be regulated by mGluR5. We 
showed that this important regulator of nociception played a key role in increasing UTI pain, as 
inhibiting this receptor with the antagonist Fenobam decreased pain. Further studies have linked 
mGluR5 activity within the right central nucleus of the amygdala in regulating bladder nociception 
[4] suggesting that bladder pain can occur in absence of a bladder injury stimulus. 
 Finally Chapter 4 has further shown that extensive damage caused by DDPS can 
simulate UPEC-induced proliferative responses in absence of inflammation. We also confirmed 
that inflammation (from LPS) without damage to the urothelium is not sufficient to instruct the 
urothelium to proliferate. Yet unlike UPEC-induced urothelial activation, DDPS injury repair 
activation does not rely on growth factor signaling. We have thus begun to better define these 
forms of damage and the host responses. Together this work extends our understanding of the pain, 
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damage, and regeneration induced by UPEC infection, and begins to tease apart which components 
of bacteria-induced injury are most important for each of the subsequent host responses.
Bladder Injury Models
The urothelium does not respond individually but unitarily with the various bladder tissue 
layers. Changes to the urothelium can lead to directional signaling to the underlying layers [5-7]. 
Our LPS model shows that mesenchymal injury also has a molecular impact on the urothelium. 
Intravascular LPS instilment to immune sensitized mice leads to a large number of whole bladder 
gene transcription changes especially increases in inflammation related genes [8]. Pathogenic LPS 
alone can nociceptively sensitize animals [3, 9]. These results suggest that mode of injury may be 
an important determinant for urothelial regeneration.
As the bladder is the site of many conditions, the more models we have to investigate 
various aspects of these afflictions will assist in attempts to better understand them. A murine 
cystitis model [10] was developed that mimics the cytology of human cystitis [11]. Murine models 
of cystitis have allowed for the dissection of intracellular and extracellular lifestyles of UPEC 
[12-17] but have also uncovered key biomarkers for disease progression and severity [18, 19] that 
can be used as potential biomarkers for triage of human UTIs. Quiescent intracellular reservoirs 
were also identified in murine models [20], which are capable of seeding recurrent infections [21]. 
Recurrence of UTIs is a burgeoning clinical issue and multiple groups are investigating routs to 
a vaccine [22]. However, new injury models assist in the identification of future biomarkers for 
disease testing in human urine or biopsy samples.
Further development of bladder injury models has also identified discrete differences 
between various models that can be utilized to dissect the underlying bladder biology. Application 
of the murine UTI model to nociceptive measurements identified that the mouse model also 
exhibits a nociceptive sensitization to infection [3, 9, 23, 24] similar to symptoms in humans 
[25-27]. Surprisingly, cellular damage alone can lead to a decreased nociceptive profile [24], and 
recent work has identified that the urothelium acts as a sensing organ in order to mediate signals 
throughout the different tissue layers [2, 28, 29]. Therefore models, like our newly developed 
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DDPS injuries, that can target specific layers of the bladder are necessary to gain further insights 
into the biological workings of this neglected organ.
Future Directions
I. Further characterization of mouse injury models and translational research 
There have been limited efforts to integrate biological insights from preclinical benign 
bladder disease models and translate them to human disease for validation and for the rational 
design of therapies. Patients with noncancerous bladder diseases (UTIs, BPS/IC, overactive 
bladder (OAB)) frequently suffer from similar symptoms of urgency, frequency, dysuria, nocturia, 
idiopathic inflammation, urothelial defects, with debilitating pain being a discordant symptom [30]. 
In fact BPS/IC and OAB have many stages, are not mutually exclusive, and can have undefinable 
etiologies [31-33]. Since the clinical population is heterogeneous, diagnosis by invasive techniques 
(cystoscopic inquires and bladder biopsies) is costly and difficult. 
Murine injury models have been used in this thesis to track the cytopathology of bladder 
damage and to identify potential urinary biomarkers that share injury- and pain-related gene 
expression. Application of these injury model expression changes could be helpful in patient 
treatment stratification utilizing human urines. 
We will validate our murine injury model expression profiles using high-throughput 
cytokine measurements in human specimens. Luminex-based multiplex cytometric bead array 
assays (BioPlex, Bio-Rad, Hercules, CA) can measure up to 23 cytokines in pg/mL (normalized 
to urine creatinine) simultaneously from a small sample volume [34]. Although cytokine bead 
arrays may have lower sensitivity than ELISA, they are more suited for the detection of a panel of 
cytokines in a high-throughput fashion [35, 36]. We will utilize patient urine specimens (UTI, BPS/
IC, OAB, and controls, n=10 per group) collected for the Biodata, Biospecimen and Bioinformatics 
Grid of Benign Urological Diseases (BIGBUD) repository to identify disease-specific markers 
linked to the murine injury models. Based on the cytokine signature, we will characterize samples 
into 3 biochemical subgroups (UTI-like inflammatory profile, non-UTI-like inflammatory profile, 
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urothelial exfoliation and regenerative profile). Major targets for disease stratification can be 
confirmed by individual cytokine ELISA analysis. These cytokine profile analyses of the disease 
subgroups can be cross checked by utilizing a pairwise cytopathological analysis and matched 
tissue biopsy histologic analysis, similar to those used in the murine injury models in this thesis. 
Histologic analyses will allow us to correlate cellular expression or morphologic abnormalities 
with disease to set up delineated pathological phenotypes.
Disease management based on individual patient pathophysiology is difficult, but urine 
BioPlex analysis is a potential non-invasive technique to assist urological clinicians in defining 
disease parameters; making diagnosis simpler in the future. It can also help to potentially predict 
those at risk for progressive sequelae. Strengthening our understanding of how the urothelium 
decides to respond to various injuries will assist efforts to develop therapeutics to induce regeneration 
of the damaged tissue while decreasing the pain experienced from those injuries. These studies 
are ongoing in our laboratory under the auspices of a P20 program project on Interdisciplinary 
Research in Benign Urology.
II. Characterization of the effects of bladder injuries on micturition using cystometry
 One of the goals of this thesis has been to understand the impact of bladder injury on the 
behavioral outcome of pain. The correlation between bladder injury and its impact on the normal 
micturition function of the bladder is unknown. We have initiated infusion cystometry experiments 
to analyze the role of injury on normal bladder function. In collaboration with David Song in Dr. 
H. Henry Lai’s laboratory wild type animals will be injured with UPEC, SDPS or LPS or treated 
with their respective controls to characterize bladder hyperactivity (n = 7-10 animals/treatment). 
Injuries will be monitored by cytopathology as previously described in Chapter 1. At 24 hpi, female 
mice will be anesthetized with urethane (1.2 g/kg s.c.), a midline incision will be made to expose 
the dome of the bladder, and the bladder will be infused via a suprapubic tube at 0.04 cc/min. 
The intravesicular pressure will be monitored continuously via a 3-way connector as previously 
described [37]. We will measure inter-micturition intervals (IMI, a measurement of bladder activity 
[23]), basal pressures (a measurement of bladder tone), voiding contraction threshold pressures, 
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voided volumes, and micturition amplitudes (a measure of in vivo contractility) [38] of both injured 
and control groups. Experiments will be conducted in a blinded fashion and statistically analyzed 
by ANOVA with Bonferroni-corrected post-hoc tests. 
Infusion cystometry will allow us to gain better insights into altered bladder function 
following various injuries. We anticipate that the knowledge gained from these experiments will 
result in an additional publication describing the effects of injury on bladder dysfunction.
III. Convergence-extensions in urothelial regenerations and estrogen signaling
Molecular investigations utilizing a microarray approach into the host response to UTI at early 
time points after infection (1.5 and 3.5 hpi) identified various genes important for differentiation, 
proliferation, inflammation, stress response and cell-cell contacts. This approach identified canonical 
BMP4 signaling, non-canonical Wnt5a signaling, hyaluronan synthase (important in ECM/wound 
repair), and heparan sulfate D-glucosaminyl-3-O-sulfotranferase-1 (HS3ST1, important for HSPG 
biosynthesis) as being modulated by infection [39]. HSPGs are known to interact with and regulate 
growth factor signaling (reviewed in [40]).  Intriguingly, HS3ST1 expression was increased by 6 
hpi, which may potentiate decreased BMP4 signaling deficiencies that occur during infection and 
may result in a more hospitable bladder environment for bacterial persistence.
One large segment of the population that experiences more frequent recurrent UTIs is 
postmenopausal women [41]. These women experience low estrogen status that may affect 
barrier capabilities of the bladder to infection. Work in our lab has recently identified that low 
levels of estrogen are sufficient to alter expression levels of enzymes that are important for GAG 
modification or biosynthesis. Furthermore animals with low estrogen status, due to oophorectomy, 
when infected were unable to properly up-regulate these target genes [42]. This deficiency in 
estrogen also leads to dysregulated repair of the urothelial barriers post infection, potentially 
indirectly through extracellular matrix GAG regulation of the BMP4 signaling pathway [43]. 
Work in Chapter 4 of this thesis together with work from our laboratory suggests that 
estrogen signaling and UPEC infection both converge upon a GAG/HSPG molecule and regulate 
it. Therefore understanding the upstream events from GAG/HSPGs will be critical to enhancing 
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our understanding of how hormone signaling and bacteria regulate host responses of regeneration 
to infection.
VI. The role of BMP signaling in urothelial development 
There has been recent interest in developmental origins of adult disease. Recent studies 
have investigated potential links between fetal development and the promotion of atherosclerosis, 
cancer and renal disease [44-46]. In order to identify linkages for developmental contributions of 
disease, a greater understanding of the developmental process must first be gained. 
Insights from adult homeostasis and regeneration, as mentioned in Chapter 1, have 
previously identified BMP4 and Shh as important regulators of proliferation and differentiation 
[47, 48] suggesting these signaling molecules may be important for initial urothelial development. 
Between embryonic days 12.5-14.5 (E12.5-E14.5) the bladder acquires its urothelial identity, but 
has not fully developed its characteristic multi-layered adult architecture. After E14.5, the bladder 
and urothelium are undergoing maturation and differentiation to result in the multifaceted adult-
like bladder structure (Figure 5.1) [49-52]. Previous in situ hybridization work identified BMP4 
expression in the adjacent bladder mesenchyme as early as E11.5 [53]. BMP and Shh signaling are 
both crucial bladder smooth muscle development [54-56], but how BMP signaling may influence 
urothelium development is not known.
To determine the role for BMP signaling in the developing urothelium, I started with the 
hypothesis that BMP signaling is necessary for the proper development and/or differentiation of 
the urothelium. To test this, I would utilize a conditional null allele of Bmpr1a flanked by loxP 
sites, (Bmpr1a floxed) [57] to ablate BMP signaling within the developing urothelium. We have 
previously generated Bmpr1a floxed animals bred to a β-actin-CreERT line that allows for inducible 
removal of Bmpr1a in a tamoxifen-dependent manner throughout the developing bladder. In order 
to assess a requirement for BMP signaling for early urothelial differentiation, our lab has also 
recently acquired uroplakin-CreERT animals that when bred to the Bmpr1a floxed animals will 
allow for a more directed ablation of BMP signaling from the urothelium as it progresses through 
differentiation. Uroplakin expression can be detected as early as E14.5 (Figure 5.1).
104
E12.5 E14.5 E16.5
K5
K7
UP3
K5
K7
UP3
K5
K7
UP3
By Congxing Lin
Figure 5.1: Wild type urothelium development at early and late embryonic time points. Histologically, the urothelium 
is present as early as E12.5, and by E14.5 the number of cell layers increases. At E12.5 the urothelium is very indistinct 
lacking K5, K7 and UP3 staining. As the urothelium begins to differentiate, K7 and UP3 expression can be seen as 
early as E14.5. P3 cell identity is not present until the late embryonic time of E16.5. Image provided by Dr. Conxging 
Lin.
Generation of Bmpr1a conditional knock out (CKO) pups from either Cre-driver will be 
produced by intraperitoneally administering tamoxifen to pregnant dams 48 and 24 hrs prior to 
the embryonic collection time point (Figure 5.2). We will assess loss of function for BMP from 
E10.5 through post natal day 9 (P9) as this is the critical window for tissue development. Cre 
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Figure 5.2: Schema of pregnant dam treatment and pup harvest.
Pup development timeline from embryonic day 7 to postnatal day 9. Arrows indicate time points at which first 
tamoxifen injection will be administered intraperitoneally to pregnant dams from wild type, β-actin-CreERT;Bmpr1a 
floxed or uroplakin-CreERT;Bmpr1a floxed matings. Red boxes indicate pup harvest time points.
expression will be confirmed using genomic PCR as in [57] from rostral tissues. Embryos or 
bladders from Bmpr1a CKO pups and age matched controls will be fixed in Bouin’s and processed 
for histological analyses. Unfixed pups or bladders will be snap frozen in OCT medium and used 
for in situ hybridization and histological analyses.
We will assess morphology, differentiation (K5, K7, UPIII), proliferation (Ki67), apoptosis 
(TUNEL, Caspase-3, Annexin V/propidium iodide), and BMP signaling pathway member 
expression (including phospho-Smad-1 and p27Kip1) in wild type and CKO pups to allow for direct 
comparisons of how loss of BMP signaling affects urothelial development and differentiation. 
We identified that β-actin-CreERT;Bmpr1a CKO mice at postnatal time points (P3 & P9) 
displayed a more differentiated urothelium by histological analysis (Figure 5.3). At E17, CKO 
animals consistently showed an increase in K5 expression by immunofluorescence analysis, 
whereas UPIII was not perturbed (Figure 5.4). P3 CKO animals displayed an increase in the 
differentiation marker UPIII (Figure 5.4). This increased differentiation will be confirmed 
through western analysis of UP1a [43]. As development and differentiation proceeds, the 
urothelium becomes progressively more quiescent [58], however, at all time points assessed 
(E17, P3 and P9) CKO animals had lower rates of urothelial proliferation as compared to their 
age-matched controls (Figure 5.5). Together these results indicate a requirement for BMP 
signaling in proper urothelial proliferation and differentiation.
BMP signaling appears to have multiple functions in the urothelium. In contrast to adult 
regeneration, loss of BMP signaling throughout the urothelium during late embryonic and early 
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Figure 5.3: Timed loss of BMP signaling results in more rapid P1 cell differentiation.
Bmpr1a mutant pups at P3 show increased incidence of P1 cells. This increased differentiation phenotype is also 
exhibited at P9. However, late embryonic pups at E17 do not appear to show histologic P1 cell differences.
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Figure 5.4: Timed loss of BMP signaling leads to higher levels of UPIII, fewer Ki67+ cells. 
E17 immunofluorescence analysis shows an increase K5 and a decrease in Ki67+ cells in Bmpr1a mutant pups. P3 
mutant pups display an increase in UPIII expression with a concomitant decrease in Ki67+ cells. By P9, mutant 
animals show a decrease in K5 cells and a decrease in Ki67+ cells.
postnatal time points results in increased differentiation at the expense of proliferation. Preliminary 
data from late embryonic and postnatal β-actin-CreERT;Bmpr1a CKO animals suggest that early 
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early postnatal time points decreases proliferation of the 
developing urothelium without affecting mesenchymal 
proliferation. 
At E17 the urothelium overall has fewer proliferating 
Ki67+ cells in mutant pups. Mutant animals at P3 and P9 
also display decreases in the total number of proliferating 
urothelial cells with the intermediate cell (IMCs) population 
most negatively affected.
embryonic time points (prior to E14.5) should 
continue to exhibit decreased proliferation 
especially of cells within the P2 layer. As P2 cell 
identity is established first (Figure 5.1), a decrease 
in proliferation of these cells may contribute to 
an increase in differentiation and therefore UP+ 
(P1) cells at the expense of K5+ (P3) and K7+ 
(P2) cell populations (See Chapter 1, Figure 1.2). 
This could occur because without proper BMP 
signaling P2 cells are forced to differentiate 
due to the lack of proper cues to proliferate and 
sustain/maintain the urothelial architecture. Loss 
of BMP signaling in development is almost the 
opposite of that in adult regeneration, suggesting 
that other signaling molecules play key roles 
alongside BMPs to regulate the proliferation and maintenance of the urothelium. In support of this, 
murine embryonic stem cells require BMP signaling in order to maintain stemness and decrease 
differentiation together with Jak/Stat signaling [59].
Investigating the role of BMP in P1 cell differentiation using uroplakin-CreERT;Bmpr1a 
CKO animals could result in a lack of identifiable P1 cells starting at E14.5. Absence of P1 cells 
could result a thickened urothelium, as cells continue to cycle instead of properly differentiate 
due to a deficiency of downstream BMP signaling [43, 47]. These results would suggest that BMP 
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signaling is required for P1 cell identity. Urothelial thickening may or may not be associated 
with changes in proliferation [43, 47, 48], which could suggest that a lack of P1 cells instructs 
underlying cell layers to proliferate. 
Alternatively, a sustained lack of BMP signaling in the developing P1 cells of uroplakin-
CreERT;Bmpr1a CKO animals could result in rapid differentiation of the urothelium that would be 
completed before wild type animals. I would not expect a change in P2 or P3 cell proliferation, 
but should that occur it would also suggest that P1 cells signal to underlying cell layers to assist 
in regulating proliferation. This result would support the phenotype observed in whole urothelial 
BMP signaling CKO animals.
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APPENDIX: Constitutive β-catenin activation induces male-specific tumorigenesis in the 
bladder urothelium
This appendix is in revision at Cancer Research.
Constitutive β-catenin Activation Induces Male-Specific Tumorigenesis in the Bladder 
Urothelium.
Lin C, Yin Y, Stemler KM, Humphrey P, Kibel AS, Mysorekar IU, Ma L
KMS assisted in experiment planning, performed experiments not included in publication, 
assisted with data analysis, and edited the manuscript.
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Abstract
The incidence for bladder urothelial carcinoma (UC), a common malignancy of the urinary 
tract, is about three times higher in men than in women. Although this gender difference has been 
primarily attributed to differential exposures, it is likely that underlying biological causes contribute 
to the gender inequality. In this study, we report a transgenic mouse bladder tumor model upon 
induction of constitutively activated WNT/β-catenin signaling in the adult urothelium. We showed 
that the histopathology of the tumors observed in our model closely resembled that of the human 
low grade urothelial carcinoma. Additionally, we provided evidence that the K5-positive;K7-
negative basal cells were the cells-of-origin for β-catenin-induced luminal tumor. Intriguingly, 
the tumorigenesis in this model demonstrated a marked difference between opposite sexes; forty 
percent of males developed macroscopically detectable luminal tumors in twelve weeks, whereas 
only three percent of females developed tumors. We investigated the mechanisms underlying this 
sexual dimorphism in pathogenesis and demonstrated that nuclear translocation of the androgen 
receptor (AR) in the urothelial cells is a critical mechanism contributing to tumor development 
in male mice. Finally, we performed global gene profiling experiments and defined the molecular 
signature for the β-catenin-induced tumorigenesis in males. Altogether, we have established a 
model for investigating sexual dimorphism in UC development, and implicated synergy between 
WNT/β-catenin signaling and androgen/AR signaling in carcinogenesis of the basal urothelial 
cells.
Introduction
Bladder cancer is the fourth most common cancer type among men, and ninth among 
women (1). Life time cost for bladder cancer patients is the highest among all cancer types on 
a per-patient basis (2). Despite its high prevalence and burden, the etiology of bladder cancer is 
poorly understood. One important feature of bladder cancer is that its incidence is three times 
higher in men than in women (1), despite the fact that the development and function of the bladder 
are not thought to be linked to sex hormones. Historically, this male predilection, similar to lung 
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cancer, was explained by higher rates of tobacco smoking in men. However, this male predilection 
existed in the non-smoking population, and contrary to lung cancers, the gender difference in 
bladder cancers remained stable even when the smoking prevalence markedly increased in women 
(3). These observations suggested intrinsic mechanisms underpinning gender-based differential 
susceptibility to bladder cancer.
The most common type of bladder cancer is urothelial carcinoma (UC) arising from 
the bladder urothelium. Normally, mature urothelium renews itself slowly but continuously by 
producing new cells in the basal layer, which differentiate into intermediate cells and terminally 
differentiated apical umbrella cells. However, under pathogenic conditions, the basal urothelial 
cells can rapidly proliferate to restore homeostasis (4, 5). Therefore, the basal cell layer has been 
proposed to be the urothelial stem cell niche (4). Interestingly, the tumor-initiating cells isolated 
from UC demonstrate basal cell characteristics (6, 7). However, the cells-of-origin for UC remains 
to be determined.
Abnormal activation of the canonical WNT/β-catenin pathway is implicated in many cancer 
types, especially those affecting epithelia of endodermal origin, such as prostate (8) and colorectal 
cancers (9). Elevated WNT activity, possibly through promoter hypermethylation mediated 
repression of WNT inhibitors, has been reported in a subset of bladder cancers (10, 11). Moreover, 
augmented expression of WNT pathway genes (6) and nuclear localization of β-catenin (12) have 
been observed in the bladder tumor-initiating cells. In mice, WNT/β-catenin signaling is required 
for basal urothelial proliferation during injury-induced regeneration (13), and forced expression of 
a constitutively activated form of β-catenin using UPII-Cre caused urothelial overgrowth, although 
no tumor developed in the absence of additional mutations (14, 15). Together, these observations 
indicate a dynamic role for WNT/β-catenin signaling in regulating homeostasis and carcinogenesis 
of the urothelium.
Androgen and androgen-receptor (AR) signaling has also been linked to bladder cancers, as 
AR knockout mice showed resistance to N-butyl-N-(4-hydroxybutyl)nitrosamine-induced 
carcinogenesis (16). Crosstalk between WNT/β-catenin and androgen-androgen receptor (AR) 
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pathways has been reported both during development (17) and in carcinogenesis, particularly in 
prostate cancer (8, 18, 19). These findings prompted us to hypothesize that β-catenin is involved in 
mediating sexual dimorphism in bladder tumorigenesis. Herein, by using an inducible transgenic 
system to force persistent β-catenin activation in adult urothelium, we established a mouse bladder 
tumor model that exhibits strong male predilection as a consequence of synergy between WNT/β-
catenin and androgen/AR signaling.
Materials and Methods
Animal Maintenance
All animals were housed in the animal facility at Washington University according to NIH and 
Animal Care and Use Committee guidelines. Dox food pellets were purchased from Bio-Serv 
(Frenchtown, NJ). Castration was performed following standard surgical procedures.
Histological Analyses
Bisected bladder were embedded in paraffin or OCT and cut into 5μm sections.
Immunohistochemical and immunofluorescence staining were performed according to standard 
protocols.
RNA Isolation, Microarray Analysis, and Real-time RT-PCR
The urothelium was physically separated from the bladder for RNA extraction, which used the 
RNeasy kit (Qiagen, Valencia, CA). Illumina (San Diego, CA) mouse-6 chips were used for 
microarray analysis.
Statistical Analyses
Student t-tests were performed to compare proliferative indices between experimental groups.
Supplemental Methods
Animal Experiments
Msx2rtTA allele was previously described (Lin et al., 2009). tetO-Cre allele was provided by Dr. 
Feng Chen in Washington University, and β-CatEx3/+ and R26mT/mG strains were purchased from 
the Jackson laboratory (Bar Harbor, Maine 04609). Animals simultaneously carrying Msx2rtTA, 
tetO-Cre, and β-CatEx3/+ alleles were considered GOF mutants, while those carrying one or two 
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alleles were phenotypically normal and considered controls. These animals were kept in a mix 
genetic background and therefore for all experiments described, only littermate controls were used 
for comparisons.
Antibody Staining
The following antibodies were used in the study: polyclonal rabbit anti-CK5 (ABCAM, 1:200), 
monoclonal mouse anti-CK7 (Millipore, 1:300); monoclonal rat anti-CD44 (BD Biosciences, 
1:50), monoclonal rat anti-Ki67 (Dakocytomation,1:10), polyclonal rabbit anti-Ki67 (ABCAM, 
1:200), polyclonal rabbit anti-PHH3 (Upstate, 1:200), polyclonal rabbit anti-laminin (ABCAM, 
1:500), polyclonal rabbit anti-Loricrin (Covance, 1:300), monoclonal mouse anti-β-catenin (BD
Biosciences, 1:300); monoclonal mouse anti-E-cadherin (BD Biosciences, 1:500); monoclonal 
rabbit anti-PS6 (Cell Signaling, 1:200); monoclonal rabbit anti-LEF1 (Cell Signaling, 1:200); 
monoclonal mouse anti-UPKIII (Fitzgerald Industries, 1:300); polyclonal rabbit anti-AR (Santa
Cruz, 1:200). Antigen retrieval was carried out using Trilogy solution (Cell Marque, Rocklin,
California).
Ki67 index and K7 Index
For each animal, the number of Ki67/K7 positive cells and the total urothelial cells on three 
randomly selected cross sections were counted and the ratio was calculated. Student t-test was 
performed to analyze the final results.
Realtime RT-PCR Analyses
Real-time RT-PCR primers were designed according to PrimerBank (The Massachusetts General 
Hospital). Standard delta-CT method was used to analyze the results.
Testosterone Measurement
Serum testosterone level was measured using Testosterone EIA kit (Cayman Chemical, Ann Arbor, 
MI) according to the manufacture’s instruction.
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Results and Discussion
Forced expression of stabilized β-catenin in mature urothelium induced luminal bladder 
tumors in male mice
Previous studies have investigated the role for sustained β-catenin activation in the 
urothelium by using a urothelial-specific UPII-Cre (14, 15). However, the urothelial expression 
of this Cre is patchy and restricted to the upper layer of differentiated cells; the basal layer, which 
contains progenitor cells that have high proliferative reserve and therefore are more likely to be 
the cells-of-origin for tumors, is largely excluded (Fig. 3C b-d in (20)). Importantly, the basal layer 
is also the endogenous site of WNT activation during injury-induced regeneration. Therefore, we 
sought to use an alternative genetic tool that can target basal urothelial cells with high efficiency. 
We adopted an Msx2rtTA;tetO-Cre system, which confers Cre expression in Msx2-expressing cells 
upon doxycycline (Dox) treatment (21). We first tested the efficacy of the system using an R26mT/
mG reporter, which expresses membrane-targeted EGFP in the presence of Cre and red fluorescent 
tdTomato (mT) protein in the absence of Cre (22) (Fig. A.1A). Trigenic Msx2rtTA;tetO-Cre;R26mT/
mG mice were treated with Dox at 4-weeks of age, and their bladders were collected five days later. 
Immunofluorescence analyses demonstrated that all cells above the basement membrane, marked 
by laminin staining (Fig. A.1B), including all cells positive for the basal-cell marker K5 (Fig. 
A.1C), expressed EGFP. Conversely, all mesenchymal cells retained tdTomato (Fig. A.1B, C). To 
test whether these EGFP-positive cells include urothelial stem cells, we performed lineage tracing 
in which the animals were treated with Dox for 5 days, and bladders were collected 20 weeks later 
for expression analysis. Because the turnover time for mouse urothelium is around 40 weeks (23), 
the percentage of EGFP-positive cells would drop if stem cells were not labeled during the initial 
treatment. In contrast, we observed that all urothelial cells remained EGFP-positive (Fig. A.1D), 
indicating that urothelial stem cells were also targeted by this system.
To assess the effects of persistent β-catenin activation, we generated trigenic Msx2rtTA;tetO-
Cre;β-CatEx3/+ animals (hereafter referred to as GOF mutants). The β-CatEx3/+ allele (24), 
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Fig. A.1 Forced β-catenin activation 
induces luminal tumors in mouse 
bladder urothelia. 
(A) A schematic of Msx2rtTA;tetO-
Cre;R26mT/mG system. (B-D) 
IF staining on reporter line using 
antibodies indicated showing 
ubiquitous EGFP expression 
throughout the urothelium 5 days 
(BC), and 5 months (D) after 
Dox treatment. (E) Macroscopic 
view of single tumor (left) and 
multifocitumors (right) in GOF males 
12 weeks after Dox treatment. (F-H) 
Histological analyses of the tumor 
showing vascularization, polypoid 
structure (F-G) and E-Cadherin 
expression (H) in tumors. (I) Tumor 
incidence in male and female GOF 
mutants. Scale bars in B-D represent 
60μm, in F-H represent 500μm.
which was also used in previous studies to study WNT activation (14, 15), allows expression 
of stabilized β-catenin upon Cre-mediated exon3 excision. These GOF mice, along with their 
littermate controls, were put on Dox-containing diet for at least three weeks to allow complete Cre-
mediated recombination, starting from postnatal day 25 when the urothelium has fully matured, 
and their bladders were analyzed after twelve weeks. Thirty-five percent of the GOF animals 
died during this period because they suffered from a variety of conditions including alopecia 
and craniofacial malformations (Supplemental Fig. 1), reflecting the consequences of abnormal 
β-catenin activation in the corresponding Msx2-expressing organs. Twenty-four percent of the 
remaining GOF mutants (29 out of 122) had macroscopically discernable tumors within the bladder 
lumen; 11 had a single tumor and 18 had multi-foci tumors (Fig. A.1E). These luminal tumors 
closely resembled low-grade papillary urothelial carcinoma (Fig. A.1F, G). They often exhibited 
polypoid structure, and the urothelium lost its typical polarity and demonstrated nuclear atypia, 
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high mitogenic activity, and considerable vascular infiltration. The vast majority of tumor cells 
stained positive for E-Cadherin, indicating their epithelial origin (Fig. A.1H). However, no nuclear 
pleomorphism or muscle invasion was observed. Notably, our results are in contrast with previous 
studies that used UPII-Cre to overexpress the same β-Catex3 allele but detected no tumors in the 
absence of additional mutations (14, 15). We suspect that this discrepancy reflects key difference 
in expression pattern of the Cre-drivers. 
Intriguingly, we noticed a striking sex difference in the rate of tumorigenesis, as we found 
that 45% (27/60) male GOF mice developed tumors, compared to a mere 3% (2/62) in females 
(Fig. A.1I). Histopathological analysis also demonstrated that urothelia in GOF males were more 
severely affected than those in GOF females (Supplemental Fig. 2). Notably, this difference was 
not due to differential expression of rtTA or β-catenin, as western blots revealed equal β-catenin 
expression in GOF males and females (Supplemental Fig. 3). The fatality noted above was not due 
to sex-related causes, however, as females and males died at similar rates (data not shown).
The K5+;K7- basal urothelial cells are the cells-of-origin for β-catenin-induced bladder 
tumors
We next sought to identify the cells-of-origin for the tumors. First, to better understand 
urothelial differentiation, immunofluorescence (IF) staining against three differentiation markers, 
keratin-5 (K5), keratin-7 (K7), and uroplakinIII (UPK3), was performed to define different cell 
types. We observed four distinct cell populations: the K5+;K7- basal cells (Fig. A.2C, red), 
K5+;K7+ basal-intermediate cells (Fig. A.2C, yellow), K5-;K7+ intermediate cells (Fig. A.2C, 
green), and K5-;UPK3+ umbrella cells (Supplemental Fig. 4C, green). Similar results were 
also obtained from staining using alternative basal marker CD44 and intermediate cell marker 
Loricrin (Supplemental Fig. 4D-I). This graded marker expression pattern, similar to that observed 
in the prostate epithelium (25), reflects a continuous differentiation process and a hierarchical 
relationship among urothelial cells, and suggests that the K5+;K7- basal cells are likely early 
urothelial progenitor/stem cells. Next, we determined which cell population is responsible for 
over proliferation driven by β-catenin mutation. Five days after Dox treatment, elevated β-catenin 
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expression and nuclear localization of the protein was observed throughout the GOF urothelium 
(Supplemental Fig. 5B). The GOF urothelia were highly proliferative as 33% of urothelial cells were 
Ki67-positive, compared to near-zero in controls (Supplemental Fig. 5C, D and G). In addition, we 
also detected considerable mitotic activity in the GOF urothelium, evidenced by the presence of 
Phospho-Histone H3-positive cells (Supplemental Fig. 5E, F). Notably, these Ki67-positive cells 
were exclusively K5+ basal cells, and this proliferation is accompanied by an expansion of the 
K5+;K7- basal cell layer (Supplemental Fig. 6). These results indicate that activation of WNT/β-
catenin signaling promotes basal cell proliferation.
Fig. A.2 K5-positive;K7-negative basal cells are the cells-of-origin for β-catenin-induced urothelial tumors. 
(A-C) Double-IF using antibodies indicated. Note that the red K5+;K7-basal cells, yellow K5+;K7+ basal-intermediate 
cells, green K5-;K7+ intermediate cells in C. (D-D’’) Histological and double-IF analyses on adjacent sections of GOF 
urothelial five weeks after starting treatment showing dysplastic nodules (arrows in D-D’’) with low-K5 expression 
(D’), and absence of K7 (D’’) expression. (E-F) Histological and K5/7 double-IF analyses 8- (E-E’’) and 12- (F-F’’) 
weeks after treatment showing tumor progression along with expansion of the K5-low;K7-negative dysplastic cells. 
(G-I) Double-IF analyses using antibodies indicated. (G) Co-staining of K7 and Ki67 revealing that the K7-negative 
nodular cells were highly proliferative. (H-I) Double IF staining showing Ki67-positive cells were localized close to 
basement membrane (H), and expressing K14 (I). (J) A model for WNT-induced tumorigenesis of basal urothelial 
cells. Scale bars in A-C represent 60 μm, in D-F represent 250μm, in G-I represent 125μm.
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To understand the dynamics of WNT-induced tumorigenesis, and define contribution from 
different urothelial cell types, we examined GOF mouse bladders every two to three weeks over 
a period of twelve weeks. Five weeks after starting Dox, GOF urothelia exhibited remarkable 
histopathological changes. They were thicker than controls (Fig. A.2D and Supplemental Fig. 7B) 
and contained histologically distinct cell nodules within the urothelium (arrows in Fig. A.2D-D’’ 
and Supplemental Fig. 7B). These nodular cells were small, and their histologically resembled 
the basal cells (Supplemental Fig. 7C). The nodular cells displayed a unique signature of low K5 
(Fig. A.2D’) and absence of K7 expression (Fig. A.2D’’). Costaining of K7 and Ki67 revealed 
high proliferative activities in these K5-low;K7-negative cells (Fig. A.2G). Moreover, these cells 
showed distinct signaling activity, evidenced by p-S6 expression, an established target of the mTOR 
pathway (Supplemental Fig. 7D). These histological/molecular signatures of the GOF urothelia 
largely persisted throughout tumorigenesis (Fig. A.2D-F, D’-F’, D’’-F’’), and the majority of the 
cells from fully developed tumor shared the same K5-low;K7-negative signature as the dysplastic 
nodules/lesions observed early on (Fig. A.2F-F’’). These results suggested that the K5+;K7- basal 
cells were the cells-of-origin for β-catenin induced luminal tumors (model in Fig. A.2J). Notably, 
we found that although most tumor cells retained their original keratin signature, only cells adjacent 
to the basement membrane were highly proliferative (Fig. A.2H), and most of these proliferating 
cells were stained positive for K14 (Fig. A.2I), an early progenitor cell marker in bladder cancers 
(26, 27). Our finding that the basal cells are responsible for tumor formation suggests that the 
failure of earlier studies to detect tumors upon expression of activated β-catenin using UPII-Cre 
can be explained by the differential oncogenic potential of progenitor and differentiated urothelial 
cell types.
Androgen-androgen receptor signaling mediates sexual dimorphism in bladder 
tumorigenesis
Next, we sought to determine the mechanisms underlying the male-predilection in this 
bladder tumor model. We observed no differences in bladders between GOF males and females 
three weeks after Dox treatment (data not shown), but bladders of GOF males five weeks after 
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treatment showed a higher proliferation index and more K7-negative cells than those of GOF 
females at the same stage (Fig. A.3A). This corresponds with the time when circulating androgen 
level peaks in male mice (28). Considering the potential interaction between WNT/β-catenin and 
androgen/AR signaling, we speculated that androgen signaling might function to enhance the 
male phenotype. We analyzed AR expression by immunohistochemistry and found that in control 
males, AR was preferentially expressed in the cytoplasm of the intermediate cells (Fig. A.3B). 
In contrast, prominent nuclear AR expression was evident in the dysplastic/tumor cells of GOF 
males (Fig. A.3C). Further analysis demonstrated a mutually exclusive expression pattern of K7 
and nuclear AR (Fig. A.3E). Indeed, nuclear AR expression clearly defined the boundary between 
tumor/dysplastic epithelium and the neighboring epithelium (Supplemental Fig. 8). In females, 
AR expression was much weaker in both controls and the GOF mutants compared to males (data 
not shown and Fig. A.3D). Notably, this nuclear AR translocation was not a result of elevated 
testosterone in the GOF males (Supplemental Fig. 9). To determine whether abnormally expressed 
AR was functionally relevant in β-catenin-induced tumorigenesis, we castrated GOF male mice 
15 days after starting Dox treatment and analyzed the effect on tumor development. Only 12.5% 
(2/16) of castrated males developed luminal tumors (Fig. A.3F), and cell proliferation of castrated 
GOF males was 20% less than non-castrated counterparts three weeks after castration (data not 
shown). These results indicated that misregulation of androgen-AR signaling contributed to male-
specific bladder tumorigenesis.
To gain insight into the molecular mechanisms underlying β-catenin-induced tumorigenesis, 
we performed expression profiling of urothelial cells from control and GOF animals three weeks after 
starting Dox, a stage when androgen starts to elevate but sexual dimorphism in bladder phenotype 
has yet to develop. Four groups representing different sex and genotypes were analyzed, each 
consisting of three pooled samples (Fig. A.4A). Comparing data acquired from GOF to control, 
we uncovered 576 genes (WNT targets) that differed in expression level by more than 2-fold, 
including 24 previously identified direct canonical WNT targets (Supplemental Table 1). This 
result validated our model and indicated that abnormal activation of canonical WNT signaling is 
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Fig. A.3 Misregulation of AR in the GOF 
mutant males. 
(A) Proliferation and K7-indice showing 
that GOF male urothelia are more 
severely affected, *p<0.025. (B-D) 
IHC against AR showing cytoplasmic 
expression in the intermediate cells of 
control males (B), nuclear expression 
in the dysplastic urothelial cells of 
GOF males (C), and weak cytoplasmic 
expression in GOF females (D). (E) 
Double-IF showing complementary 
expression of AR and K7. (F) Reduced 
tumor incidence in castrated GOF males. 
All scale bars represent 60μm.
the major event caused by β-catenin-GOF mutation. Next, we compared data sets from GOF males 
to GOF females to identify genes underpinning sexual dimorphic tumorigenesis. We found 130 
genes that were differentially regulated (male tumor genes), among which were 68 WNT targets, 
an additional 17 potential (changed in the GOF males relative to the control males by 1.5-fold-2-
fold) WNT targets, and 11 genes differentially expressed in opposite sexes in controls (Fig. A.4B, 
C, and Supplemental table 2). Close examination of the 85 WNT targets revealed that 83 were 
changed more prominently in the GOF males than in females (Fig. A.4D), suggesting that WNT 
responsiveness is higher in males than in females. These genes were further categorized by their 
biological functions (Fig. A.4E). Furthermore, we compared our results with existing microarray 
databases and found 8 known downstream targets of AR in the male tumor genes (Supplemental 
Table 3). The expression of these genes was further verified by real-time PCR (Supplemental Fig. 
10). Together, these data revealed that sexual dimorphic gene regulation responsive to hyperactive 
WNT/β-catenin signaling is the underlying mechanism for differential tumorigenesis, and suggested 
two mechanisms mediated by AR and contribute to this male predilection: 1) AR augments WNT 
responsiveness in males, and 2) AR activates a distinct set of downstream target genes. Notably, 
we did not observe co-activation of SHH and FGF signaling, indicating that β-catenin-induced 
bladder tumor development is independent of these oncogenic pathways (Supplemental Fig. 11).
The exact mechanisms leading to androgen-dependent nuclear AR expression in the tumor 
cells remain to be determined, although physical interactions between β-catenin and AR have been 
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Fig. A.4 Sexual dimorphic gene 
regulation by hyperactive WNT/
β-catenin signaling in the bladder 
urothelium. 
(A) A schematic for microarray 
analyses. (B) Hierarchical 
clustering heat map of the 130 
male tumor genes. Note that most 
genes are not distinguishable 
between WT males and females, 
but are changed prominently in 
GOF males. (C) Composition of 
male tumor genes. (D) Star glyph 
distribution of the fold-change 
of the 85 male tumor WNT 
targets revealed sexual dimorphic 
response to WNT activation. Log2 
values of fold-change for each 
gene were shown. Note that the 
peaks were eminent in male for all 
genes except for two (asterisks). 
This change reflects a higher 
WNT-responsiveness in males. 
(E) Classification of the 85 genes based on GO biological processes. Note that some genes have multiple functions 
and may be represented in more than one category.
well documented (18, 29). It is possible that the large amount of the exon3Δ form of β-catenin can 
bind to liganded AR and shuttle it into the nucleus. However, this does not explain why the nuclear 
AR expression was detected only in the basal cell-derived dysplastic/tumor cells in the mutant. 
The fact that other cell types, especially intermediate cells, which express even higher levels of AR 
under normal circumstances (Fig. A.3B), did not demonstrate this nuclear expression suggested 
additional obligatory co-factors that are only expressed in the mutant basal cells. Collectively, we 
established a bladder tumor model that exhibited a remarkable male predilection and indicated a 
key role for androgen-AR signaling in enhancing β-catenin-induced tumorigenesis. Our data also 
suggest that the K5-positive;K7-negative basal cells are the cells-of-origin for urothelial tumors. 
This model is an important addition to bladder cancer research because 1) the genetics is defined, 
and the histopathology of the luminal tumors faithfully recapitulates that of the low grade papillary 
UC, 2) the tumor development is fast and the incidence is relatively high in males, which makes 
it suitable for testing therapeutic approaches, and 3) this model is an excellent tool to investigate 
sexual dimorphism in bladder pathogenesis.
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Supplemental Fig. 1 Phenotype of -catenin GOF mutants 12 weeks after doxycycline treatment. 
(A) Gross appearance of WT and GOF mutants showing alopecia and craniofacial malformations 
in the mutant. (B) Survival curve of GOF mutants over a period of 12 weeks since starting 
doxycycline. 
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S2 
 
Supplemental Fig. 2 Phenotypic comparison of GOF males and females 12 weeks after treatment. 
(A-F) Histopathology of bladders from a representative litter of GOF mutants. The 
histopathology of three females (A-C) and three males (D-F) were shown. Note that the males 
were far more severely affected than the females. 
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S3 
 
 
Supplemental Fig. 3 Western blot analyses showing equal -catenin expression in GOF males 
and females. (A-B) The expression of WT and exon3Δ forms of -catenin, and GAPDH in 
urothelia of WT and GOF mutants. The non-specific band was shown by asterisk.  
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S4 
 
Supplemental Fig. 4 Differential expression of marker genes revealing distinct cell types in the 
adult mouse urothelium (A-C, D-F, G-I) Double-IF staining of WT urothelium using antibodies 
indicated. Note that the KRT5+ cells and UPK3+ cells are mutually exclusive (A-C), also note 
the presence of KRT5+;LOR-, and CD44+;KRT7- basal cells in KRT5+ cell population(red in F 
and I). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131
S5 
 
Supplemental Fig. 5 (A-F) Immunostaining on control and GOF urothelia 5 days after Dox 
showing enhanced and nuclear (arrows in inset) -catenin expression (B compared to A, insets 
showing boxed regions at higher magnification), and more Ki67+ (D) and pHH3+ (F) cells in the 
GOF mutants. (G) Quantitative analyses on proliferation index, *p=4.4x10-5. All scale bars 
represent 60μm. 
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Supplemental Fig. 6 Ectopic WNT activation induces basal urothelial proliferation 5 days after 
starting doxycycline treatment. (A-D) Triple-IF staining using antibodies indicated. Note that 
Ki67 expressing cells largely reside in the KRT5+ basal layer (compare A with C), also the 
marked expansion of the KRT5+;KRT7- basal cells (red in D). 
 
 
 
S7 
 
Supplemental Fig. 7 Histopathology of GOF urothelium 5 weeks after starting Dox (A-C) H&E 
staining showing a normal urothelium (A) in the control, and a hyperplastic urothelium 
(indicated by double headed arrow) in the GOF mutant (B-C). Note the distinct histological 
appearance of the small dysplastic nodular cells (arrow in B, C) (D) IHC against p-S6 showing 
augmented p-S6 expression in the dysplastic cells.  
 
 
133
S8 
 
Supplemental Fig. 8 Nuclear AR expression demarcates the dysplastic/tumor epithelium. (A-B) 
IHC against AR showing nuclear AR expression in dysplastic (A) and tumor epithelium (lower 
part in B) in the GOF mutants. Note that nuclear expression of AR was absent in the relatively 
normal neighboring epithelium (upper left side in A and upper part in B).   
 
 
S9 
 
Supplemental Fig. 9 Serum testosterone level of control and GOF mutant animals 8 weeks after 
Dox treatment measured by ELISA assay. Note that there is no significant difference between 
control males and GOF males.  
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S10 
 
Supplemental Fig. 10 Realtime RT-PCR analyses on known AR targets identified in microarray 
analyses.  
 
 
S11 
 
 
Supplemental Fig. 11 Real time RT-PCR using urothelial cells isolated from animals of different 
genotypes and sexes indicated. The GOF males with and without tumor development were 
separated to test whether tumors demonstrate distinct gene expression. Note the downregulation 
of HH and FGF pathway genes in the GOF mutants in particular the males. Also note that the 
expression between GOF males with and without tumor development was comparable.  
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Supplemental table 1
PROBE_ID SYMBOL Fold-Change 
(KO/WT)
KO/WT p-
value
ILMN_1232887 LOC382393 78.44 0.048
ILMN_2678144 3010033K07Rik 8.19 0.05
ILMN_2641201 Sp5 6.98 0.041
ILMN_2754940 2310031A18Rik 11.88 0.026
ILMN_1226541 5430417J04Rik 0.26 0.007
ILMN_2753792 Stra6 12.65 0.019
ILMN_2619952 Mmp10 7.89 0.032
ILMN_2513826 Tnfrsf11b 11.5 0.024
ILMN_2965660 Apcdd1 5.35 0.028
ILMN_2680387 Cpz 0.25 0.001
ILMN_2696611 Nkd1 5.02 0.034
ILMN_1246201 Cacna1h 0.33 0.001
ILMN_2932164 5730593N15Rik 3.33 0.048
ILMN_1232265 LOC331239 0.4 0.003
ILMN_2638473 1190003M12Rik 3.71 0.031
ILMN_2804685 Defb1 0.33 0.003
ILMN_2614655 Gpnmb 2.69 0.041
ILMN_2606746 Car2 9.23 0.017
ILMN_3161790 AI451557 0.48 0.006
ILMN_3131478 Bcat1 0.4 0.005
ILMN_1244272 Epb4.1l3 0.41 0.006
ILMN_2672297 Gcnt1 0.49 0.022
ILMN_2778872 Mad2l1 3.26 0.022
ILMN_1226293 Slc39a4 5.34 0.014
ILMN_3118584 Bex4 0.35 0.002
ILMN_2732079 AI836003 4.67 0.021
ILMN_2699522 Dyrk3 4.81 0.011
ILMN_2463181 Tnc 0.36 0.001
ILMN_2747923 Slc40a1 5.54 0.009
ILMN_2838501 Slc24a3 6.04 0.009
ILMN_2934522 Spin2 2.21 0.046
ILMN_2449157 Tnfsf9 5 0.014
ILMN_1240124 Tcrd-V1 4.3 0.013
ILMN_2851288 Ngfr 5.83 0.009
ILMN_2440679 D1Ertd471e 0.39 0.001
ILMN_1250766 Pvrl3 2.1 0.05
ILMN_2600255 Bcl9 2.98 0.022
ILMN_1221684 Scp2 4.85 0.015
ILMN_2675232 Prss19 0.41 0.001
ILMN_2606162 Pdlim4 5.9 0.006
ILMN_2767039 2310007B03Rik 12.37 0.006
ILMN_1214126 Hes6 2.71 0.029
ILMN_1225182 Cdca3 4.61 0.009
ILMN_1220560 Pgm5 0.47 0.008
ILMN_2678134 Bspry 2.81 0.018
ILMN_2640330 Cd44 4.67 0.009
ILMN_2929896 Pbk 6.76 0.009
ILMN_1243616 Cdkn3 6.25 0.008
ILMN_1238995 BC062650 6.03 0.008
ILMN_1213921 Troap 7.26 0.008
ILMN_1255053 Plk1 5.37 0.009
ILMN_2896314 Axin2 4.77 0.008
136
ILMN_2491589 Vgll4 2.21 0.028
ILMN_2778111 Etv4 9.3 0.006
ILMN_2687040 Echdc2 2.17 0.038
ILMN_2685770 Ltap 2.38 0.023
ILMN_2650008 Gpr49 5.78 0.006
ILMN_2680054 D0H4S114 2.22 0.036
ILMN_1221640 Gabrp 9.14 0.004
ILMN_2727472 Isl1 3.1 0.014
ILMN_2643355 Edaradd 2.24 0.025
ILMN_2691352 Efna4 2.27 0.021
ILMN_2485323 Trf 0.46 0.001
ILMN_2771219 1110001A05Rik 2.02 0.033
ILMN_1252399 Tbx1 0.33 0.001
ILMN_1228232 Cpe 4.04 0.007
ILMN_2529797 LOC213948 5.72 0.004
ILMN_2976191 Stat5a 3.42 0.009
ILMN_2635784 Gpc1 3.61 0.005
ILMN_2645816 Cpxm1 0.3 0.001
ILMN_3160369 Nos3as 5.28 0.002
ILMN_2651734 Gpr87 2.03 0.024
ILMN_1213191 Brrn1 2.08 0.025
ILMN_2612206 Cdc20 6.29 0.002
ILMN_1238696 Fanca 2.43 0.008
ILMN_2797642 Ncaph 2.48 0.009
ILMN_1246270 4833427B12Rik 2.81 0.006
ILMN_2970532 Mcm10 4.52 0.004
ILMN_2888552 Slc1a4 2.84 0.006
ILMN_3085841 Shroom3 3.11 0.006
ILMN_2606072 Hrb 2.07 0.015
ILMN_2784580 Cd3e 3.37 0.005
ILMN_1238568 Sema3c 2.27 0.007
ILMN_2706514 Bcl2 2.33 0.01
ILMN_2804166 Igsf9 2.03 0.01
ILMN_2728134 5430433G21Rik 2.31 0.008
ILMN_2777308 S100a14 2.46 0.005
ILMN_2893879 Gdpd3 0.5 0.001
ILMN_2707107 C76566 0.5 0.001
ILMN_2726931 Blnk 2.06 0.005
ILMN_2620767 Abhd2 2.28 0.005
ILMN_2690077 Nde1 2.17 0.004
ILMN_2838372 2010111I01Rik 2.03 0.005
ILMN_1227993 Vav3 2.42 0.001
ILMN_2430220 Tmem2 2.08 0.001
ILMN_3132262 Ihpk2 3.04 0.002
ILMN_2651019 Bhmt2 -0.01 0.001
ILMN_2687014 Cyp2e1 0.34 0.036
ILMN_1213311 Gfra3 0.33 0.002
ILMN_2443330 Ttr 0.19 0.017
ILMN_2859613 Ogn 0.38 0.013
ILMN_1254016 Adora1 0.34 0.004
ILMN_2667635 Clic6 9.15 0.041
ILMN_2636005 4632411J06Rik 9.88 0.036
ILMN_1236136 Corin 0.18 0.01
ILMN_2604873 1700124P09Rik 0.13 0.003
ILMN_2423835 Wnt6 6.64 0.039
137
ILMN_2777319 Stc1 8.64 0.037
ILMN_2684250 Hhip 0.23 0.001
ILMN_2906226 Cyp4f15 0.3 0.003
ILMN_2948143 Slc7a11 9.94 0.04
ILMN_2699923 2300003P22Rik 12.2 0.046
ILMN_2642800 Sostdc1 0.26 0.002
ILMN_2633179 Igh-1a 8.82 0.027
ILMN_2636183 Scube2 0.32 0.003
ILMN_2907285 Krt20 0.42 0.009
ILMN_2541614 LOC382110 0.14 0.001
ILMN_1245238 LOC381960 15.2 0.02
ILMN_1237583 Galntl1 0.32 0.002
ILMN_2686700 Abca8a 0.35 0.009
ILMN_1230224 Dnajc6 0.29 0.001
ILMN_1214459 Krt1-24 12.29 0.026
ILMN_2734097 Btc 3.34 0.046
ILMN_2804559 Tmem108 7 0.04
ILMN_2615096 Dpp4 8.17 0.02
ILMN_2667665 Rptn 9.79 0.045
ILMN_1220763 Rnase1 8.97 0.019
ILMN_1238627 E130013N09Rik 0.37 0.007
ILMN_2778151 Sox9 5.46 0.02
ILMN_2701778 Itga11 0.24 0.001
ILMN_3144535 Dmrtc1a 0.28 0.001
ILMN_1232858 A530006F08Rik 6.03 0.035
ILMN_3043109 Cnfn 18.07 0.038
ILMN_1230099 2010016F14Rik 8.64 0.034
ILMN_2872965 Sprrl5 34.9 0.035
ILMN_1257547 Tox 7.86 0.017
ILMN_2545782 9030625A11Rik 0.33 0.001
ILMN_2761645 Fetub 5.99 0.035
ILMN_2631591 E030049G20Rik 0.41 0.003
ILMN_1225835 Mfap5 0.44 0.004
ILMN_2671165 Krt1-23 7.49 0.015
ILMN_2635229 Thbs2 0.35 0.001
ILMN_2834563 Serpinb11 24.01 0.022
ILMN_2466180 7330410H16Rik 0.42 0.01
ILMN_2634167 Cldn3 8.91 0.022
ILMN_1230080 S100a15 5.49 0.046
ILMN_1258732 Cryba4 12.71 0.03
ILMN_2752064 Htr1d 0.37 0.027
ILMN_2849016 1300013J15Rik 0.3 0.001
ILMN_1234820 Sprrl3 19.89 0.047
ILMN_2802979 Shh 0.47 0.011
ILMN_1212867 LOC385103 7.94 0.026
ILMN_2650953 Slc12a7 0.47 0.014
ILMN_1257551 1810049K24Rik 0.4 0.002
ILMN_2952098 A930034L06Rik 0.39 0.004
ILMN_1227553 Plce1 0.35 0.002
ILMN_1229313 LOC329164 0.47 0.014
ILMN_2609897 Prss35 0.26 0.002
ILMN_2674483 Gpx2 6.18 0.025
ILMN_2890935 Avpr1a 0.38 0.001
ILMN_3163255 C130090K23Rik 4.29 0.031
ILMN_2687628 Ckap2 6.21 0.016
138
ILMN_2675833 Dlx3 6.87 0.022
ILMN_2730909 Gprasp2 0.37 0.001
ILMN_1216639 Pak3 0.48 0.014
ILMN_1235868 2310015J09Rik 15.09 0.024
ILMN_3162925 LOC620078 0.35 0.001
ILMN_2984153 Zfp667 0.43 0.01
ILMN_1234720 4930565N07Rik 0.31 0.001
ILMN_1239166 Sprrl7 19.23 0.042
ILMN_2523012 Gtl2 0.25 0.001
ILMN_3092046 Sema3b 0.38 0.001
ILMN_1248788 0610005K03Rik 17.16 0.025
ILMN_3105563 Dmkn 5.94 0.036
ILMN_3162060 MGC99845 0.3 0.009
ILMN_2653765 Nusap1 3.42 0.025
ILMN_2529062 LOC380986 0.43 0.007
ILMN_1228958 Fst 7.45 0.024
ILMN_3089725 Cxadr 2.77 0.043
ILMN_2942551 Sh3rf2 3.68 0.029
ILMN_2753497 Ccnb1 9.37 0.01
ILMN_2857748 Wif1 8.01 0.013
ILMN_1255307 9230114N12Rik 0.45 0.04
ILMN_2750740 Flrt3 0.43 0.003
ILMN_2625279 Pacrg 0.31 0.001
ILMN_2721385 Dst 0.41 0.013
ILMN_2795317 Ugt1a6a 0.5 0.01
ILMN_1246307 2310058A03Rik 0.41 0.001
ILMN_2601519 Abp1 7.32 0.029
ILMN_2635700 Lgi2 5.98 0.039
ILMN_2441642 D230034L24Rik 2.1 0.04
ILMN_2675289 Amn 0.32 0.001
ILMN_3156058 Aspscr1 2.5 0.024
ILMN_2575526 A530078M04Rik 0.41 0.001
ILMN_1243551 1110001M24Rik 24.33 0.026
ILMN_1241366 Rshl3 0.34 0.001
ILMN_2850253 Ptpru 0.49 0.009
ILMN_2732634 Cspg5 0.46 0.017
ILMN_1221568 Cdca7 4.98 0.009
ILMN_2687391 BC028975 0.49 0.018
ILMN_2831799 Bace2 0.48 0.005
ILMN_1235433 Bmp3 0.44 0.001
ILMN_2460094 Wnt10a 3.76 0.024
ILMN_2445249 Krt1-5 9.96 0.008
ILMN_2434472 Tpd52l1 2.74 0.046
ILMN_2838564 Tsku 0.47 0.012
ILMN_1226785 Homer1 0.49 0.008
ILMN_2894211 8430408G22Rik 0.38 0.001
ILMN_2524846 Defcr4 8.27 0.035
ILMN_2635272 Igh-VJ558 7.87 0.026
ILMN_2479977 1110065P19Rik 0.5 0.017
ILMN_2860699 Epb4.9 0.48 0.002
ILMN_1221257 BC026585 0.45 0.002
ILMN_3133352 Ung 3.42 0.012
ILMN_1222794 1110054N06Rik 0.39 0.03
ILMN_2509327 BQ952480 10.06 0.003
ILMN_3009243 Dusp2 7.5 0.015
139
ILMN_2699139 Sprr1b 7.75 0.02
ILMN_2637742 Padi1 2.81 0.049
ILMN_2619639 AI428936 3.37 0.029
ILMN_1237529 1110014K05Rik 3.22 0.036
ILMN_2697643 2410039E07Rik 40.77 0.037
ILMN_2744374 Sbsn 3.39 0.012
ILMN_2759914 Scnn1g 0.42 0.002
ILMN_1247267 Smox 5.15 0.006
ILMN_2858359 Clspn 6 0.004
ILMN_1233376 AW548124 0.38 0.004
ILMN_2705689 Gga2 0.43 0.002
ILMN_2466164 Wfdc1 0.44 0.002
ILMN_1245549 6330404C01Rik 8.45 0.01
ILMN_1227075 Fut2 7.23 0.009
ILMN_2617228 Stk6 3.33 0.009
ILMN_2657844 Cdc2a 7 0.005
ILMN_2670057 BC021608 3.35 0.009
ILMN_2945551 Ptplb 0.46 0.003
ILMN_2630047 Car3 0.42 0.03
ILMN_1257623 1810044J04Rik 4.04 0.008
ILMN_2798138 Gipc2 2.11 0.046
ILMN_1233823 Lamc2 2.58 0.025
ILMN_1213278 Raver2 0.35 0.001
ILMN_2673332 9530051K01Rik 0.48 0.01
ILMN_1255925 Col8a1 0.31 0.003
ILMN_1229155 Sele 0.43 0.004
ILMN_2681321 Cntnap2 0.36 0.002
ILMN_2598478 Sncg 4.45 0.006
ILMN_2578681 C130080K17Rik 0.43 0.001
ILMN_1221160 LOC235480 0.37 0.001
ILMN_1213227 Krt2-19 11.13 0.018
ILMN_2925424 Slc2a13 0.44 0.007
ILMN_2684205 4930431B09Rik 4.96 0.047
ILMN_2632712 Birc5 5.41 0.008
ILMN_1226183 Antxr1 0.44 0.001
ILMN_1225029 Oact1 2.34 0.021
ILMN_2985042 Krt36 11.36 0.006
ILMN_1238547 Areg 6.54 0.024
ILMN_2993174 Defcr-rs1 9.54 0.02
ILMN_2709337 Sp6 2.24 0.033
ILMN_2696749 Rac3 3.94 0.009
ILMN_1259632 1700051I12Rik 0.43 0.001
ILMN_1238276 Hist1h2ai 3.02 0.011
ILMN_2976821 Fzd10 2.29 0.039
ILMN_2822850 Serpinh1 0.48 0.004
ILMN_1253808 Oas1g 3.1 0.043
ILMN_1230926 Odz4 8.52 0.004
ILMN_1219574 Hist1h2af 3.03 0.017
ILMN_2629663 E430002D04Rik 3.08 0.045
ILMN_1236611 Mark1 2.92 0.011
ILMN_2629112 CRG-L1 0.5 0.003
ILMN_2668927 Apod 2.02 0.035
ILMN_3107945 Ccdc46 2.24 0.02
ILMN_2605890 Tk1 3.54 0.011
ILMN_2699637 Lisch7 2.18 0.046
140
ILMN_2491719 Zfp612 0.43 0.005
ILMN_2775937 Plat 3.47 0.014
ILMN_2710121 Pgcp 0.47 0.004
ILMN_2677824 E430021N18Rik 0.28 0.001
ILMN_2622255 Ephb2 2.21 0.025
ILMN_1254082 Chodl 0.33 0.001
ILMN_1220029 1700110N18Rik 0.5 0.002
ILMN_2555264 A030001L21Rik 0.45 0.015
ILMN_2950343 Rasef 0.48 0.016
ILMN_2470876 2310002D06Rik 0.44 0.006
ILMN_1250956 6330414G02Rik 0.49 0.002
ILMN_2689790 Igfbp6 0.48 0.002
ILMN_2761720 2610019F03Rik 0.46 0.003
ILMN_1218747 Gldc 0.47 0.003
ILMN_1221594 Pparg 0.45 0.003
ILMN_1218312 2010317E24Rik 3.52 0.005
ILMN_1232458 C1qtnf2 0.45 0.001
ILMN_3156246 Cdh3 2.53 0.01
ILMN_1259101 D630008P07Rik 0.44 0.004
ILMN_2595260 Creb3l1 0.48 0.004
ILMN_1237061 Dm15 2.51 0.01
ILMN_2812614 Reck 0.47 0.001
ILMN_2660766 Cd59b 0.39 0.004
ILMN_2762326 Kif22 5.43 0.004
ILMN_3162511 Shrm 3.39 0.004
ILMN_2684324 Dock11 4.41 0.003
ILMN_2607127 Adcy8 5.43 0.003
ILMN_2847144 Hist1h2ak 4.2 0.007
ILMN_2622374 Ndn 0.46 0.001
ILMN_2645865 2810022L02Rik 0.46 0.001
ILMN_2641678 Dhrs6 0.46 0.005
ILMN_2634083 Cdkn1a 2.83 0.004
ILMN_2777019 Spo11 5.42 0.013
ILMN_2517041 Uhrf1 4.46 0.005
ILMN_1235861 Sec15l1 0.43 0.001
ILMN_2757125 Prc1 4.79 0.003
ILMN_2904137 Ambp 0.18 0.001
ILMN_1224840 2610202E01Rik 2.37 0.015
ILMN_1242286 C730033N22Rik 0.45 0.001
ILMN_1216764 Ier3 2.53 0.009
ILMN_2730329 Hist1h2ah 4.06 0.008
ILMN_1218967 Kif2c 8.1 0.007
ILMN_1213811 Hsd17b2 0.35 0.001
ILMN_1228948 Ugt1a1 4.03 0.004
ILMN_2738893 D19Wsu12e 0.48 0.002
ILMN_1239230 Aurkb 5.23 0.005
ILMN_2649199 Hpgd 0.41 0.002
ILMN_1253650 Smarca1 0.48 0.001
ILMN_2877628 Krt42 10.39 0.035
ILMN_1258935 Sult4a1 0.19 0.001
ILMN_1236574 Cenpa 3.95 0.007
ILMN_2740902 Mki67 4.55 0.002
ILMN_2718314 Sema4g 0.49 0.005
ILMN_1377919 Tubb2b 2.36 0.007
ILMN_1258158 Aldh6a1 0.44 0.019
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ILMN_1252990 Cck 0.37 0.001
ILMN_2588362 Cdca8 3.88 0.011
ILMN_2543393 1110017L21Rik 4.3 0.005
ILMN_1216322 Hmgcs2 0.5 0.007
ILMN_2933022 Plekhb1 0.42 0.001
ILMN_2662926 Egr1 2.84 0.02
ILMN_2509918 Tm4sf6 0.46 0.014
ILMN_2892211 2310002J15Rik 4.68 0.01
ILMN_2854943 Gprc5a 3.8 0.008
ILMN_2723718 Rcn3 0.5 0.003
ILMN_2661950 2810418N01Rik 2.21 0.008
ILMN_1227679 1810019D21Rik 0.43 0.002
ILMN_2741985 Rad54l 3.37 0.004
ILMN_2615855 Hnrpa2b1 2.12 0.022
ILMN_1244213 Sox5 0.5 0.004
ILMN_1226839 Hist1h2ag 3.29 0.005
ILMN_3126277 Palmd 2.35 0.008
ILMN_1248830 Hist1h2an 2.8 0.014
ILMN_2643212 Reprimo 5.73 0.012
ILMN_2674966 Igsf10 0.46 0.007
ILMN_2635708 3100002J23Rik 0.48 0.003
ILMN_2424060 Ace 2.77 0.008
ILMN_1256063 2900060P06Rik 0.34 0.001
ILMN_1254335 Rgpr 0.41 0.015
ILMN_1229210 2610318C08Rik 3.71 0.002
ILMN_2680628 3110049J23Rik 0.44 0.001
ILMN_2979824 Rgs5 0.33 0.015
ILMN_2669416 Mgst1 0.43 0.003
ILMN_2974343 Pla1a 2.01 0.038
ILMN_2448749 Zfp185 2.5 0.003
ILMN_2417926 Tcrb-V13 2.61 0.049
ILMN_1225261 Uchl1 0.37 0.002
ILMN_1226979 Kifc5a 3.88 0.002
ILMN_1216669 4931406O17Rik 0.43 0.001
ILMN_2654582 BC034834 0.28 0.001
ILMN_2543929 2610036L11Rik 3.14 0.006
ILMN_1229142 E530004K11Rik 0.5 0.002
ILMN_1236788 Igfbp2 0.43 0.003
ILMN_2836654 Hist1h2ao 3.31 0.006
ILMN_2774007 Bub1b 2.98 0.012
ILMN_2795040 Hist1h2ad 3.68 0.004
ILMN_2595597 Anln 4.29 0.001
ILMN_2772077 Bok 2.96 0.007
ILMN_2664686 Chaf1b 2.85 0.003
ILMN_1237993 Nasp 2.23 0.011
ILMN_1240084 Upk1a 0.44 0.001
ILMN_2535227 M32486 2.76 0.006
ILMN_2888144 Slc29a1 0.47 0.01
ILMN_1242170 Adra2a 3.21 0.013
ILMN_2466809 1810018P12Rik 3.62 0.015
ILMN_2686611 Acsbg1 4.22 0.018
ILMN_1241171 Anxa3 2.13 0.005
ILMN_2980044 Asah2 0.48 0.001
ILMN_2654624 AI593442 0.48 0.031
ILMN_2830661 Top2a 4.12 0.001
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ILMN_2659997 MGC29978 0.43 0.001
ILMN_2673776 E2f2 2.55 0.006
ILMN_1232537 Arl4c 2.7 0.002
ILMN_2760434 Liph 0.48 0.001
ILMN_2742849 Mcm5 3.78 0.003
ILMN_3007758 Creb5 0.45 0.006
ILMN_2744587 Cib2 3.35 0.001
ILMN_2432550 Trib2 2.43 0.009
ILMN_2684465 2310043J07Rik 3.45 0.014
ILMN_2621659 Elf3 2.32 0.034
ILMN_1222751 Abhd9 3.15 0.002
ILMN_1230648 Rerg 0.46 0.037
ILMN_1220166 Slc9a2 0.47 0.003
ILMN_1255287 Mela 2.86 0.003
ILMN_2929572 Ccdc68 0.34 0.001
ILMN_2749717 Bcl3 3.34 0.017
ILMN_2609516 1300006C19Rik 0.47 0.001
ILMN_1258028 Gal3st1 2.24 0.05
ILMN_1214117 9530065M15Rik 3.39 0.005
ILMN_1254059 Col4a6 0.43 0.001
ILMN_2734252 Heph 2.68 0.009
ILMN_2793522 Tnfrsf19 2.16 0.026
ILMN_2844642 9530066K23Rik 0.48 0.003
ILMN_2727184 Paqr6 0.31 0.001
ILMN_2676243 Hist1h2be 0.22 0.001
ILMN_2515816 Cldn10 0.5 0.003
ILMN_1218538 E130115E03Rik 0.46 0.001
ILMN_2805051 Upk3a 0.49 0.001
ILMN_2749052 Ramp3 9.44 0.021
ILMN_2801427 Cmtm8 2.51 0.012
ILMN_2634317 Slc1a3 0.43 0.027
ILMN_2711948 Slc7a5 2.61 0.004
ILMN_2993314 Clec4n 2.99 0.009
ILMN_2467292 AI505012 0.49 0.001
ILMN_1245924 Map3k8 2.19 0.002
ILMN_2809701 Emid1 0.35 0.001
ILMN_2700608 Stx1a 2.17 0.007
ILMN_2903945 Gadd45g 2.64 0.005
ILMN_2776278 Ly6e 2.48 0.004
ILMN_2756665 Cbr2 2.03 0.003
ILMN_2623216 Pgrmc1 0.45 0.009
ILMN_1224336 4930422J18Rik 2.19 0.009
ILMN_1227535 LOC243341 0.31 0.002
ILMN_1222389 0610010I15Rik 0.46 0.001
ILMN_2658501 Ifitm3 2.06 0.005
ILMN_1213954 Sgk 2.59 0.001
ILMN_2753589 3632451O06Rik 0.39 0.006
ILMN_2736197 2610307O08Rik 3.25 0.008
ILMN_1225876 5830482G23Rik 2.05 0.043
ILMN_2771991 Ndrg2 0.45 0.007
ILMN_2757986 Card14 0.45 0.003
ILMN_3156604 Hmgb2 2.61 0.004
ILMN_1225376 Smoc1 0.46 0.004
ILMN_2979307 Nek3 0.5 0.001
ILMN_1258770 1700008D07Rik 0.47 0.001
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ILMN_2701271 Plscr1 2.47 0.039
ILMN_2611658 Krt1-4 7.98 0.024
ILMN_2650667 Clic3 10.94 0.003
ILMN_1251178 AW536289 15 0.014
ILMN_2625035 2010005O13Rik 2.38 0.044
ILMN_2729958 Hist1h3d 2.3 0.014
ILMN_2732782 Krt2-10 10.15 0.048
ILMN_2865016 Cd83 3.82 0.005
ILMN_2851040 Mcm3 2.13 0.019
ILMN_2526227 LOC381260 0.5 0.002
ILMN_2589015 Pacsin3 2.43 0.001
ILMN_2889482 Sox7 3.34 0.007
ILMN_1250253 Itm1 0.5 0.001
ILMN_1239397 Hk2 2.62 0.015
ILMN_2909105 2310047D13Rik 2.12 0.01
ILMN_2516565 1110008P08Rik 0.49 0.011
ILMN_1250689 Rgs9 0.46 0.007
ILMN_2756421 Lrrc15 7.99 0.004
ILMN_1246800 Serpina3n 2.21 0.04
ILMN_1217180 Ifitm1 2.23 0.01
ILMN_1259075 Nme7 2.28 0.002
ILMN_2722616 Krt1-14 12.11 0.001
ILMN_2527805 LOC228862 0.41 0.011
ILMN_2725188 Atp10a 2.64 0.002
ILMN_2543108 Wdt3-pending 2.34 0.006
ILMN_2890069 Tmprss11a 2.33 0.004
ILMN_2765759 Asb2 2.18 0.041
ILMN_2663281 2310045A20Rik 2.37 0.002
ILMN_2640097 Aox3 0.39 0.001
ILMN_1259473 Fen1 2.6 0.003
ILMN_2718843 4632417K18Rik 2.01 0.047
ILMN_2594202 Rpl21 0.46 0.038
ILMN_2491469 Tens1 2.38 0.003
ILMN_1228867 LOC382896 2.94 0.012
ILMN_2424299 Tnfrsf12a 4.06 0.006
ILMN_2628567 Phlda3 2.08 0.012
ILMN_2693403 Ela1 0.5 0.001
ILMN_2687165 Chst2 0.35 0.001
ILMN_1259467 9230106L14Rik 0.46 0.001
ILMN_1219286 scl0003377.1_167 0.46 0.003
ILMN_2617858 Ovol1 2.42 0.008
ILMN_2428961 Xpnpep1 2.48 0.036
ILMN_2781784 Osr2 10.43 0.009
ILMN_2690256 Insig2 2.47 0.005
ILMN_2737685 Mmp13 8.78 0.006
ILMN_2609868 AI427122 2.26 0.01
ILMN_2764846 Tcfap2a 3.87 0.001
ILMN_2753750 Sprrl1 9.29 0.006
ILMN_2703182 Lgals7 13.55 0.002
ILMN_2733524 Nrm 3.81 0.003
ILMN_2606295 Gch1 4.16 0.017
ILMN_2448591 A730017D01Rik 0.46 0.001
ILMN_2753149 Avil 5.47 0.046
ILMN_2722784 Cd3g 3.99 0.005
ILMN_2746895 Gpr120 3.25 0.005
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ILMN_2661107 Arl6ip2 2.33 0.003
ILMN_2901944 Col7a1 2.98 0.01
ILMN_1245043 LOC226017 0.47 0.011
ILMN_1244291 Gja1 2.4 0.002
ILMN_1254295 Sox21 9.91 0.001
ILMN_1220360 Unc13b 2.16 0.002
ILMN_3072427 Il1rn 4.75 0.013
ILMN_2964185 H2-M2 3.22 0.022
ILMN_2622983 Dusp1 2.08 0.001
ILMN_2767615 Atp1b1 2.49 0.003
ILMN_1226546 C79267 2.04 0.004
ILMN_1237578 Aldh1a3 17.77 0.048
ILMN_1250907 Mcm2 2.17 0.001
ILMN_1217458 8430403J19Rik 2.98 0.001
ILMN_2652500 Lrg1 3.52 0.036
ILMN_1241161 2900075A18Rik 2.88 0.017
ILMN_2951691 Hist1h3e 2.21 0.008
ILMN_2636403 Axud1 0.19 0.001
ILMN_1256792 2610028H07Rik 0.5 0.001
ILMN_2770609 Ier5l 2.28 0.001
ILMN_1231204 LOC270152 2.59 0.023
ILMN_2742075 Cd14 2.11 0.042
ILMN_2973288 Lama1 2.49 0.025
ILMN_2748164 Hist1h3b 2.91 0.014
ILMN_2603791 Sprr2g 21.38 0.042
ILMN_2895177 Epm2aip1 0.44 0.002
ILMN_2832979 Gpc3 0.46 0.001
ILMN_2941749 2310007F04Rik 8.88 0.003
ILMN_3049559 C4 3.19 0.002
ILMN_1237695 Pfkp 2.62 0.05
ILMN_2730005 Rpl29 2.7 0.012
ILMN_1230443 scl0003547.1_6 3.02 0.02
ILMN_2712895 4631423B10Rik 2.03 0.001
ILMN_1215092 Slp 2.98 0.006
ILMN_3160218 Amica1 2.59 0.016
ILMN_1216213 Incenp 3.45 0.004
ILMN_2660555 Bcl2a1d 2.84 0.034
ILMN_1246609 Rasgrp1 2.62 0.011
ILMN_2437728 2310006E12Rik 2.72 0.013
ILMN_2574191 A330072B11Rik 0.44 0.001
ILMN_2660263 Bcl2a1b 3.07 0.034
ILMN_2590884 Plaur 2.11 0.004
ILMN_2513870 Zap70 3.52 0.017
ILMN_2436183 9130430L19Rik 2.93 0.001
ILMN_1221789 Osbpl6 0.46 0.002
ILMN_2610594 2310002A05Rik 22.85 0.028
ILMN_2697415 Cd3d 3.19 0.007
ILMN_2612325 4931406C07Rik 0.5 0.005
ILMN_3160137 Aldoc 2.04 0.028
ILMN_1218226 2210413P12Rik 3.11 0.006
ILMN_1225764 1700018O18Rik 2.71 0.009
ILMN_1255516 1810041L15Rik 0.41 0.001
ILMN_2805339 Hspb6 2.3 0.03
ILMN_1233857 Mcm6 2.04 0.001
ILMN_2646625 Jun 2.59 0.001
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ILMN_2770386 Fhl2 2.4 0.003
ILMN_3136983 Mpn 2.12 0.005
ILMN_2907972 B3gnt3 3.62 0.012
ILMN_2944824 Hp 3.93 0.024
ILMN_2762109 Pkp1 3.39 0.001
ILMN_1246808 Serpine2 3.59 0.017
ILMN_1251725 Ly6g6c 3.28 0.008
ILMN_2682268 BC004853 2.46 0.006
ILMN_2611022 Bcl11b 2.54 0.001
ILMN_2636339 Isgf3g 2.02 0.025
ILMN_1239863 7420404O03Rik 2.19 0.006
ILMN_2739740 Krt2-16 13.44 0.003
ILMN_2581247 E030007H10Rik 0.49 0.001
ILMN_1256817 Slpi 11.53 0.016
ILMN_2781181 D10Bwg1379e 0.48 0.003
ILMN_1246733 Gm22 0.42 0.028
ILMN_1229813 Krt1-16 13.73 0.003
ILMN_2749958 Cerk 2.44 0.009
ILMN_2489801 2310030B04Rik 2.03 0.002
ILMN_2728270 Galgt1 4.98 0.016
ILMN_2684575 C630049M13 2.01 0.001
ILMN_2758198 Sdh1 2.05 0.001
ILMN_1233840 LOC381283 0.39 0.001
ILMN_3160190 Capn13 3.09 0.001
ILMN_1226990 D130017D19Rik 0.46 0.001
ILMN_1222071 C920004C08Rik 2.93 0.005
ILMN_2763194 ORF9 9.16 0.025
ILMN_2702950 Kb40 2.27 0.033
ILMN_2598877 Slc7a8 2.54 0.044
known targets of canonical WNT signaling 
according to the WNT homepage at
http://wnt.stanford.edu
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PROBE_ID SYMBOL Fold-Change 
(MKO/FKO)
MKO/FKO 
p-value
ILMN_1232887 LOC382393 7.44 0.039
ILMN_2753792 Stra6 3.7 0.013
ILMN_2767039 2310007B03Rik 2.34 0.045
ILMN_2754940 2310031A18Rik 3.99 0.013
ILMN_2513826 Tnfrsf11b 3.61 0.039
ILMN_2778111 Etv4 2.22 0.048
ILMN_2606746 Car2 2.78 0.05
ILMN_1221640 Gabrp 2.12 0.047
ILMN_2678144 3010033K07Rik 5.53 0.019
ILMN_2619952 Mmp10 3.62 0.031
ILMN_1213921 Troap 2.28 0.05
ILMN_2641201 Sp5 4.04 0.048
ILMN_2929896 Pbk 2.3 0.039
ILMN_1243616 Cdkn3 2.29 0.038
ILMN_2838501 Slc24a3 0.41 0.005
ILMN_1238995 BC062650 2.29 0.049
ILMN_2606162 Pdlim4 2.35 0.005
ILMN_2851288 Ngfr 2.41 0.042
ILMN_2650008 Gpr49 2.18 0.043
ILMN_2529797 LOC213948 2.02 0.05
ILMN_2747923 Slc40a1 2.52 0.013
ILMN_1255053 Plk1 2.28 0.044
ILMN_2965660 Apcdd1 3.51 0.018
ILMN_1226293 Slc39a4 2.67 0.027
ILMN_2696611 Nkd1 3.46 0.048
ILMN_2449157 Tnfsf9 2.46 0.035
ILMN_1221684 Scp2 2.37 0.048
ILMN_2699522 Dyrk3 2.6 0.006
ILMN_2896314 Axin2 2.25 0.017
ILMN_2732079 AI836003 2.65 0.038
ILMN_2640330 Cd44 2.3 0.023
ILMN_1225182 Cdca3 2.33 0.04
ILMN_1240124 Tcrd-V1 2.44 0.014
ILMN_1228232 Cpe 2.04 0.025
ILMN_2680387 Cpz 0.29 0.031
ILMN_1226541 5430417J04Rik 0.27 0.017
ILMN_2638473 1190003M12Rik 3 0.027
ILMN_2976191 Stat5a 2.01 0.026
ILMN_2932164 5730593N15Rik 3.33 0.045
ILMN_2778872 Mad2l1 2.67 0.006
ILMN_1246201 Cacna1h 0.3 0.003
ILMN_2727472 Isl1 2.1 0.032
ILMN_2804685 Defb1 0.35 0.024
ILMN_1252399 Tbx1 0.49 0.014
ILMN_2600255 Bcl9 2.38 0.016
ILMN_3118584 Bex4 2.67 0.047
ILMN_2678134 Bspry 2.31 0.006
ILMN_2463181 Tnc 0.39 0.045
ILMN_1214126 Hes6 2.34 0.046
ILMN_2614655 Gpnmb 2.82 0.024
ILMN_2440679 D1Ertd471e 0.42 0.041
ILMN_3131478 Bcat1 0.37 0.037
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ILMN_1232265 LOC331239 0.31 0.049
ILMN_2675232 Prss19 0.43 0.003
ILMN_1244272 Epb4.1l3 0.38 0.016
ILMN_2685770 Ltap 2.19 0.04
ILMN_2691352 Efna4 2.08 0.025
ILMN_2643355 Edaradd 2.09 0.019
ILMN_2680054 D0H4S114 2.17 0.032
ILMN_2934522 Spin2 2.46 0.016
ILMN_2491589 Vgll4 2.23 0.006
ILMN_2485323 Trf 0.49 0.03
ILMN_1220560 Pgm5 0.44 0.024
ILMN_2687040 Echdc2 2.22 0.03
ILMN_1250766 Pvrl3 2.38 0.017
ILMN_3161790 AI451557 0.37 0.027
ILMN_2672297 Gcnt1 0.38 0.016
ILMN_2771219 1110001A05Rik 2.06 0.015
ILMN_1256851 Arhgap20 0.47 0.033
ILMN_2674122 Pkia 0.48 0.039
ILMN_2739760 Prelp 0.48 0.019
ILMN_1248999 LOC380928 2.22 0.012
ILMN_1231083 5830484A20Rik 0.5 0.04
ILMN_1218358 Gypc 0.47 0.023
ILMN_2745551 Olfml2b 0.44 0.031
ILMN_2814865 Qpct 0.49 0.002
ILMN_2639972 Ppp1r3b 0.49 0.016
ILMN_2643495 Fez1 0.4 0.036
ILMN_1231439 Aatk 0.47 0.042
ILMN_2711562 Pip5k1a 0.44 0.028
ILMN_2691951 Polydom 0.45 0.012
ILMN_1228535 Pmp22 0.45 0.014
ILMN_2740407 Pde2a 0.39 0.007
ILMN_1253797 Slit2 0.5 0.011
ILMN_2718401 Htra3 0.5 0.008
ILMN_3161834 Olfm4 7.68 0.045
ILMN_2635462 Cxcl15 6.98 0.036
ILMN_3137570 Pdlim5 2.58 0.008
ILMN_2701664 Dsip1 0.39 0.001
ILMN_2652527 Catnd2 2.44 0.038
ILMN_1223875 Rasd2 2.52 0.019
ILMN_3033621 4933421E11Rik 3.03 0.001
ILMN_1212717 Tgif 2.24 0.044
ILMN_1243873 DKFZp434J1813 2.13 0.022
ILMN_2718266 Fkbp5 0.48 0.008
ILMN_2829594 Hspa1a 0.45 0.019
ILMN_1251713 Car12 0.48 0.047
ILMN_2698221 Bean 2.36 0.006
ILMN_1221973 9430029P12Rik 2.21 0.049
ILMN_1249635 Leprel1 0.44 0.017
ILMN_2712668 C230090D14 0.48 0.004
ILMN_2573036 D130032J17Rik 0.46 0.007
ILMN_2816180 Lbh 0.5 0.021
ILMN_2852380 Srp54 2.25 0.031
ILMN_2700408 Mgll 0.41 0.036
ILMN_2472093 BC020108 0.41 0.05
ILMN_3161289 Gnaz 0.46 0.027
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ILMN_2807335 3110001A13Rik 0.46 0.009
ILMN_2459899 Tsrc1 0.48 0.002
ILMN_1248340 D16Bwg1547e 2.01 0.008
ILMN_1229544 D130083G05Rik 2.02 0.048
ILMN_2653860 Slc15a2 0.33 0.032
ILMN_2693858 D14Ertd449e 2.04 0.039
ILMN_2737200 Mbp 0.43 0.011
ILMN_1232121 Zfhx1b 0.47 0.006
ILMN_1222969 4930404F20Rik 4.45 0.034
ILMN_2618364 1110055E19Rik 0.5 0.027
ILMN_1235808 9430041O17Rik 2.38 0.015
ILMN_1247765 Mfhas1 0.47 0.001
ILMN_1234171 Ezh2 2.17 0.045
ILMN_2520264 2010016I18Rik 2.83 0.008
ILMN_2475156 Xist -0.01 0.013
ILMN_1242390 Actn4 2.07 0.029
ILMN_1255621 9530053J19Rik 0.45 0.008
ILMN_1250779 5730543M03Rik 2.84 0.002
ILMN_2994173 Hccs 2.52 0.002
ILMN_2642052 3010003L21Rik 2.46 0.009
ILMN_1223682 Fbln1 0.39 0.009
ILMN_2899599 Ddx3y 12.24 0.001
ILMN_1248022 E330020G21Rik 0.37 0.002
WNT targets
others
sex-specific genes
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Supplemental Table 3: Known AR target differentially regulated in male and female GOF 
bladders. 
 
Gene Symbol Fold-change (MGOF/FGOF) Known Function 
Mmp10 (1) Up 3.62-fold 
Breakdown of extracellular matrix. It involves in 
embryogenesis, implantation (2), angiogenesis 
(3) and metastasis (4). It has also been 
implicated in cancer stem cell vitality (4). 
Pdlim4 (1) Up 2.34-fold Implicated in cytoskeleton organization, cell fate decision, organogenesis, and oncogenesis (5). 
Scp2 (1) Up 2.37-fold Mediates non-specific lipid-transfer. May play a role in regulating steroidogenesis (6). 
Cd44 (1) Up 2.30-fold 
Membrane glycoprotein involved in cell 
interaction, adhesion and migration. Elevated 
level of standard and variant CD44 isoforms has 
been reported in exfoliated urothelial cells of 
patients with bladder cancer and severe 
urothelial dysplasia (7). 
Pde2a (1) Down 2.57 -fold A phosphodiesterase regulating pathways using cGMP or cAMP as a second messenger (8).  
Fkbp5 (9) Down 2.09-fold 
An immunophilin implicated in progesterone and 
other corticoid receptor pathways (9), as well as 
NFκB and AKT pathways (10). Decreased 
expression of FKBP5 and increased 
chemoresistance were reported in pancreatic 
and breast cancer cell lines (11, 12). 
Slc15a2 (13) Down 3.11-fold H+/dipeptide transporter normally expressed in kidney, lung, mammary gland and brain (14). 
Ddx3y (1) Up 12.24-fold 
RNA helicase important for spermatogenesis (15). 
It transcriptionally regulates p21waf1/cip1 
expression and affects cell survival in various 
human cancer cell lines (16). 
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